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ABSTRACT
The Plasmodium falciparum parasite is thought to be responsible for more than a 
million deaths every year from severe malaria. Although malaria is a treatable disease, 
many of the mortalities occur in the first 24 -  48 hours after hospital admission, despite 
administration of antimalarial drugs. An important contributory factor to severe disease 
is the ability of the parasite, during the intraerythrocytic development phase, to cause 
infected red blood cells to sequester in host microvasculature. These sequestered 
parasitized red blood cells (PRBC) contribute to severe disease by impeding 
microcirculatory flow and possibly contributing to damage to the host endothelium. 
Sequestration is a result of the cytoadherence interaction between parasite proteins on 
the surface of the PRBC, and host endothelial adhesion molecules. Whilst many 
adhesion receptors have been identified, adhesion to ICAM-1 has been, in some 
cases, potentially linked with one of the most severe forms of malaria, cerebral malaria.
We have investigated what might happen in terms of cytoadherence during the first 24 
hours after administration of antimalarials. We find that despite loss of viability, 
parasites are still able to cytoadhere at significant levels for many hours after 
administration of antimalarials. These results indicate that changes made by the 
parasite to a PRBC are stable even after parasite death, and any pathophysiological 
effects resulting from the ability of the PRBC to sequester in microvasculature may be 
continuing for long after parasite death. We also investigate the increased rigidity of 
PRBC, and find that this feature is also maintained long after administration of 
antimalarials.
These results highlight a potential need for adjunct therapy that could be administered 
along with antimalarial treatment which may reverse sequestration of PRBC. Whilst 
many studies have investigated the inhibition of adhesion, few have looked at the 
potential to reverse sequestered populations. We show for the first time that the strong 
adhesion of PRBC to ICAM-1 can be not only inhibited, but also reversed by both a 
monoclonal antibody and a recombinant protein. This suggests that the reversal of 
cytoadherence and removal of sequestered populations may be feasible.
Finally, we have investigated a natural host response to infection, fever, which is an 
almost ubiquitous symptom of P. falciparum infection as a result of parasite stimulation 
of inflammatory responses. We find that the levels of cytoadherence are reduced 
following exposure of host endothelial cells to febrile temperatures. This illustrates the 
potentially protective nature of host responses to infection.
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CHAPTER 1 - INTRODUCTION
Plasmodium falciparum is the intracellular protozoan parasite that is responsible for 
over a million deaths from severe malaria every year. During one stage of its complex 
life cycle, the intraerythrocytic asexual development stage, the parasite can cause the 
potentially fatal symptoms of severe malaria. This thesis focuses on the interactions 
that occur during this life cycle stage between the parasite and the human host. An 
important aspect of P. falciparum malaria is the intimate cytoadherence process that 
leads to the sequestration of P. falciparum infected red blood cells (PRBC) in 
microvasculature. We investigate how natural host responses (fever) and artificial 
interventions (antimalarial treatments) may affect this cytoadherence interaction and 
look at the potential for adjunct therapies to prevent or reverse this potentially 
pathophysiological interaction.
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1 -1 Malaria Parasites -  Plasmodium Species
The most severe form of malaria is caused by Plasmodium falciparum parasites. 
Recent work suggests that over 2 billion people live in areas at risk of P. falciparum 
transmission (Guerra et al., 2008), with parasite distribution encompassing much of 
Africa, South-east Asia, and South and Central America. There are five species of 
Plasmodium that can cause human malaria, however, malaria caused by P. falciparum 
is thought to account for around 50% of infections and 95% of global malaria 
mortalities. There are still up to 2 million deaths a year attributed to P. falciparum 
malaria, with many of these deaths occurring in young children in sub-Saharan Africa. 
The four other Plasmodium species that infect humans and cause disease are: 
Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and recently recognised 
as causing human disease is Plasmodium knowlesi.
Symptoms of P. vivax infection are generally less severe than P. falciparum, but it is 
thought that as much of the world’s population is at risk of P. vivax infection as is at risk 
of P. falciparum infection. Up to 50% of malaria cases in South and Southeast Asia are 
attributed to P. vivax, and this figure is up to 70% for South and Central America (Price 
et al., 2007). The parasite is largely absent from Western Africa, probably due to a 
common blood type mutation which renders the parasite unable to invade host red 
blood cells.
The impact of P. ovale and P. malariae is less than that of P. falciparum or P. vivax, 
however still could be important. P. malariae has been detected in most malaria 
endemic countries, including those in Asia, the Middle East, S. and Central America, 
although it is most common in sub-Saharan Africa and SW Pacific. P. ovale infections 
are less common, both in distribution and frequency. While both infections result in mild 
symptoms there is the possibility for chronic infections, and recurrence of infection 
decades after original exposure (Mueller et al., 2007). Recently identified as being an 
important human pathogen in its own right is P. knowlesi, which had previously been 
described as a primate species (Singh et al., 2004, Cox-Singh et al., 2008). Using PCR 
genotyping techniques increasing numbers of cases are now being attributed to P. 
knowlesi rather than the morphologically indistinguishable P. malariae (Ng et al., 2008, 
Luchavez et al., 2008), although questions still remain as to whether the parasite is 
transmitted between humans.
One interesting difference between the parasite species is that only the most virulent of
the established human malaria parasites, P. falciparum, has been shown to sequester
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in microvasculature. Cytoadherence of P. falciparum PRBC is thought to be an 
important determinant in the severity of disease and is the focus of this thesis.
1-2 Plasmodium falciparum life cycle
The vector for P. falciparum transmission is the female anopheline mosquito, which 
passes on around 15 -  150 sporozoites from her salivary gland whilst taking a blood 
meal. On biting a mammalian host the mosquito injects from her salivary gland factors 
to help facilitate her ingestion of the blood meal, including vasodilators and anti­
coagulants. If the mosquito is infected, sporozoites are injected into the host skin from 
where they travel rapidly via the bloodstream to the liver. Interaction between a 
sporozoite and liver cells seems to be mediated by the parasite circumsporozoite 
protein (CSP) interacting with Heparan Sulphate proteoglycans (HSPGs) on liver cells.
Within the liver the sporozoite passes through several cells before coming to rest in a 
hepatocyte in which it forms a parasitophorous vacuole. Within this the parasite 
develops into thousands of merozoites. These are released into the blood stream 
following the budding off of a merozoite-filled vesicle which is probably then 
proteolytically degraded in the blood stream to release the merozoites (Prudencio et 
al., 2006). The liver stage is largely asymptomatic and for P. falciparum lasts around 
5Vz days. The resulting merozoites then are able to initiate rounds of asexual 
multiplication inside red blood cells.
A merozoite, although small at 1.5 pm by 1 pm (Baum et al., 2005), the size of most 
bacteria, is a highly specialised polar cell. The pear-shaped merozoite attaches to the 
surface of an RBC then must then orient itself so that the apical end of the cell is 
attached to the RBC surface. After reorientation a tight junction is formed which moves 
around the cell to engulf the parasite in its parasitophorous vacuole (Gaur et al., 2004). 
Key to these processes are the specialised microneme and rhoptry structures 
underneath the apical surface membrane of the merozoite.
In the host RBC the parasite develops within the parasitophorous vacuole (PV). Young
parasites are termed “rings” due to their characteristic ring-shaped appearance. Over
the next 48 hours of development in the RBC the parasite makes many changes to the
cell which will be described in more detail later. For the first 18 hours of development P.
falciparum PRBC are freely circulating in the bloodstream, however the mature
trophozoite stages from around 18 hours post invasion (hpi) disappear from peripheral
circulation and become sequestered in microvasculature (Fig 1.2). This sequestration
is a result of the cytoadherence interaction between parasite protein, (mainly PfEMP-1)
on the surface of a PRBC, and host endothelial cell adhesion receptors. From around
34 -  48 hours the parasite is undergoing schizogony, nuclear division. By 48 hours
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following initial merozoite invasion the PRBC is packed with up to 32 daughter 
merozoites ready for release to begin a new invasion cycle.
Release of merozoites from a PRBC is a disruptive process destroying the cell; the 
resulting loss of RBC may contribute to the anaemia often seen in severe malaria. 
Merozoites have to escape from two membranes, the PV membrane and the RBC 
plasma membrane. Although several models for the release of PRBC have previously 
been proposed (Rayner, 2006), recently, careful microscopy has suggested that an 
explosive release of merozoites is preceded by some swelling of the schizont before 
almost simultaneous rupture of the PVM and RBC PM (Glushakova et al., 2005).
Once the P. falciparum asexual infection is established, parasites adapted for mosquito 
transmission, the gametocytes, start to emerge. The commitment to form gametocytes 
occurs during schizont development, such that all merozoites from a committed 
schizont once reinvaded will not only all develop into gametocytes, but will all become 
the same sex. The precise triggering factor for gametogenesis is unknown, but 
stressful conditions encountered at high parasite densities are known to be involved. 
Gametogenesis takes around 10 days for P. falciparum and during most of this time, as 
seen with mature trophozoites, the cells are absent from peripheral circulation. Unlike 
mature trophozoites which sequester in a variety of tissues, gametocytes can be found 
specifically in bone marrow. Whereas it is well established that the protein responsible 
for adhesion of asexual stages is PfEMP-1 (see later), it is less clear what is mediating 
the cytoadherence and sequestration of developing gametocytes in the bone marrow. 
The developing gametocytes have been shown to have low levels of var transcripts 
and PfEMP-1, and do not express the knob structures that are necessary for correct 
display of PfEMP-1 and efficient cytoadherence. The mature gametocytes (known as 
stage V) which have a characteristic crescent shaped appearance and show no 
cytoadherence phenotype are found in peripheral circulation. It is these cells that, after 
being taken into a mosquito in her blood meal, are capable of developing and further 
transmission (Alano, 2007).
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Figure 1.1. Life cycle of Plasmodium falciparum (Figure taken from Scherf 2008 (Scherf et al., 
2008)). See text for life cycle description.
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Figure 1.2. Development and cytoadherence of intraerythrocytic stages of P. falciparum. Illustrating 
the morphology of the developing parasite from Ring stage (Oh -  14h). Ring-trophozoite transition stage 
(14-18h). Young trophozoite (18-24h). Mid-trophozoite (24-28h). Mature trophozoite (28-32h). Developing 
Schizont (32-42h). And Schizont (42-48h). Cytoadherence to endothelial cells and sequestration in 
microvasculature occurring from around 18 h onwards.
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1-3 The Infected Red Blood Cell
As a parasite matures inside a host red blood cell, the cell becomes capable of 
cytoadherence, adhesion to the endothelial cells that line blood vessel walls. Infected 
red blood cells are also significantly more rigid than the highly deformable red blood 
cell (Cranston et a/., 1984). It is widely thought that it is the increased rigidity of P. 
falciparum PRBC is responsible for the ability of the spleen to recognise and clear 
PRBC, either through destruction of the PRBC, or through removal of the parasite by 
the mechanical process of pitting (Engwerda et al., 2005, Chotivanich et a/., 2002, 
Angus et al., 1997, Safeukui et al., 2008). Sequestration in the microvasculature is a 
mechanism by which the rigid PRBC can escape from circulation and avoid passage 
through, and destruction by, the spleen. P. vivax PRBC are not known to cytoadhere, 
so remain in peripheral circulation during intraerythrocytic development. However, P. 
vivax infection does not lead to increased rigidity of the PRBC. It has been suggested 
that the P. vivax PRBC are more deformable than uninfected RBC (Suwanarusk et al., 
2004). An alternative mechanism for avoidance of splenic clearance of P. vivax PRBC 
has been proposed based on adhesion of P. vivax PRBC to barrier cells in the spleen 
preventing entry into the spleen and subsequent clearance (del Portillo et al., 2004), 
but there is little evidence to support this.
The many modifications that a parasite makes to the host red blood cell might 
contribute to the decreased deformability of the PRBC (Cooke et al., 2001). Changes 
made by the parasite to the RBC include: i) Expression of parasite proteins on the 
cytoplasmic face of the RBC membrane; ii) Expression of parasite proteins on the 
surface of the PRBC and insertion of novel, or modification of existing channels in the 
RBC membrane to form the new permeation pathways (NPP); iii) The modification of 
RBC membrane cytoskeletal components. These structural changes made by the 
parasite occur alongside the increasing physical size of the parasite within the RBC, 
and the increase in components of the RBC cytoplasm such as solutes being taken up 
into the cell by the parasite (Kirk, 2001). The resulting increased rigidity may be a factor 
in impairing microcirculatory blood flow (Dondorp et al., 2008), and determination of 
disease severity (Dondorp et al., 2000).
RBC Membrane Cytoskeleton
A red blood cell needs to be highly deformable to allow passage through small blood 
vessels throughout its 120 day lifespan. This deformability is a result of a highly 
specialised membrane cytoskeleton structure with elastic properties. Spectrin is the 
main component of the cytoskeleton, and is composed of an a and a (3 chain that form
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antiparallel heterodimers which then associate to form tetramers. Junctional complexes 
connecting spectrin tetramers comprise mainly of protein 4.1, and actin. These are 
connected to the membrane through interactions between protein 4.1 and ankyrin to 
the integral membrane proteins band 3 and glycophorin C. In PRBC this membrane 
cytoskeleton is altered by parasite proteins that interact with the host membrane or 
cytoskeleton, as well as parasite induced modifications to endogenous host proteins 
(Cooke et al., 2001). Some of these changes may contribute to the increased rigidity of 
PRBC compared to uninfected RBC (Cranston et al., 1984).
Protein 4.1
Protein 4.1 appears to be essential for the proper development of P. falciparum. It has 
been shown that protein 4.1 is phosphorylated to a greater extent in PRBC than in 
uninfected RBC, and the parasite protein, mature parasite-infected erythrocyte surface 
antigen, (MESA) is known to interact with protein 4.1 (Bennett et al., 1997). Failure to 
interact with protein 4.1 leads to accumulation of MESA in the RBC cytoplasm and 
reduced parasite viability. However, the precise role of MESA is unknown and MESA is 
not thought to be important for the formation of knobs or cytoadherence (Lustigman et 
al., 1990, Magowan et al., 1995).
Knobs
A major change to the PRBC is the formation of knobs which anchor the variant protein 
PfEMP-1 on the surface of the PRBC; knobs have been shown to be essential for the 
ability of PRBC to cytoadhere under flow conditions (Crabb et al., 1997). Knobs are 
formed from the interaction with parasite proteins PfEMP3 and knob associated 
histidine rich protein (KAHRP) with host spectrin, actin and ankyrin. PfEMP-1 protein is 
anchored to knobs through association between the PfEMP-1 cytoplasmic C-terminal 
domain acidic terminal segment (ATS) and KAHRP (Rug et al., 2006, Pei et al., 2005, 
Oh et al., 2000).
KAHRP
KAHRP has binding sites for Spectrin, Ankyrin and PfEMP-1. The presence of KAHRP 
is essential for formation of knobs on the surface of PRBC, and also for the display of 
PfEMP-1, and proper cytoadherence. In the absence of KAHRP, whether through 
chromosomal deletion or targeted genetic deletion, the level of PfEMP-1 on the surface 
is reduced, the distribution of the protein is altered, and cytoadherence under flow is 
not possible (Horrocks et al., 2005, Crabb et al., 1997). The formation of knobs has 
been shown to be a major determinant in the reduced rigidity of PRBC (Paulitschke &
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Nash, 1993), and KAHRP specifically has been shown to have an important role in this 
reduced rigidity (Glenister et al., 2002).
PfEMP-3
PfEMP-3 has been shown to interact with spectrin and actin (Waller et al., 2007), 
destabilising the RBC membrane cytoskeleton (Pei et al., 2007) and playing a role in 
the reduced deformability of PRBC (Glenister et al., 2002). PfEMP-3 is located in the 
PRBC membrane cytoskeleton and can be found in knobs (as well as distributed 
throughout the cytoskeleton) but is not essential for their formation. A truncated mutant 
of PfEMP-3 fails to reach the surface and also disrupts proper PfEMP-1 trafficking 
(Waterkeyn et al., 2000).
Band 3 and Glycophorm
Parasites also induce changes to erythrocyte proteins. Components of the red blood 
cells cytoskeleton Band 3 and Glycophorin show restricted mobility within the 
membrane as compared with uninfected erythrocytes. This could to be due to the effect 
of parasite proteins or due to oxidative stress induced by the parasite (Parker et al., 
2004). Modified band 3, (previously known as Pfalhesin) may have a role in 
cytoadherence to CD36 (Crandall et al., 1994).
NPP
Proteins inserted into the erythrocyte membrane form, or partly make up, components 
of the new permeation pathways (NPP). These pathways induced by the parasite 
enable it to take up the nutrients needed for rapid growth and differentiation. The NPP 
increases flux of many solutes, including amino acids, sugars, nucleosides, vitamins 
and other inorganic and organic anions and cations. (Kirk, 2001). Although precise 
components of the NPP are unknown, and they may consist of modified host pathways 
(Kirk et al., 1994), the involvement of parasite proteins in these pathways has been 
shown (Baumeister et al., 2006).
Surface Exposed Proteins
Parasite proteins including the protein responsible for cytoadherence, PfEMP-1 (see 
below), are known to be exposed on the surface of a PRBC (Fig. 1.3) (Craig & Scherf, 
2001). Other major proteins exposed on the surface of the PRBC are another family of 
variant proteins, RIFINs, as well as the modified host Band 3.
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PfEMP-1
PfEMP-1 is the major exposed parasite protein, it is the protein responsible for 
cytoadherence, and, encoded for by the family of var genes is the major antigenically 
variant protein. One of around 60 var genes is expressed at a time, each encoding a 
PfEMP-1 variant with unique antigenic and cytoadherent properties. The structure of 
PfEMP-1 and its role in antigenic variation and cytoadherence is discussed in more 
detail later. PfEMP-1 has a large extracellular portion comprising several DBL domains, 
and a small intracellular domain which interacts with KAHRP to localise PfEMP-1 to 
knobs.
Figure 1.3. Parasite protein on the surface of a PRBC (See chapter 3). Example of parasite protein 
PfEMP-1 expressed on the surface of an infected red blood cell. Confocal immunofluorescence 
microscopy image of (unfixed) infected (left) and uninfected (right) RBC. Showing phase contrast image 
(Phase), ethidium bromide staining for parasite (EtBr) and top plane and centre plane of PfEMP-1 on the 
PRBC surface.
RIFINs
RIFINs are encoded by the clonally variant rif family of genes. There are an estimated 
200 copies of rif per haploid genome and the genes are located subtelomerically, close 
to var genes. mRNA encoding rifins is detectable in trophozoite-stage parasites from 
around 18-23 hours post-invasion, i.e. slightly later than seen for var genes. RIFINs 
are 27-34 kDa proteins and are detectable in the RBC cytoplasm as well as associated 
with the mature PRBC membrane (Kyes et al., 1999). RIFINs were originally identified 
as being involved in rosetting (Helmby et al., 1993), a virulence associated phenotype 
involving the adhesion of a PRBC with one or more uninfected RBC through the 
complement receptor CR1 (Cockburn et al., 2004). However, it is now thought that 
PfEMP-1 is the major ligand mediating rosetting (Rowe et al., 1997).
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STEVOR is a third large family of clonally variant proteins which although expressed in 
many life cycle stages is now not thought to be exposed on the surface of asexual 
stage PRBC (Blythe et a/., 2004).
Protein trafficking in the PRBC
PfEMPI
nucleus
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Figure 1.4. Trafficking pathways in trophozoite stage PRBC. (Figure taken from Tilley 2008 (Tilley et 
at., 2008)) Soluble proteins destined for export are directed into the ER and pass through cis-Golgi and 
trans Golgi compartments en route to the parasitophorous vacuole (PV). Some proteins are retrieved from 
the plasma membrane or diverted from the ER or Golgi to intracellular organelles, such as the digestive 
vacuole (DV) and the apicoplast or (in the schizont stage) to regulated secretory compartments, such as 
the dense granules, rhoptries and micronemes. Following transport across the PV membrane, soluble 
proteins (such as KAHRP) may form complexes as they diffuse across the RBC cytoplasm and interact 
with the cytoplasmic surface of the MC before redistribution to the RBC membrane skeleton. Plasmodium 
falciparum erythrocyte membrane protein-1 may also be trafficked in protein complexes and may become 
membrane-embedded by inserting into MC from the RBC cytoplasm. Integral membrane proteins destined 
for the MC (such as STEVOR) may be transferred to the PV membrane and then accumulate in nascent 
MC. Vesicle-like structures are observed in the infected RBC cytoplasm; however, their role in protein 
trafficking is unclear. TVN, tubulovesicular network.
As illustrated in figure 1.4, trafficking of Plasmodium proteins destined for outside of the 
parasitophorous vacuole (PV) is a complicated process. Proteins targeted to the 
outside of the PV, (i.e. KAHRP and PfEMP-1) are first targeted to the PV by a 
hydrophobic signal sequence (Wickham et ai, 2001). A further signal sequence then 
targets them for export to the RBC cytoplasm, or membrane. This signal sequence has 
been identified as the Pentameric Plasmodium EXport ELement (Pexel) motif which 
appears to be able to direct the transport of exported proteins to outside of the PV
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(Marti et a/., 2004). It is predicted that up to 8% of the Plasmodium genome (MOO 
proteins) contain this sequence and are targeted for export, although this number 
includes multigene families such as var (encoding PfEMP-1), rif and stevor (families 
containing ~60, ~200 and ~25 paralogues respectively). The study also noted however, 
that some known exported proteins did not contain a recognisable pexel motif (Marti et 
al„ 2004).
Trafficking of proteins through the RBC cytoplasm to the RBC membrane is thought to 
be through Maurer’s clefts structures (Wickham et al., 2001). These membranous 
vesicular networks have recently been visualised by electron tomography imaging to be 
flattened disc-like structures that are tethered to the RBC membrane (Hanssen et al., 
2008, Tilley et al., 2008).
The functions of some of the identified exported proteins are known. The surface 
proteins, PfEMP-1, and the knob associated proteins are thought to have roles in 
antigenic variation and virulence through cytoadherence phenotypes. Some of the 
identified exported proteins are known to be located in Maurer’s clefts and may play a 
role in protein trafficking. However, the function of many of the exported proteins, and 
their role in parasite virulence is unknown. In order to determine the essentiality and 
role of some of this large number of predicted exported P. falciparum proteins, a large 
project to knock out all of the exported proteins was undertaken (Maier et al., 2008). 
This work by Maier et. al resulted in successful genetic disruption of 53 genes. The 
inability to create knock out clones of 30 genes hints that they may be essential for the 
parasite even under the in-vitro conditions of these experiments.
Potential functions for the 53 knock out proteins were assessed by looking at virulence- 
related phenotypes of cytoadherence and rigidity in the knock out parasite lines. 
Analysis of the mutants revealed six clones with very low or reduced level of PfEMP-1 
on the surface. These clones also showed no or very low cytoadherence in flow 
adhesion assays. The identified proteins were shown to act on different stages of the 
trafficking pathway, with roles apparently specific for the trafficking of PfEMP-1. Three 
identified proteins acted on early stages of trafficking, as the mutant parasites showed 
low levels of PfEMP-1 in the RBC. Three other mutants showed PfEMP-1 localised in 
the Maurer’s clefts indicating they had a role in the trafficking of PfEMP-1 from 
Maurer’s clefts to the PRBC surface. Two proteins were identified which disrupted 
formation of knobs, and as expected these mutants also showed reduced 
cytoadherence phenotypes. Along with this, several other mutants appeared to show 
some reduction in the level cytoadherence, although PfEMP-1 was apparently present
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on the surface of the PRBC hinting at more subtle roles in PRBC remodelling (Maier et 
al., 2008). This study makes important contributions into both elucidating the detail of 
the complex PfEMP-1 trafficking mechanism, and identification of other potential 
parasite virulence factors.
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1-4 PfEMP-1: Cytoadherence and Antigenic Variation
PfEMP-1 is the large variant protein that is implicated in cytoadherence to many host 
endothelial cell adhesion receptors. The protein is encoded for by var genes (Su et al., 
1995, Baruch et al., 1995), with one of 60 var genes expressed at a time. Different 
PfEMP-1 proteins have different phenotypes in terms of both antigenicity and adhesion 
phenotype and are clonally expressed (Smith et al., 1995). As described below there is 
a large range of endothelial cell adhesion receptors to which PfEMP-1 proteins can 
adhere. Different PfEMP-1 variants can bind to different receptors potentially mediating 
sequestration in different tissues (Montgomery et al., 2007). High levels of 
recombination between var genes result in a huge repertoire of unique PfEMP-1 
proteins within parasite populations leading to a wide range of antigenic and 
phenotypic diversity (Kraemer et al., 2007).
PfEMP-1 proteins comprise a domain structure consisting mainly of several Duffy- 
binding like (DBL) domains and cysteine-rich interdomain (CIDR) regions (Fig. 1.5). 
The gene structure for PfEMP-1 comprises two exons, with exon two encoding a small 
conserved C-terminal domain, known as the acidic terminal segment (ATS). This 
intracellular domain is involved in interaction with KAHRP on the cytoplasmic face of 
the RBC plasma membrane, resulting in the anchoring of PfEMP-1 in PRBC surface 
knobs. Exon 1 encodes the extracellular portion of the protein and the huge variability 
in PfEMP-1 proteins arises from proteins with different combinations of DBL domains, 
and their high sequence variability of the DBL domains.
At the N terminal end of PfEMP-1 is a semi-conserved head structure consisting of a 
cysteine-rich interdomain region (CIDR) domain coupled to a DBL-a domain. DBL-a 
domains have been shown to be able to mediate resetting, the adhesion of a PRBC to 
uninfected RBCs, through the complement receptor 1 (CR1) (Rowe et al., 1997). The 
CIDR region is implicated in the adhesion to CD36 (Smith et al., 1998, Baruch et al., 
1997). A portion of the DBL-a domain is often used as a sequence tag to distinguish 
between and identify different (var genes) PfEMP-1 proteins (Kraemer et al., 2003, Bull 
et al., 2005).
DBL-3 type domains are known to bind to Intercellular adhesion molecule 1 (ICAM-1) 
(Springer et al., 2004, Smith et al., 2000), more detail of ICAM-1 and this adhesion is 
discussed below. The domain architecture of a commonly used ICAM-1 binding clone, 
A4, which contains an ICAM-1 binding DBL-(3 domain is illustrated (Fig. 1.5). DBL-(3
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sequences are always found in tandem with a C2 domain and are usually referred to 
together as DBL-(3.
Adhesion to chondroitin sulphate A (CSA) as implicated in placental malaria, is 
mediated through DBL-y or DBL-3x domains. One var gene, var2csa implicated in 
adhesion to CSA (Viebig et a/., 2007), is unusually conserved across diverse parasite 
populations (Fried et a/., 1998, Fried & Duffy, 2002, Kraemer et al., 2007). The 
mechanism for the selection for this PfEMP-1 variant is as yet unknown (Nunes & 
Scherf, 2007). This adhesion of VAR2CSA to CSA is through a DBL-3X domain 
(Gamain et al., 2005), the structure of which has recently been solved both alone 
(Higgins, 2008b) and in co-crystal with CSA (Singh et al., 2008).
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Figure 1.5. Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1); protein architecture 
and binding domains. (Figure adapted from Smith 2001 (Smith eta/., 2001))
Top illustrates a schematic of possible DBL and CIDR domains that may be found in a PfEMP-1 protein. 
Below is illustrated the specific architecture for a known PfEMP-1 protein A4var41, from the well 
characterised ICAM-1 binding A4 clone. The intracellular domain ATS is highly conserved and anchors 
PfEMP-1 to parasite-induced knobs that facilitate infected erythrocyte sequestration. The extracellular 
domain is highly variable but is predominantly assembled from four building blocks: NTS, DBL, CIDR and 
C2 domains. Based on sequence similarity, DBL domains group as five types (a- t )  and CIDR domains 
as three types (a-y) The prototypical PfEMP-1 extracellular region (a) consists of an NTS and DBL1a- 
CIDR1 ‘semiconserved head structure’ followed by a DBL25-CIDR2 tandem. Larger PfEMP-1 proteins 
also include the DBLp, y and etypes arrayed differently. CD36 is considered to be the major endothelial 
sequestration receptor; other receptors are recognized less frequently but might have important roles in 
disease. Abbreviation: CR1, complement receptor 1. Abbreviations: ATS, acidic terminal segment; CIDR, 
cysteine-rich interdomain region; DBL, Duffy-binding-like domain; ICAM-1, intracellular adhesion molecule- 
1; NTS, N-terminal segment; TM, transmembrane domain.
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1-5 Molecular basis of Antigenic Variation
The strategy of antigenic variation is used by many pathogens as a method for evading 
host antibody-mediated immune defences (Lopez-Rubio et a/., 2007b); and parallels 
are often drawn between antigenic variation in African trypanosomes (T. brucei) and P. 
falciparum (Lopez-Rubio et al., 2007b, Borst et a/., 1995). As described earlier, a P. 
falciparum genome contains around 60 var genes. It is known that host immune 
responses can result in the production of antibodies targeted to PfEMP-1. Repeated 
exposure to P. falciparum infection is thought to lead to the development of partial 
immunity through the production of anti PfEMP-1 antibodies (Bull et al., 1998). 
Switching of expressed PfEMP-1 to an antigenically distinct PfEMP-1 could protect the 
parasite from destruction and allows for propagation of infection within a host. An 
important aspect of antigenic variation is the regulation of the expression of var genes, 
and crucially the silencing of the non-expressed, or silent var genes.
Expression of var genes has been shown to be regulated at the level of transcription 
initiation (Kyes et al., 2007a, Schieck et al., 2007, Scherf et al., 1998). Switching 
between expressed var genes occurs at this level by the turning on or off of var 
promoters. Switching rates have been estimated at up to roughly 2% per generation 
(Roberts et al., 1992) but are thought to vary between different var genes, with different 
promoters having different “off’ rates (Horrocks et al., 2004). For example, centrally 
located var genes appear to have slower switching rates than telomeric var genes 
(Dzikowski et al., 2007). In T. brucei the antigenic surface molecule is the variant 
surface glycoprotein (VSG), encoded for by a vsg gene which is located in a 
polycistronic, telomeric vsg expression site. Switching of vsg expression in T. brucei is 
complicated by the additional possibility of recombination mediated switching. As well 
as the possibility of switching which vsg expression site promoter is active, T. brucei 
often exchange vsg within an active expression site by recombination, or, since all vsg 
expression sites are telomerically located, telomere exchange (Aitcheson et al., 2005). 
In contrast, switching var though recombination mechanisms is not thought to occur in 
P. falciparum, although high rates of recombination between var genes are responsible 
for the high sequence diversity observed between parasite populations (Kraemer et al., 
2007).
There is evidence that the transcriptional silencing of inactive var genes is controlled by 
epigenetic mechanisms. Most var genes have 5’ upstream promoter regions of one of 
three types, upsA, upsB and upsC which appear to be important in the control of the 
transcriptional silencing (Voss et al., 2006). Epigenetic marks in these regions, i.e.
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histone modifications are important in maintaining the transcriptional state of these 
promoters (Lopez-Rubio et al., 2007a), although the histone marks identified may 
reflect a general genome wide histone modification pattern (Comeaux & Duraisingh, 
2007).
Chromatin at activated var loci is remodelled from a transcriptionally inactive 
heterochromatin structure, maintenance of which requires (in some cases) the PfSir2 
protein (Freitas-Junior et al., 2005), to a transcriptionally competent euchromatin. 
Further to this chromatin remodelling requirement, the transcription of var loci appears 
to be restricted to a specific location on the nuclear periphery (Duraisingh et al., 2005, 
Ralph et al., 2005). Broad similarities can be seen with control of vsg expression site 
silencing in T. brucei. The involvement of chromatin remodelling factor in silencing 
suggests that chromatin structure may play a role in vsg expression site regulation 
(Hughes et al., 2007). Similarly, restriction of transcription to a unique expression 
location, in T. brucei known as the expression site body (ESB) has been shown 
(Navarro & Gull, 2001).
The interesting complication of antigenic variation in Plasmodium falciparum is the role 
of the antigenic protein PfEMP-1 as the major cytoadherence ligand, whereas in T. 
brucei no other function for the major antigenically variant protein, VSG, has been 
established. The requirement for variation as the antigenically variant protein may 
complement the role for PfEMP-1 as the cytoadherence ligand. Variation of the 
proteins is a requirement for antigenic variation, and may result in phenotypic variation 
i.e. the ability to adhere to different host receptors. This is apparent in disease situation 
where P. falciparum populations expressing different variant PfEMP-1 proteins can be 
found sequestered in different tissues, probably through adhesion to different host 
receptors (Montgomery et al., 2007).
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1 -6 Host Adhesion Receptors
Endothelial cells can express many different adhesion molecules on the cell surface, 
many of which are highly glycosylated proteins which have roles in immune response, 
often acting as receptors for other immune cells. The expression of many receptors is 
increased in response to immune stimuli, including Tumor necrosis factor (TNF) which 
is known to be upregulated in malaria. PRBC have been shown to be able to bind to 
many of these receptors, and in some cases there is a link with disease phenotype, 
notably a link between adhesion to ICAM-1 and cerebral malaria, and CSA and 
placental malaria. In most cases the adhesion has been shown to be mediated by the 
parasite protein PfEMP-1. The variant properties of PfEMP-1 enable different variant 
PfEMP-1 proteins to be able to have different cytoadherent properties, resulting in a 
large range of adhesion receptors to which PRBC expressing different PfEMP-1 
proteins can bind. Here we briefly describe some of the endothelial cell receptors 
involved in cytoadherence. Since most of the work presented in this thesis looks at 
adhesion to the receptor ICAM-1, this is discussed in detail in a separate section.
Thrombospondin (TSP)
Thrombospondin (TSP) is a large adhesive glycoprotein that is associated with 
endothelial cell surfaces and has binding sites for a wide range of ligands, from calcium 
up to glycolipids (Lawler & Hynes, 1986). TSP has been implicated in binding under 
both static (Roberts et al., 1985) and flow conditions (Rock et a!., 1988). However, 
binding to TSP alone is not thought to be sufficient to mediate cytoadherence (Ho & 
White, 1999, Cooke et al., 1994). The modified band three protein has been implicated 
in adhesion to TSP as opposed to the major adhesion ligand PfEMP-1 which is thought 
to be responsible for adhesion to most other identified receptors (Eda et al., 1999, 
Lucas & Sherman, 1998).
CD36
CD36 is an important adhesion receptor that was another of the first PRBC receptors to 
be identified, and it has since been revealed that most P. falciparum isolates tested 
have some ability to adhere to CD36. It was initially identified since adhesion to cells 
could be inhibited using an antibody to an 88 kDa glycoprotein, subsequently identified 
as CD36 (Barnwell et al., 1985, Barnwell et al., 1989, Ockenhouse et al., 1989). CD36 
is a cell surface class B scavenger receptor with a large highly glycosylated 
extracellular domain, which can be found on different cell types, including 
microvascular endothelial cells, and platelets. The endogenous function for CD36 is as 
a receptor for fatty acids, TSP and collagen, and it is a phagocytic receptor for
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apoptotic cells. PRBC were shown to require knobs for adhesion to CD36, and it has 
been shown that only more mature stages were able to adhere (Ockenhouse et al., 
1989). Phosphorylation of the CD36 ectodomain is thought to be important in regulating 
substrate specificity. Alternative phosphorylation at this site may also play a role in 
regulating PRBC adhesion, with dephosphorylation of this residue required for optimal 
adhesion (Ho et al., 2005). Furthermore, an inhibitor of this dephosphorylation reaction 
(Levamisole) seemed to reduce sequestration in vivo (Dondorp et al., 2007). PRBC 
have also been shown to be able to bind to platelets in both static and flow conditions 
through binding to platelet-expressed CD36 (Cooke & Nash, 1995). This provides a 
mechanism for CD36 mediated binding of PRBC to endothelium devoid of CD36 using 
the platelets as a bridging interaction (Wassmer et al., 2004).
Vascular Cell Adhesion Molecule-1 (VCAM-1)
VCAM-1 is a member of the immunoglobulin (Ig) superfamily of adhesion receptors, 
along with ICAM-1 and PECAM-1, and is upregulated on endothelium in response to 
inflammatory mediators. VCAM consists of 6 Ig domains and is predicted to form a bent 
rod structure protruding out from the endothelial cell surface, similar to ICAM-1. PRBC 
have been shown to bind to VCAM-1 although VCAM-1 binding under flow conditions 
may be less important than adhesion to ICAM-1 or CD36 (Ockenhouse et al., 1992b, 
Yipp et al., 2007).
Platelet/endothelial cell adhesion molecule-1 (PECAM-1 /CD31)
PECAM-1/CD31 is another glycosylated member of the Ig superfamily. The protein is 
130 kDa consisting of 6 extracellular Ig domains with 9 N-linked glycosylation sites. 
PECAM is expressed on endothelial cells and intravascular cells i.e. granulocytes, 
monocytes and platelets and is thought to act as a homing receptor for leukocytes to 
pass through junctions of endothelial cells (Newman et al., 1990). The protein is 
normally localized to cell junctions but on stimulation with Interferon-gamma (IFN-y) 
can be relocalised to all over the cell surface, increasing binding. Binding of PRBC to 
CD36 negative but PECAM-1 positive endothelial cells has been shown, as has 
adhesion to immobilized soluble PECAM-1 (Treutiger et al., 1997).
Neural cell adhesion molecule (NCAM)
Recently the identification of an adhesion receptor on chicken brain tissue, suggested 
to be NCAM, (another member of the Ig superfamily) illustrates the increasing number 
of endothelial adhesion molecules known to be important for cytoadherence (Pouvelle 
et al., 2007). Due to the nature of the PfEMP-1 variation it is possible that variants exist 
that can adhere to most existing endothelial cell adhesion receptors. NCAM is known
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to be expressed on endothelium in two sites where sequestration is commonly 
observed in severe disease, skin and brain, tempting speculation that it may be an 
important receptor in severe disease (Pouvelle et al., 2007).
gC1qR/HABP1
Another recently identified receptor for PRBC adhesion is gC1qR/HABP1. This is a 32 
kDa membrane protein that is expressed on resting endothelial cells and resting 
platelets, as well as other cell types. Three out of 8 field isolates tested, and two out of 
three lab isolates showed ability to bind to this receptor, independent of ability to bind 
to ICAM-1 or CD36. This receptor was also able to mediate platelet clumping (as can 
CD36) so may prove to be an important receptor for different types of pathogenesis 
(Biswas et al., 2007). The existence of gC1qR/HABP1 on resting endothelium may 
indicate a role in adhesion early on in infection before the cytokine stimulated 
upregulation of other widely used receptors such as ICAM-1.
P-Selectin
Selectins are characterised by an N-terminal domain of 117 -  120 amino acids that is 
homologous to Ca2+ dependent animal lectins, and P-Selectin has been shown to be 
involved in PRBC cytoadherence (Udomsangpetch et al., 1997). The binding site for 
PRBC on P-selectin is thought to be on the lectin domain but distinct from that of a 
natural ligand PSGL-1 (Ho et al., 1998). A significant point about P-selectin is the 
distance from the endothelial cell surface that the molecule protrudes, this enables it to 
be potentially above the glycocalyx, an important consideration in leukocyte recruitment 
(Patel et al., 1995) which may well also be relevant for PRBC adhesion. E-selectin is 
another member of the selectin family that has been suggested to be able to be 
involved in adhesion (Ockenhouse et al., 1992b).
CSA
Adhesion of PRBC to Chondroitin Sulfate A (CSA) is uniquely linked with placental 
adhesion in malaria in pregnancy (Scherf et al., 2001). Malaria in pregnancy is 
associated with an increased risk of maternal anaemia, and a low birth weight. 
Adhesion to CSA has been shown to be a firm adhesion with little rolling interaction, 
and is able to withstand high shear stress levels (Rogerson et al., 1995, Cooke et al., 
1996). Adhesion to CSA has been shown to be mediated by PfEMP-1 (Reeder et al., 
1999), and interestingly the PfEMP-1 variant known to be able to adhere to CSA is 
unusually conserved between different parasite isolates (Fried et al., 1998, Fried & 
Duffy, 2002, Kraemer et al., 2007).
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Cytoadherence to multiple receptors
Cytoadherence under flow conditions is thought to involve multiple adhesion receptors 
acting cooperatively, shown with CD36, ICAM-1 and P-Selectin (McCormick et al., 
1997, Gray et al., 2003, Yipp et al., 2007). A model has been widely proposed where 
PRBC are captured from flow by one receptor, roll along endothelial cells before firm 
adhesion, possibly being mediated by a different receptor. This may separate out roles 
for difference receptor families, where a selectin (i.e. P-selectin) or Ig superfamily 
receptor (i.e. ICAM-1) may be required to capture PRBC from flow followed by firm 
adhesion to a different class of receptor i.e. CD36. Firm adhesion may also require or 
be enhanced by interactions with more than one receptor concurrently (i.e. ICAM-1 and 
CD36).
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1-7 ICAM-1
Adhesion to ICAM-1 has been suggested to be linked with cerebral malaria as post 
mortem studies showing increased parasite sequestration in the brain of patients 
diagnosed with severe malaria also showed increased ICAM-1 expression (Turner et 
al., 1994, Newbold et al., 1997),. Isolates from patients have also shown the ability to 
adhere in vitro to ICAM-1. Most of the work presented in this thesis looks at aspects of 
cytoadherence to ICAM-1. This is due to interest in this interaction because of the link 
with cerebral malaria (Chakravorty & Craig, 2005), but also due to the availability of 
well characterised parasite isolates with known adhesive properties to ICAM-1, and 
endothelial cells that are known to express ICAM-1.
ICAM-1 is an endothelial cell adhesion receptor that is involved in leukocyte 
recruitment through the Lymphocyte function-associated antigen-1 (LFA-1). The 
receptor also has a binding site for rhinovirus (Staunton et al., 1990). ICAM-1 protein 
expression on many types of endothelium can be stimulated by cytokines including 
TNF and IL-1; and PRBC have been shown to increase ICAM-1 levels through 
Plasmodium glycosylphosphatidylinositol anchor (GPI) (Schofield et al., 1996) -  or 
directly through adhesion (Tripathi et al., 2006). ICAM-1 consists of 5 Ig domains and is 
predicted to have a “bent rod” structure (Staunton et al., 1990). Homodimers are 
formed on the surface of cells with interactions of the transmembrane domain and Ig 
domain 4 (towards the C terminal, membrane end of the molecule), as well as a 
weaker interface between domains 1. It is possible that the interactions between 
transmembrane domains, and the domain 4 interactions allow for dimérisation, and 
domain 1 interactions allow for multimerisation on the surface (Fig. 1.6) (Yang et al., 
2004).
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Figure 1.6. ICAM-1 mutimerisation and dimérisation. Figure taken from Yang 2004 (Yang et al., 
2004) Illustration of dimérisation of ICAM-1 through D4 and potential multimerisation through D1, the LFA- 
blndlng domain.
The binding site for Lymphocyte function-associated antigen-1 (LFA-1, also known as 
CD11a/CD18, or aL(32), rhinovirus and P. falciparum are on the most N terminal of 5 
the Ig domains in ICAM-1 (D1), with the binding site for P. falciparum probably distinct 
but overlapping that of LFA-1 or rhinovirus (Berendt et al., 1992). LFA-1 is an abundant 
and widely expressed beta2-integrin and is required for many cellular adhesive 
interactions during the immune response including the adhesion of leukocytes to 
endothelial cells prior to transmigration through endothelial layers following interaction 
with ICAM-1. The integrin Mac-1 (also known as aM(32 or CD11b/CD18) is associated 
with monocyte adhesion to endothelium and is known to bind to ICAM-1 on domain 3 
(Diamond et al., 1991).
Extensive mutagenesis studies have mapped the P. falciparum binding site to a region 
comprising three beta sheet strands known as the BED region of D1 (Tse et al., 2004). 
Figure 1.7a illustrates the location of residues which when mutated lead to a significant 
reduction in the adhesion of ItG PRBC to ICAM-1, under both static and flow 
conditions, as determined by Tse et al (Tse et al., 2004). This work also showed that 
different PRBC isolates had slightly different binding sites. As illustrated in figure 1.7b, 
two mutations are used to characterise between the adhesion of two parasite isolates, 
A4 and ItG. A mutation of K29, as found in the ICAM-1 variant ICAM-1 Kilifi (red 
residue in figure 1.7b) results in reduced adhesion of A4 PRBC, whereas no effect on 
ItG PRBC adhesion is seen. Mutation of S22 (purple residue in figure 1.7b) results in 
loss of ItG PRBC adhesion but does not affect A4 binding. However, the monoclonal 
antibody mAb 15.2 is known to block adhesion of all tested PRBC isolates, the epitope 
of mAb 15.2 adhesion involves L42 (blue residue in fig 1.7b).
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Figure 1.7. Domain 1 of ICAM-1. Domain 1 of ICAM-1 (light blue) shown with part of modelled PfEMP-1 
(translucent grey), Model PM0074932 (Bertonati 2007) (Bertonati & Tramontano, 2007) see below. 
Annotated using VMD. Highlighted residues in A are residues implicated in adhesion of ItG PRBC to 
ICAM-1 in both static and flow conditions as determined by mutagenesis in (Tse et al„ 2004). Highlighted 
resides in B are: Red - K29 implicated in adhesion of A4 PRBC to ICAM-1; Purple -  S22 implicated in 
adhesion of ItG PRBC to ICAM-1 and Blue L42 implicated in adhesion of general blocking antibody mAb 
15.2 to ICAM-1. Orientation of ICAM-1 D1 is shown as in (Tse et al., 2004).
ICAM-1 is known to form homodimers, mainly due to contacts between domain 4 of the 
protein, but also some interactions at domain 3, and possibly the transmembrane 
domain. The BED region of D1 is also thought to be involved in dimerisation contacts 
through weaker polar interactions of side chains. This may be involved in the 
multimerisation seen on ICAM-1 clustering during activation (Fig. 1.6). If there is a 
protein-protein interaction interface using this BED region of D1 this puts the binding 
site for PfEMP-1 in a groove formed between two D1 domains. Figure 1.8 illustrates the 
residues shown to be involved in a) PfEMP-1 adhesion, and b) dimerisation interface 
(Casasnovas et al., 1998, Jun et al., 2001a, Jun et al., 2001b), mapped onto a second 
possibility for PfEMP-1 adhesion as predicted by computation modelling. This recent in 
silico molecular modelling of the interaction suggests that P. falciparum could bind 
slightly further toward the end rather than in the groove of D1 (Fig. 1.8) (Bertonati & 
Tramontano, 2007).
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Figure 1.8. Modelled PfEMP-1 bound to ICAM-1. “PfEMP-1” (Grey) bound to ICAM-1 domain 1 (Blue) 
indicating residues involved in A) cytoadherence and B) D1 dimérisation. Model PM0074932 (Bertonati 
2007 (Bertonati & Tramontano, 2007)) annotated using VMD. A) Resides implicated in cytoadherence as 
in Tse 2003 marked in yellow. B) Resides involved in D1 dimérisation interface in yellow (Casasnovas 
1998) and Orange (Jun 2001). ICAM-1 orientation showing BED p sheets facing upwards.
Mutagenesis studies (Tse et al., 2004) showed that different ICAM-1 binding variants 
appeared to have different binding sites but the modelled interaction was made using a 
consensus of known binding sequences. Inaccuracies in this model may also occur as 
the PfEMP-1 DBL-(B domain is a modelled structure on a non-PfEMP-1 DBL domain 
(EBA 175), furthermore modelling of protein-protein interactions is not accurate. 
Attempts to create a crystal structure of an ICAM-1 binding PfEMP-1 DBL domain are 
currently in progress (Higgins MK); and the structure of a CSA binding PfEMP-1 DBL 
domain (DBL-3X) has recently been solved both alone (Higgins, 2008b) and in complex 
with CSA (Singh et al., 2008). This structure suggests the involvement of conformation 
changes to the DBL domain on binding such that a hinge region may fold over to create 
the binding contacts. A co-crystal structure of the DBL-(3 domain from PfEMP-1 bound 
to ICAM-1 is essential to resolve the exact DBL-|3:ICAM-1 binding mechanism. 
However, there will still be the limitation that different DBL-p domains may bind 
differently, and there may be differences in adhesion mechanisms under static and flow 
conditions. Further knowledge of the detail of the interaction between PfEMP-1 DBL-p 
domains and ICAM-1 may enable development of targeted anti-adhesion adjunct 
therapies, as discussed in chapter 6.
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1-8 Cytoadherence -  Post Adhesion events
PRBC adhesion to endothelial cells may result in damage to the endothelial layer, 
potentially contributing to pathogenesis. An important consequence of adhesion to host 
endothelium is the induction of signalling events within endothelial cells (Chakravorty et 
a/., 2008). Signalling pathways in mammalian cells are complex, with many interacting 
pathways present. In brief, signalling pathways in cells are commonly activated by 
ligation of adhesion receptors on the cell surface. Adhesion of ligand to the 
extracellular domains of a receptor can lead to intracellular events, often initiated by 
phosphorylation events on, or by a cytoplasmic tail of the receptor. Signalling through 
ICAM-1 results from adhesion of ligands to the extracellular domains of ICAM-1, mainly 
using binding sites on domain 1. This results in clustering and multimerisation of ICAM- 
1 on the cell surface (Yang et al., 2004), and signalling requiring the small C terminal 
cytoplasmic domain (Greenwood et al., 2003). A series of intracellular phosphorylation 
events, often through MAP kinase signalling cascades can result in nuclear 
translocation of transcription factors, and activation of transcription of target genes.
It has been shown that MAP kinase signalling pathways, including ERK, JNK and P38 
pathways are activated on adhesion of PRBC to ICAM-1 (Jenkins et al., 2007a). 
Activation of such pathways may result in translocation of transcription factors, i.e. NF- 
kB to the nucleus (Tripathi et al., 2006) and activation of transcription of many targets. 
These targets may include adhesion molecules such as ICAM-1. In this way adhesion 
of PRBC may itself induce increased ICAM-1 expression, leading to greater adhesion. 
This ability of PRBC to induce ICAM-1 levels has been shown on human brain 
endothelial cells (HBEC) and also on human umbilical vein endothelial cells (HUVEC) 
where there was a requirement for very low levels of TNF (Tripathi et al., 2006, 
Chakravorty et al., 2007).
Another widely discussed consequence of adhesion to endothelial cells is the induction 
of apoptosis in the endothelial cells. There are three ways in which endothelial cell 
apoptosis may be stimulated in malaria. It has been shown that soluble parasite 
derived factors can induce apoptosis in endothelial cells (Wilson et al., 2008). Host 
derived inflammatory factors present in malaria may influence apoptosis (Combes et 
al., 2006, Wassmer et al., 2006a, Wassmer et al., 2006b, Hemmer et al., 2005), and 
there is also evidence suggesting that cytoadherence of PRBC can directly induce 
apoptosis. All published data showing in vitro evidence for cytoadherence-induced 
apoptosis is based on assays using human lung endothelial cells (Toure et al., 2008,
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Pino et al., 2003, Siau et a/., 2007). However, it has been suggested that there is 
upregulation of pathways protective against apoptosis following cytoadherence in some 
endothelial cell types, i.e. HUVEC (Chakravorty et al., 2007). These differences may 
reflect differences between endothelial cell types, or illustrate that endothelial cell 
responses may include activation of a range of signalling pathways, the balance of 
which may result in either apoptosis, or cellular protection.
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1-9 Studying Cytoadherence
Assay Types
Adhesion to endothelial receptors has been assayed in vitro in various ways. To assay 
binding under static conditions protein can be immobilised on a plastic Petri dish, or 
endothelial cells grown on cover slips. Assays are also carried out under flow 
conditions, to either immobilised protein or to endothelial cell lines. Flow assays can be 
carried out using microslides or parallel plate chambers, and are set up to enable a 
defined physiologically relevant wall shear stress to be created (Cooke et al., 1994). 
Although animal models of malaria cannot be used for adhesion studies a skin-graft 
technique has been used where human skin tissue has been grafted onto mice to allow 
an interesting way to assess cytoadherence in vivo (Yipp et al., 2003b). Microfluidics 
systems have recently been developed that mimic adhesion under both physiologically 
relevant shear stress and the diameter constriction of narrow vessels (Antia et al., 
2007).
Adhesion of PRBC under flow conditions is a more complicated process than static 
adhesion. Binding mimics that of leukocyte recruitment in that PRBC first have to be 
captured from flow, often seen as a rolling interaction that occurs along endothelial 
cells before firm adhesion results. The microfluidics system showed that the rolling 
interaction was abolished while PRBC traversed a narrow constriction, however, 
quickly restarted when the channel opened out again. This could be due to the 
increased shear stress in these constrictions, or physical constraints reducing the 
interaction between receptor and ligand (Antia et al., 2007).
In this thesis we investigate cytoadherence using static and flow adhesion assays to 
both endothelial cells and protein.
Parasite Isolates
As described earlier, different PRBC isolates have different cytoadherent 
characteristics, and by the process of antigenic variation an isolate can change 
cytoadherent phenotypes by switching of expressed PfEMP-1. In order for comparable 
results between experiments, PRBC isolates expressing known PfEMP-1 proteins are 
often used in the study of cytoadherence, and these are regularly maintained by 
selection for the expected PfEMP-1 expression. For the study of ICAM-1 
cytoadherence parasite isolates of the IT lineage are often used. A series of three 
isogenic isolates with different ICAM-1 avidity are available, ItG (Ockenhouse et al., 
1992a) A4 and C24 (Roberts et al., 1992). Of the three, ItG shows the highest levels of
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adhesion to ICAM-1, A4 shows moderate levels of adhesion, and C24 shows little or no 
adhesion to ICAM-1. However, all three bind to CD36. These three were derived by 
cloning and selection procedures from a single original isolate (Roberts et al., 1992). A 
fourth isolate often used for ICAM-1 cytoadherence studies is JDP8 (Chattopadhyay et 
al., 2004), which is known to have a very high ICAM-1 adhesion phenotype but 
unusually low adhesion to CD36. These isolates are all able to bind to ICAM-1 under 
both static and flow conditions (Tse et al., 2004, Gray et al., 2003).
Most of the work presented in this thesis uses the parasite isolates ItG and A4, 
although JDP8, C24 and a recent patient isolate (unpublished) are also used in some 
experiments.
Endothelial Cells
Primary human endothelial cells can be grown in vitro and are often used as models 
for PRBC adhesion. Primary cells from various sources have been used in the study of 
PRBC cytoadherence, including human umbilical vein endothelial cells (HUVEC), 
human dermal microvascular endothelial cells (HDMEC), human pulmonary vein 
(Lung) endothelial cells (HLEC). All of these cells can be purchased from a commercial 
supplier (such as Promocell) as pooled batches, and all are routinely assessed by the 
manufacturers for expression of endothelial cell markers, such as presence of Von 
Willebrand factor (VWF) (Promocell).
All types of cell mentioned have very low basal expression levels of many endothelial 
cell receptors in culture conditions, as expected from resting endothelial cells. 
However, as with the in vivo situation, adhesion receptors such as ICAM-1 can be 
stimulated by the addition of inflammatory cytokines, such as TNF. HUVEC do not 
express the common receptor CD36, a similar characteristic to brain endothelial cells, 
and these are often used as a model for ICAM-1 mediated adhesion, without the 
complication of additional CD36 adhesion. HDMEC and HLEC express CD36 as well 
as ICAM-1 (after TNF stimulation) making them a useful model for analysis of more 
complex adhesion phenotypes. Other endothelial cell lines are available, including 
transformed brain endothelial cells, HBEC (Tripathi et al., 2006, Tripathi et al., 2007) . 
Similarly to HUVEC, these do not express CD36, and ICAM-1 expression can be 
stimulated by addition of TNF. While a useful model for cerebral malaria, these cells 
are transformed therefore one step further away from a physiologically relevant model.
Most of the work presented in this thesis uses HUVEC and HDMEC, although HLEC 
and HBEC are also used in some experiments.
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1-10 Malaria -  Severe Disease
Malaria is a complicated disease with possible symptoms that range from 
asymptomatic parasitaemia, through mild febrile illness to severe disease that may 
result in death. Clinical symptoms of severe disease include severe malarial anaemia 
(SMA), respiratory complications (including pulmonary oedema), multi-organ failure, 
and the coma of cerebral malaria. Many of the disease symptoms may result from 
general host inflammatory responses to the parasite. As an inflammatory disease 
malaria results in increased levels of many host cytokines, including TNF, IL-1, IL-6, 
and TGF-p. Increased levels of host pyrogens, such as TNF, are thought to be 
responsible for induction of fever in patients, an almost universal symptom of malaria 
that is discussed in more detail below.
Other factors that contribute to severe disease are related to the parasite induced 
changes to the red blood cell. Resulting increased rigidity of RBC may be linked to 
disease severity (Dondorp et at., 1997), as could the ability of PRBC to adhere to 
uninfected RBC, resetting (Rowe et at., 1995). Both phenotypes may contribute to 
microcirculatory dysfunction resulting in complications due to hypoxia. Cytoadherence 
to endothelium, and post-adhesive changes to endothelium are thought to be a major 
contributor to the pathophysiology of disease. We will specifically discuss the example 
of cerebral malaria which has been suggested to result from adhesion of PRBC to 
cerebral microvasculature (Turner et at., 1994, Newbold et at., 1997), and is 
responsible for significant numbers of deaths particularly of children in Africa.
A link between sequestration in the brain and cerebral malaria has been shown; 
examination of post mortem sections of the brain has revealed significant PRBC 
sequestration in cerebral vasculature of patients dying from cerebral malaria compared 
with other types of malaria. Furthermore, this has been linked specifically with ICAM-1 
upregulation and the ability of PRBC isolates to adhere to ICAM-1 (Turner et ai., 1994, 
Newbold et al., 1997). Although there is no evidence for widespread endothelial 
damage even in cerebral malaria, there are often observed small ring haemorrhages 
indicative of some damage resulting in leakage of blood through the endothelial layer. 
The endothelial layer in the brain is a unique layer with tight junctions between 
endothelial cells.
Disruption of the blood brain barrier (BBB) is hypothesised to be responsible for many 
of the symptoms of cerebral malaria, including coma. As illustrated in figure 1.9 
(Medana & Turner, 2006), possible damage to the blood brain barrier could have
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several causes. Some of these are not directly related to cytoadherence, for example 
the release of cytokines by leukocytes stimulated by release of malaria toxins on RBC 
rupture. However, this could be more significant where a large mass of PRBC are 
present in a small area due to sequestration, concentrating the malaria toxins locally. 
Altered blood flow resulting in hypoxia could be contributed to by the increased rigidity 
of PRBC, and PRBC rosetting and clumping. Again, microvascular obstruction due to 
cytoadherence is likely to play an important role. There are also likely to be direct 
effects of cytoadherence playing a role in potential damage to BBB. As discussed 
earlier, cytoadherence has been shown to directly lead to signalling events within
endothelial cells. The consequences of these signalling events could lead to increased
junctional permeability (Fig. 1.9 (Medana & Turner, 2006, Tripathi et al., 2007)).
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Figure 1.9. The blood-brain barrier (BBB) in malaria. (Figure taken from Medana 2006 (Medana & 
Turner, 2006)). The diagram shows a schematic representation of the structures forming the BBB, the 
events occurring during malaria and some of the possible mechanisms that may influence function of the 
BBB during cerebral malaria (CM). The key structural elements of the BBB include cerebral endothelial 
cells (EC), with specialised tight junctional complexes regulating the permeability of the paracellular space. 
Pathological changes to BBB structure, and therefore function, may be broadly divided into ‘distant’ effects 
of severe disease, such as acidosis or hypoxia due to anaemia, and local factors acting in the brain. Both 
may involve cell adhesion-dependent and non-adhesion-dependent pathways. Adhesion to the EC by 
parasitised red blood cells (PRBC), host leukocytes or platelet-fibrin thrombi, the influence of cytokines or 
parasite toxins such as pigment may also cause direct cellular damage. These events may initiate 
signalling within EC that could influence junctional protein expression, and also directly activate 
perivascular and parenchymal effector cells.
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1-11 Antimalarial Treatment
Malaria is a treatable disease, and many anti-malarial drugs are available that kill 
parasites. However, an emerging problem is that of parasite resistance to many 
currently used antimalarials. This is particularly a problem with resistance to 
chloroquine and sulfadoxine-pyrimethamine (SP) mainly seen in SE Asia, however also 
increasingly a problem throughout Africa (WHO). Resistance to chloroquine and SP 
has prompted a move to alternative new treatments, particularly artemisinin based 
combination therapies (ACT). ACTs combine an artemisinin derivative with a partner 
drug. Here, we briefly introduce artemisinin, along with two of the partner drugs, 
lumefantrine and piperaquine. Lumefantrine is used in conjunction with the artemisinin 
derivative artemether, a formulation marketed as “Coartem”. Piperaquine is marketed 
in formulation with dihydroartemisinin as “Artekin”. These are compared with traditional 
quinine, which is used as a first line therapy for severe malaria in many areas.
It is known that all of these treatments are effective on parasites, killing them rapidly, 
although as described there are different stage-specificities of each treatment, as well 
as differences in pharmacodynamic properties. However, little is known about the effect 
of these treatments specifically on cytoadherence. It has been suggested that after 
treatment with antimalarials PRBC can still cytoadhere to endothelium, however this 
has not been shown directly. This question will be addressed in this thesis where, in 
chapter 3, we investigate cytoadherence of PRBC after treatment with these selected 
antimalarials.
Quinine
Like many antimalarial drugs, including commonly used chloroquine, quinine works by 
inhibiting haem metabolism by the parasite. The build up of toxic waste products as a 
result of haemoglobin breakdown is lethal for the parasite. A consequence of this 
mechanism of action is that the drug is only effective against later stages of parasites, 
when haem build up reaches toxic levels.
Artem isinins
Artemisinin is derived from the Chinese wormwood plant (Artemisia annua) and has 
been known about as a cure for fever for centuries. Semi-synthetic derivatives of this; 
artesunate, artemether and dihydroartemisinin are all rapidly acting and effective 
antimalarials; however, the drugs have a short half life. This short half life increases 
potential for recrudescence and increases risk of emergence of resistance so
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artemisinins are used in combination with a longer lasting partner drug, i.e. piperaquine 
or lumefantrine.
Antimalarial activity of artemisinins is dependent on an endoperoxide bridge structure 
and is thought to require the addition of iron or haem. Artemisinin acts rapidly on 
parasites. After a short time lag of 1 -  4 hours the effect on parasite metabolism is 
rapid. A similar delay is seen with other drugs i.e. quinine, however killing activity is 
then slower (ter Kuile et a/., 1993). Artemisinins are known to act on young ring stage 
parasites whereas other treatments, quinine particularly, only acts on mature 
trophozoites (Skinner et al., 1996). Artesunate (art) and artemether are both 
hydrolysed in vivo to dihydroartemisinin, which is an effective treatment in its own right. 
The activity of these three different artemisinin derivatives has been shown to be 
similar (Price et al., 1998).
It has been hypothesised that an advantage of artemisinin based treatments may be 
the prevention of development of ring stage PRBC to cytoadherent trophozoite stages 
(Checkley & Whitty, 2007). This was suggested to potentially play a role in the slight 
advantage of artesunate over quinine that was observed in some groups in a large 
study, the South East Asian quinine artesunate malaria trial (SEAQUAMAT) (Dondorp 
et al., 2005). This is discussed in more detail in chapter 3.
Piperaquine
Piperaquine is a 4-aminoquinoline, like chloroquine. However piperaquine is a 
bisquinoline with two rings, this larger structure is possibly important in reducing 
resistance to piperaquine. One of the proposed resistance mechanisms to chloroquine 
involves a transporter, Plasmodium falciparum chloroquine resistance transporter 
(PfCRT) located in the parasite food vacuole (Bray et al., 2005). The transporter may 
be inhibited by the larger size of the piperaquine molecule. Hence there is limited 
evidence of cross resistance with chloroquine despite the shared mechanism of action. 
A by-product of haemoglobin metabolism by the parasite is the toxic molecule haem, 
which must be rendered harmless by the parasite by conversion to haemozoin crystals 
(malaria pigment). 4-aminoquinoline drugs work by interfering with this haem 
metabolism (Davis et al., 2005).
Lum efantrine
Lumefantrine (previously known as Benflumetol) is in the amino alcohol group of 
antimalarials which includes quinine, mefloquine, and halofantrine. In vitro sensitivity 
assays suggest no cross-resistance with chloroquine however cross resistance is
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possible with mefloquine and halofantrine due to the predicted similar mechanism of 
action. This is based on a shared hydroxyl group near the ring structure which has 
been predicted to be crucial for their antimalarial activity (Basco et at., 1998). The 
antimalarial property is probably a result of interference with haem metabolism. The 
oral availability of both piperaquine and lumefantrine is increased by addition of fat 
(Winstanley & Ward, 2006).
artesunate quinine
lum efantrine
Figure 1.10. Structures of selected antimalarials
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1-12 Fever
Fever is induced in P. falciparum malaria by factors released on schizont rupture. In a 
synchronous population of parasites schizont rupture will occur simultaneously giving 
rise to the classically expected peaks of fever every 48 hours. Fever is thought to be 
caused by the host pyrogen TNF (Kwiatkowski et a!., 1997), production of which is 
induced by the malarial GPI molecule that is released on schizont rupture (Schofield & 
Hackett, 1993).
The classic expected pattern for fever in malaria is peaks of fever induced on schizont 
rupture every 48 hours (WHO). However, in acute infections more commonly observed 
is a more irregular generally raised temperature (Fig. 1.11) (Peters, 1995).
Figure 1.11. Schematic of possible expected patterns of fever in malaria. A) classic expected pattern 
of fever peaks every 48 hours each lasting around 12 hours (WHO) and B) more commonly observed in 
acute infections a general irregular raised temperature (Peters, 1995).
Antipyretic (fever-reducing) treatment is standard adjunct therapy for malaria 
(Winstanley & Ward, 2006), however, studies assessing the effects of antipyretic 
treatment on disease have not shown evidence for an advantage of giving antipyretic 
treatment in terms of parasite clearance time or disease outcome (Meremikwu et a/., 
2000). In one study paracetamol led to a significantly increased time to parasite 
clearance when compared to mechanical antipyresis alone. (Brandts et al., 1997). 
Similar results were seen with other antipyretics metamizol and naproxen, where a 
slight difference in parasite clearance time was observed but this could not be linked to 
any significant difference in fever reduction compared to controls (Lell et al., 2001). 
Furthermore, although anti-TNF therapy has been shown to have a significant effect on 
decreasing fever in cerebral malaria no beneficial effect on disease could be detected 
(Kwiatkowski et al., 1993).
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Some studies have looked at the effect of fever on parasite growth, however almost all 
cytoadherence studies are carried out at 37°C. One published study assessed the 
effect of incubation of PRBC at febrile temperatures on subsequent cytoadherence 
(Udomsangpetch et a/., 2002), but no studies report the effect of endothelial cell 
exposure to febrile temperatures on cytoadherence. There are some studies showing 
effects of febrile temperatures on endothelial cell characteristics that may be relevant to 
cytoadherence. However, it is clear that endothelial cell responses may vary depending 
on cell type and exact conditions used, and it is unclear what the resulting effect on 
cytoadherence may be. In chapter 5 we specifically address the question of how 
endothelial cells may respond to febrile temperatures in terms of the ability of PRBC to 
adhere.
Effect o f fever on Parasites
Febrile temperatures have been shown to affect the intra-erythrocytic growth of P. 
falciparum parasites; growth of parasites is generally reduced on exposure to febrile 
temperatures (~40°C) (Oakley et a/., 2007, Kwiatkowski, 1989). Mature parasites 
(trophozoites in the second half of the 48 hour maturation cycle) appear to be sensitive 
to increased temperature and may be killed by heat exposure. However, the viability of 
young ring stage parasites is not reduced by increased temperature, and the growth 
and development of this stage may even be more rapid at fever range temperatures 
(Long et a!., 2001, Kwiatkowski, 1989, Pavithra et al., 2004). This difference in 
sensitivity to febrile temperatures of different stages may play a role in increasing the 
synchronicity of cultures. Febrile episodes in malaria are classically linked with schizont 
rupture at the end of the 48 hour cycle. The increased resistance of young ring-stage 
parasites, or even enhanced growth of this stage could increase survival of young ring 
stage parasites while reducing viability of remaining mature parasites which could 
result in synchronisation of cultures (Kwiatkowski, 1989, Gravenor & Kwiatkowski, 
1998).
A large microarray study has assessed the effects of febrile temperature on 
expression of parasite genes. Oakley et. al. (Oakley et al., 2007) showed up-regulation 
of a wide array of transcripts after exposure to febrile temperatures (41 °C), including 
families involved in protein stability, i.e. heat shock proteins and other chaperones. 
Ubiquitination of proteins was reduced, correlating with the reduced expression levels 
of ubiquitinating enzymes. The up-regulation of several exported parasite proteins 
potentially involved in parasite sequestration, including var and rif genes was observed. 
This might be due to the fact that preferential increased expression of subtelomeric 
genes was observed -  possibly reflecting increased sensitivity of chromatin structure at
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chromosome ends to the higher temperatures. Several genes involved in chromatin 
structure were upregulated, including PfS/r2.
Effect o f Fever on Cytoadherence
Exposure of parasites to fever range temperatures has been reported to increase 
cytoadherence (Udomsangpetch et al., 2002). Binding normally occurs at mature 
trophozoite-stage, however, exposure to higher temperatures enabled binding slightly 
(around 2 h) earlier than parasites maintained at 37°C. Some increase in binding of 
mature trophozoite stage parasites to receptors at higher temperatures was also seen 
which appeared to correlate with an increased expression of PfEMP-1 on the surface of 
parasites. However, this up-regulation of PfEMP-1 was not seen in a separate study 
(Oakley et al., 2007), where an up-regulation of other var gene transcripts was reported 
and hypothesised to increase chances of parasite sequestration.
Effect o f fever and heat shock on endothelial cells
Different subsets of endothelial cells vary in many ways, including in their adhesion 
receptor expression profile. It is also possible that they differ in their response to febrile 
temperature. While there is a clear effect of febrile temperatures on High Endothelial 
Venule cells, (HEV), the effect on other endothelial cell lines is less apparent. HEV are 
reported to be stimulated by febrile temperatures to increase ICAM-1 expression 
through IL-1. This leads to increased binding and migration of leukocytes (Chen et al., 
2006).
It is possible that cells respond differently to heat shock temperature (>~42°C for short 
periods) as opposed to febrile range temperatures (~38°C -  ~41°C), or “mild heat 
stress”. The responses to different conditions have been described as “distinct but 
partially overlapping processes” (Hasday & Singh, 2000). While the upregulation of 
heat shock proteins through HSF-1 activation (see below) occurs in both cases, there 
are differences. Many of the responses to heat shock, or “severe heat stress” result in 
cell morbidity, whereas responses to “mild heat stress” lead to adaptation of growth 
conditions to enhance survival (table 1) (Park et al., 2005).
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Table 1. Comparison of cellular responses to mild and severe heat stress, (Taken from Park 2001)
Heat shock temperatures (> 42°C) for short periods of time have been suggested to 
increase ICAM-1 levels in the macrovascular endothelial cell line HUVEC (Lefor et al., 
1994). However, a recent study using Human Aortic endothelial cells showed reduced 
stimulation of adhesion molecule expression (E-Selectin and VCAM-1) after TNF 
stimulation following heat shock (42°C for 1 hour). This was shown to be due to 
reduced NF-kB signalling pathway response in cells exposed to the heat shock 
(Nakabe et al., 2007). A separate study (Kohn et al., 2002) also sees reduced ICAM-1 
stimulation in response to TNF after heat shock treatment.
Exposure of endothelial cells to lower, fever-range temperatures (39°C -  41 °C as 
opposed to heat shock temperatures of > 42°C) has been reported to show more 
subtle effects. Expression of various adhesion receptors (including ICAM-1) in HUVEC 
was not increased after 40°C incubation for 12 hours, and cytokine expression was not 
affected (Shah et al., 2002). A slightly altered response to TNF was seen in pulmonary 
artery endothelial cells. A small reduction in adhesion of neutrophils was suggested 
after incubation at 39.5°C compared to 37°C after TNF stimulation, along with a slight 
reduction in barrier function (Hasday et al., 2001). Although no effect on the levels of 
cell surface ICAM-1 has been shown in HUVEC, exposure to febrile temperatures has 
been shown to slightly increase levels of soluble adhesion receptors. The levels of 
soluble ICAM-1, PECAM-1 and E-Selectin were slightly increased after TNF stimulation 
after fever (Gnant et al., 2000).
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Heat Shock Response Pathway
The heat shock response pathway is a stress response activated in mammalian cells in 
response to environmental stresses -  including heat shock (temperature of >42°C) 
(Morimoto, 1998). Environmental stresses result in the activation of production of a 
number of heat shock proteins (HSPs) including HSP70. These HSPs are well 
conserved across species and many family members function as chaperones involved 
in protein folding (Lindquist & Craig, 1988, Hartl, 1996). The transcription factor Heat 
Shock Transcription Factor 1 (HSF-1) is responsible for the increased transcription of 
these HSPs. HSF-1 is thought to be maintained in an inactive state through interactions 
with HSP90. On exposure to heat shock, HSP90 dissociates from HSF-1 allowing 
HSF-1 to trimerise and autophosphorylate into an active DNA-binding form which can 
bind to heat shock elements (HSE) upstream of target genes (i.e. HSPs) (Morimoto, 
1998) (Fig. 1.12 (Powers & Workman, 2007)). Although it was thought that inactive 
HSF-1 was mainly cytoplasmic, it has now been shown that in many mammalian cells 
HSF-1 appears to be predominantly localised to the nucleus even in the absence of 
stress (Mercier et al., 1999). However, on activation HSF-1 appears to redistribute from 
a general nuclear localisation to localise to nuclear stress granules (Jolly et al., 1999, 
Nonaka et al., 2003). Similarly, in our HUVEC endothelial cells HSF-1 appears 
predominantly nuclear localised, with a granular distribution becoming apparent on 
exposure to heat shock.
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Cellular stress
Figure 1.12. Activation and modulation of HSF-1 (Figure taken from Powers 2007 (Powers & 
Workman, 2007)) transcriptional activity (a) Under normal conditions HSF-1 exists as a monomer held in a 
repressed state by an interaction with HSP90 and HSP70. (b) Cellular stress causes an increase in 
denatured proteins (c) which leads to the dissociation of HSP90 and HSP70 from HSF-1. (d) Monomeric 
HSF-1 is then free to trimerize, translocate to the nucleus and (e) undergo a series of post-translational 
phosphorylation events, (f) HSF-1 activates the transcription of a number of HSP genes, including HSP90 
and HSP70. (g) The increased cellular concentration of these chaperones can then inactivate HSF-1 by 
binding to monomeric or trimeric forms of the transcription factor.
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THESIS AIMS
In the introduction we have discussed how some of the changes that the P. falciparum 
parasite makes to the PRBC may result in the cytoadherence of the PRBC to 
endothelium. This is an interaction that is thought to contribute to many of the 
symptoms of severe malaria. We have identified some aspects of the cytoadherence 
interaction where there are gaps in current knowledge, and address the following 
questions:
1) What is the potential for non-viable, antimalarial treated PRBC to retain the 
ability to cytoadhere?
2) How is the rigidity of PRBC affected by antimalarial treatment?
3) What effect does exposure of endothelial cells to fever have on cytoadherence?
4) What is the potential to not only inhibit but to reverse the cytoadherence 
interaction between PRBC and endothelial cells?
The first question we address is what may happen, in terms of ability to cytoadhere, 
after parasites have been killed by antimalarial treatment. It is known that many of the 
deaths from severe malaria occur within the first 24 hours after hospital admission and 
administration of antimalarials (Marsh et a!., 1995). While it has been hypothesised that 
these drug-treated PRBC may still be able to sequester and contribute to disease this 
has not previously been shown in controlled in vitro experiments. In chapter 3 we show 
the ability of PRBC to cytoadhere for many hours following loss of viability after 
antimalarial treatment. This result highlights a potential need for an adjunct therapy to 
reverse the cytoadherence interaction, which we address in chapter 6.
Directly related to that question is the effect of the antimalarial treatment on another 
major consequence of P. falciparum infection of RBCs, the increased rigidity of the 
PRBC. In chapter 4 we ask the question of how the rigidity of PRBC is affected by 
antimalarial treatments. In answering this question we also look into some of the 
factors affecting the increased PRBC rigidity.
After studying cytoadherence interactions at 37°C we consider how fever, a common 
consequence of malaria, may affect cytoadherence. While some studies have looked at 
the effect of fever on parasites there are fewer studies looking at how endothelial cells 
may respond to fever, and how this may affect cytoadherence. Our striking result that 
we present in chapter 5 is that natural host responses may be protective against 
cytoadherence.
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A question following on from results presented in chapter 3 is what is the potential to 
reverse cytoadherence interactions? While many studies have presented work 
inhibiting, or blocking cytoadherence there are few results showing reversal or 
desequestration of already adhered PRBC. We address this question in chapter 6 
where we show the potential for a monoclonal antibody and a recombinant protein to 
reverse cytoadherence.
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CHAPTER 2 - MATERIALS AND METHODS
2-1 PLASM ODIUM  FALCIPARUM  METHODS 
Parasite Strains
Parasite lines used were ItG (Ockenhouse et al., 1992a), A4 (Roberts et al., 1992), 
C24 (Roberts et al., 1992) and JDP8 (Chattopadhyay et al., 2004). All have been 
previously characterized for their adhesion phenotypes to ICAM-1 and CD36 (Gray et 
al., 2003). All parasite lines are subject to antigenic switching and so were used for 
only up to 3 weeks post-selection to minimise the effect of mixed populations. ItG was 
selected on ICAM-1 protein and expression of the expected var gene confirmed by 
cloning and sequencing a DBLa tag from cDNA (see below). A4 was selected for 
binding to the monoclonal antibody BC6 (Horrocks et al., 2002, Smith et al., 1995) 
followed by immunofluorescence analysis of expressed PfEMP-1 and sequencing of 
the expressed var tag. Populations used were ~80% homogeneous for the expected 
vartag.
Parasite Culture
Blood-stage parasites were cultured under standard conditions (Trager & Jensen, 
1976). Parasites were maintained in complete parasite medium which consists of 
HEPES buffered RPMI-1640 medium (Sigma), with the addition of 0.2% Glucose, 2 
mM Glutamine and gentamycin along with 10% human serum. Serum was obtained 
from the Haematology department of the Royal Liverpool University hospital and 
batches pooled from 10 individuals. Cultures were maintained at 2 -  10% parasitaemia 
by dilution on trophozoite days in washed red blood cells along with replacement of 
media. Red blood cells were obtained from the British transfusion service by 
centrifugation of whole type O + blood through Histopaque (Sigma) to remove plasma 
and lymphocytes. Washed red blood cells (WRBC) were resuspended to 50% 
haematocrit (hct) in incomplete parasite medium (as complete medium described 
above with the exception of serum) and stored at 4°C for up to 10 days. Cultures were 
maintained at 1% hct and in a gas mixture of 3% C02, 1% 0 2 maintained by gassing of 
flasks each time they were opened.
Blood smears for determination of parasitaemia
Parasitaemia and growth stage of parasite culture was determined by daily blood 
smears. 300 pi of culture was pelleted by centrifugation in an Eppendorf centrifuge for 
30 seconds and resuspended in around 50 pi final volume. This was placed on a
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microscope slide and a thin smear made using a second slide. The blood smear was 
dried and fixed by 5 sec incubation in 100% methanol, rinsed and air dried then stained 
by incubation for 20 min with 5% Giemsa stain (in Giemsa buffer). The slide was rinsed 
in water and dried before microscopic examination using a 100 X oil immersion 
objective. At least 400 RBC were counted and the number and stage of infected cells 
calculated as a percentage of the total RBC counted.
Cryopreservation of Parasites
Parasites were frozen by resuspending a pellet of washed parasite culture at 3 -  5% 
parasitaemia at ring stage in glycerolyte freezing medium in a ratio of 5 vol freezing 
medium to 3 vol cell pellet. One volume of freezing medium was added and cells 
allowed to stand for 5 min before slow addition of the remaining 4 volumes. The 
solution was gently mixed and transferred to cryovials (0.5 ml per vial) before wrapping 
in tissue and polystyrene containers to allow slow freezing at -80°C overnight before 
transfer to liquid nitrogen for long term storage.
Reconstitution of frozen Parasites
After careful removal of stabilate from liquid nitrogen the solution was allowed to thaw 
rapidly at 37°C. As soon as the stabilate was thawed the 0.5 ml contents were 
transferred to a 15 ml Falcon conical tube and 100 pi 12% NaCI was added. After 5 min 
standing at room temperature 2.5 ml 1.8% NaCI was added over 10 min, followed by 
2.5 ml 0.9% NaCI containing 0.2% glucose. After 10 min standing the mix was 
centrifuged at 1600 rpm in bench top centrifuge for 4 min then washed in incomplete 
parasite medium. The cell pellet was resuspended in 8 ml complete medium, 
transferred to small culture flask and gassed for 30 seconds before transfer to 37°C 
incubator. The following day parasitaemia was assessed and washed red blood cells 
added as appropriate.
Synchronisation of parasites -  Sorbitol Lysis
Parasites were synchronised at ring stage using sorbitol lysis. This method works on 
the basis that sorbitol is taken up through the NPP of mature PRBC causing lysis of the 
cell, however is excluded from and therefore does not affect uninfected RBC or ring 
stage parasites. Parasites were resuspended in sterile 5% sorbitol solution for 15 min 
at 37°C before washing twice in incomplete medium and returned to culture in 
appropriate volume of complete medium. For increased synchronicity this process was 
repeated at a 4 -  6 hour interval. For some experiments two parasite cultures were 
maintained to be at the same stage on alternate days so the sorbitol synchronisation 
process was carried out at the same time on alternate days to the relevant culture. For
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some experiments (notably Lorca) the sorbitol treatment appeared to affect the results 
on subsequent days so synchronisation was not carried out within 3 days prior to 
performing experiments.
Trophozoite Enrichment -  Plasmagel Flotation
One method used to enrich for trophozoite stage parasite was Plasmagel flotation 
which is based on the ability of knob positive PRBC to float on 3% gelatin solution 
(Jensen, 1978). We used Plasmion; a physiological saline solution containing 3% 
gelatin. The parasite pellet was resuspend in a ratio of 2 vol pellet to 3 vol incomplete 
medium and 5 vol Plasmagel, and this mixture transferred to suitable tube (15 ml 
Falcon conical tube for sterile applications or 5 ml FACS tube for non-sterile 
procedures) and allowed to settle for 30 - 45 min. Trophozoite stage PRBC in the top 
layer were carefully transferred to a clean tube then washed three times in incomplete 
medium and parasitaemia assessed by Giemsa stained smear. For most experiments 
the effect of Plasmagel on the RBC was controlled for by exposing uninfected RBC to 
Plasmagel in a similar way, however, the cells were retrieved from the bottom 
Plasmagel layer as no uninfected cells remain in the upper phase.
Trophozoite Enrichment -  Magnetic Enrichment
Since the above method of enrichment is dependent on the presence of knobs on the 
parasites, in some cases a magnetic method was used to enrich for the mature stages 
(Staalsoe et al., 1999). This method is based on the paramagnetic property of mature 
parasites due to the stacking of the iron content of the haemozoin product of 
haemoglobin breakdown (Paul et al., 1981). Parasite culture was resuspended in 15 ml 
of binding solution, (2% BSA 0.2% glucose in PBS) and applied to a CS column 
against a VarioMACS magnet (Miltenyi Biotec) (Miltenyi et al., 1990). The column had 
been pre-washed in the binding solution and was not allowed to dry out at any point 
during the procedure. The column, against the magnet, was then washed with binding 
solution to wash off any unbound cells until the flow through was clear. The column 
was then removed from the magnet and parasites eluted by washing with 15 ml of 
binding solution (away from the magnet). Parasites were washed in incomplete 
medium and the parasitaemia was checked as above. After use the columns were 
washed three times in each of: binding solution; 1% Tween20; distilled water; and 
finally 100% Ethanol. After drying under vacuum the columns were stored for re-use.
Selection on ICAM-1
To increase the homogeneity of the ItG parasite population which expresses a PfEMP- 
1 protein with a high affinity for ICAM-1, the population was subject to selection on
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ICAM-1 protein. ICAM-1 protein (Craig et a/., 1997) (prepared by Tadge Szestak) was 
diluted to 20 pg/ml in sterile dPBS. 1.5 ml was used to coat a sterile 60 mm diameter 
bacteriological petri dish (Falcon #351007) at 37°C in a humid chamber for 2 hours. 
The dish was blocked overnight at 4°C in sterile PBSBSA (dPBS containing 1% BSA). 
ItG Parasites at mid-trophozoite stage were enriched by Plasmagel separation to 60% 
parasitaemia then washed 3 x 10 ml warm incomplete medium, 1 x 10 ml binding buffer 
(RPMI1640 with 5 mM glucose at pH 7.2) then resuspended at 1% haematocrit in 
binding buffer. The blocked ICAM-1 coated dish was warmed to 37°C and block 
solution removed. 1.25 ml parasite mix was added to the dish and incubated at 37°C 
for 30 min with gentle mixing every 10 min. Unbound parasites were removed by 
pipetting and washing with approx 5 x 2 ml of binding buffer (37°C) until few loose cells 
were visible. Bound red blood cells were removed by scraping with a sterile cell scraper 
and returned to culture in fresh warm medium (25 ml) with fresh washed red blood cells 
(200 pi pellet). This was repeated on the same dish 3 times until all parasite culture had 
been used and all bound parasites pooled. After expansion for one week under normal 
culture conditions RNA was isolated from ring stage parasites, expressed var tag was 
checked by cloning from cDNA and sequencing and a large batch of stabilates frozen. 
These were then used for a maximum of three weeks. (Alternatively, a method using 
selection on magnetic beads was used. This was as described below for selection on 
BC6, except that beads were coated with 2.5 pg ICAM-1 protein per 50 pi of protein A 
Dynabeads).
Selection on BC6
BC6 antibody (Horrocks et al., 2002, Smith et al., 1995) (B Pinches, Oxford) was used 
to coat Protein A Dynabeads (Invitrogen #100.01 D). 50 pi of Magnetic beads were 
washed twice in 1 ml of Dulbecco’s PBS (Sigma #D8537) with 1% Bovine serum 
albumin (BSA) (PBSBSA) (Filter sterilised) in a 1.5 ml sterile Eppendorf. Beads were 
resuspended by gentle pipetting in PBSBSA then the Eppendorf placed next to the 
magnet for 10 seconds before careful removal of wash solution. Beads were gently 
resuspended in 380 pi of PBSBSA and 20 pi of BC6 monoclonal antibody was added 
and incubated for 1 hour at room temperature with gentle rotation. Unbound antibody 
was removed by 1 x wash with 1 ml PBSBSA and beads resuspended in 200 pi of 
PBSBSA. A4 parasite culture (50 ml at 10% mid-trophozoite parasitaemia) was 
enriched for trophozoites using Plasmagel flotation to achieve 50% parasitized RBC. 
50 pi pellet was washed 2 x 5 ml of yellow medium, 1 x 5 ml PBSBSA and 
resuspended by adding 150 pi of PBSBSA. Resuspended parasites (200 pi) were 
added to 200 pi of prepared beads and allowed to bind at room temperature for 40 
minutes with gentle rotation. Unbound parasites were removed by placing the
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Eppendorf tube next to the magnet for 10 seconds and careful aspiration of 
supernatant. Beads were gently resuspended in 1 ml of PBSBSA and wash solution 
removed as above. Beads were resuspended in 1 ml of culture medium and transferred 
to culture in 25 ml of medium with addition of 200 pi of washed red blood cells (50%). 
Parasitaemia was checked and adjusted to <2% for normal culture. After 1 week of 
culture, selection was repeated and immunofluorescence analysis used to confirm the 
homogeneity of the resulting culture. Stabilates were made after 1 week expansion and 
used for no more than three weeks of further culture.
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2-2 EXPRESSED VAR TAG ANALYSIS
RNA Isolation and cDNA Preparation
RNA was isolated from approx 10 ml culture at around 5% parasitaemia synchronised 
ring stage parasites (approx 1 2 - 1 8  hours post-invasion) using Trizol (Kyes et al., 
2000). RNA was resuspended in 40 pi diethylpyrocarbonate (DEPC) treated water. Half 
of the RNA prep was treated using DNAse I (Ambion) as instructions and cDNA 
synthesised using Bioline reverse transcription kit. Random hexamers were used as 
primers and synthesis was at 45°C for 1 hour after a 3 minute 96°C denaturation of the 
RNA. As a control a reaction was set up in parallel that did not include the reverse 
transcriptase enzyme.
Var tag PCR
cDNA was used as a template for PCR using primers 2002aAF and alphaBR (Bull et 
al., 2005). PCR amplification was using Qiagen Taq polymerase MgCI2 concentration 
of 1.5 mM, and primers at 4 pM and dNTPs at 0.2 pm (each). A reaction size of 50 pi 
was used for cloning. The PCR was an initial 95°C melt for 2 min followed by 30 cycles 
of 30 sec 95°C melt then annealing step at 45°C for 30 seconds and elongation at 
72°C for 30 seconds. A 10 min final elongation was included. The negative control of 
RNA treated with no reverse transcriptase was also used as a control template. 5 pi of 
each reaction was checked on a 2% agarose gel to ensure no product was seen in the 
no-RT reactions. The remaining 45 pi of the reaction was then run and the ~400 bp 
PCR product was excised from a 1% agarose gel (in Tris-Acetic acid EDTA buffer 
(TAE) Sambrook et al.) and purified using an Amicon column.
Cloning into TOPO
4.5 pi of purified PCR product was added to 0.5 pi of TOPO TA vector (Invitrogen) and 
1 pi salt solution (1.2 M NaCI and 0.06 M MgCI2) (as manufacturer’s recommendations) 
and ligation at room temperature for 5 min. Chemically competent Top10 Escherichia 
coli cells were prepared as Sambrook et. al and aliquots stored at -80°C with the 
addition of 10% glycerol. One 100 pi aliquot of cells was thawed rapidly then placed on 
ice and % the ligation reaction added. Cells were left on ice for 20 min with occasional 
gentle mixing by tapping. Heat shock was at 42°C for 1 min 15 seconds, then cells 
were placed on ice for 2 minutes before addition of 400 pi LB (Luria-Bertani broth 
(Miller) Sigma #L3152). After 45 min at 37°C with shaking the cells were plated onto LB 
agar plates containing ampicillin (50 pg/ml) and X-gal (40 pg/ml) coating to facilitate 
blue-white selection. The following day white colonies were picked into 1 ml LB plus
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ampicillin (50 (jg/ml) for 4-6 hours then grown overnight in 5 ml LB plus ampicillin (50 
pg/ml).
Mini Preps
DNA was prepped from 5 ml overnight cultures using Qiagen mini prep kit as the 
standard manufacturer’s protocol, final resuspension of DNA was in 40 pi of distilled 
water. Alternatively an alkaline lysis method based on Sambrook et. al was used. DNA 
concentration and quality were checked by spectrometry and running a sample on an 
agarose gel.
Restriction Digest Mapping
EcoRI digestion was used to confirm the presence of an insert, then restriction 
mapping of the fragment was carried out by digesting 2 pg of DNA (~5 pi from mini 
prep as above) with EcoRI in double digests with Sspl, Oral and Rsa\. Double digests 
were performed using 0.25 pi EcoRI and 0.5 pi of the second enzyme in appropriate 
buffer for 2 -  4 h at 37°C. The enzymes were chosen based on a high frequency of 
cutting in P. falciparum genome but few sites in the TOPO vector (table 2.1)
Enzyme Buffer Sequence Pf. Freq TOPOpCR2.1 Fragment Size
Sspl EcoRI AATATT 304 None 3900*
Oral 4 TTTAAA 394 3 19; 692; 3189
Rsa\ 1 GTAC 206 3 684; 1511; 1705
Table 2.1 Restriction Digests for analysis of expressed var tag. Pf. Freq is the frequency of sites (if 
they were evenly distributed) in bp. Cuts in the TOPOpCR2.1 vector and fragment sizes are based on the 
vector backbone.
Patterns were analysed by running digests on a 2% agarose gel. The expected pattern 
of the vector backbone served as a control for complete digestion. Analysis of 
published var tag sequences from A4 and 3D7 strains available in the EBI database 
using NEB digest tool suggest that the enzymes used should not result in identical 
restriction patterns for any different var gene tags so far published (although clearly this 
method would not detect point mutations or smaller changes within var tags unless 
occurring in an enzyme site). Also given the variation in var tags it is probable that 
similar restriction patterns could emerge from unrelated var tags from different isolates. 
Selected clones were sent for sequencing by the LSTM sequencing service in forward 
and reverse directions using M13 forward and reverse primers. Freely available
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software Chromas lite and packages from EBI (www.ebi.ac.uk) were used to analyse 
sequences.
BC6 Immunofluorescence for microscopy
Trophozoite stage A4 parasites (approx 5 pi pellet) were washed once with 5 ml serum- 
free culture medium, followed by washing with 1 ml Dulbecco’s PBS with 1% BSA 
(PBSBSA) and resuspended in 50 pi of BC6 antibody diluted 1:25 in PBSBSA. These 
were incubated at room temperature for 1 hour, then washed 2 x 0.5 ml PBSBSA. The 
pellet was resuspended in 50 pi of rabbit anti-mouse antibody (Abeam) diluted 1:50 in 
PBSBSA. After 40 min incubation at RT cells washed 2 x 0.5 ml in PBSBSA and 
resuspended in 50 pi of Alexa 488 goat anti-rabbit antibody (Invitrogen) diluted 1:1000. 
This was incubated at room temperature for 40 minutes then washed 1 x 0.5 ml 
PBSBSA. For IFA parasites were stained with 10 pg/ml Ethidium Bromide (EtBr) for 5 
min at RT before washing. Parasites were wet mounted on a slide under a cover-slip, 
sealed with nail varnish and visualised immediately using Confocal microscopy.
BC6 Immunofluorescence for Flow Cytometry Analysis
A 10 pi pellet of trophozoite stage parasites at 3-10% parasitaemia was washed in 
serum-free culture medium and resuspended in 100 pi of BC6 antibody diluted 1:50 in 
PBSBSA. This was incubated at 37°C for 30 min, washed 3 x 1  ml in PBSBSA and 
resuspended in 100 pi secondary rabbit anti-mouse antibody diluted 1:100 in PBSBSA. 
After 30 minutes at 37°C the cells were washed as above then resuspended in 100 pi 
goat anti-mouse alexa 488 conjugated antibody at 1:2500 dilution in PBSBSA 
containing 1 pg/ml ethidium bromide. The cell pellet was washed 3 x 1 ml PBS after 30 
minutes incubation at 37°C and resuspended in 100 pi PBS. 25 pi was diluted into 1 ml 
PBS for FACS analysis (Williams & Newbold, 2003) using Beckman Coulter XL flow 
cytometer.
57
2-3 ENDOTHELIAL CELL METHODS
Endothelial Cell Culture
HUVEC and HDMEC were obtained from Promocell and cultured as per 
manufacturer’s instructions. Cells between passage 3 and 6 were used for 
experiments. Before assays cells were generally stimulated by the addition of 1 ng/ml 
TNF for 18-20 hours. This was shown by immunofluorescence and FACS using anti 
ICAM-1 monoclonal antibody 15.2 (Serotec), to induce the surface expression of ICAM- 
1.
Endothelial Cell Immunofluorescence staining for ICAM-1 expression analysis by 
FACS
One confluent well of a 6 well plate was washed 2 x Dulbecco’s PBS and trypsinised by 
addition of 0.5 ml trypsin/EDTA solution (Promocell). After cells were observed to have 
rounded up and detached trypsinisation was stopped by addition of 0.5 ml trypsin 
neutralisation solution (TNS) (Promocell). After careful mixing the cells were split to two 
Eppendorfs and pelleted by centrifugation at 3500 rpm in an Eppendorf centrifuge for 5 
min. Cells were washed 2 x in Dulbecco’s PBS with 1% BSA (PBSBSA) then 
resuspended in 50 pi PBSBSA with primary ICAM-1 monoclonal Ab 15.2 (Serotec) 1:50 
dilution, or negative control with no primary antibody. Cells were incubated at 37°C for 
45 min then washed 3 x in PBSBSA and incubated for 45 min at 37°C with secondary 
antibody FITC conjugated goat anti-mouse (Sigma) 1:100 dilution in PBSBSA. 
Alternatively a FITC-conjugated version of the same anti-human ICAM-1 monoclonal 
antibody 15.2 (Sigma) was used at 1:50 dilution along with the FITC-conjugated 
matched isotype control (Sigma). (No difference was seen between the two labelling 
techniques). After staining cells were washed 3 x in PBSBSA and resuspended in 250 
pi 4% paraformaldehyde in PBS pH 7.2. Fixed cells were stored at 4°C and washed 3 x 
in PBS by centrifuging at 5000 rpm 5 min and resuspension in 500 pi PBS for FACS 
analysis. An example of ICAM-1 expression in shown in figure 2.1.
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Figure 2.1. ICAM-1 expression on endothelial cells. Characterisation of ICAM-1 expression after 16 h 
stimulation with 1 ng/ml TNF. Staining as described above on HUVEC (left) and HDMEC (right). Negative 
controls shown (black open line) are with TNF stimulation and secondary antibody but no primary antibody 
(+TNF -Ab). Other negative controls (no primary antibody and no TNF) gave the same result as + TNF - 
Ab. ICAM-1 levels shown without TNF stimulation (open green line) and with TNF stimulation (grey solid)
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2-4 ADHESION ASSAYS
Static Protein Assay
Static protein binding assays were carried out as previously described. ICAM-1-Fc 
(Craig et al., 1997) (Prepared by Tadge Szestak, LSTM) was diluted to 50 pg/ml and 
25 pg/ml in PBS and 2 pi spots were placed around a defined diameter of a sterile 60 
mm diameter bacteriological Petri dish (Falcon 351007). CD36 protein (R&D) was 
spotted at 25 pg/ml, and a negative control PBS spot included. Triplicate spots per dish 
were prepared, and usually two or three dishes prepared per parasite line/experimental 
condition. Dishes were incubated in a humidified chamber for 2 h at 37°C. Protein 
spots were aspirated off and dishes blocked overnight at 4°C in 1% BSA in PBS. After 
overnight incubation blocking solution was removed and the dish washed in warm 
binding buffer (37°C). Parasites were prepared after appropriate treatment and washed 
1 x 5 ml in binding buffer then resuspended in warm binding buffer to 1% Hct and 3% 
parasitaemia. 1.25 ml of parasite suspension was added to each dish. Dishes were 
incubated at 37°C for 1 h, with re-suspension by gentle rotation for approx 30 seconds 
every 10 min. Unbound RBC were removed by approx 10 x 2 ml washes with binding 
buffer and bound cells fixed with 1% glutaraldehyde for at least 1h. Dishes were 
stained with 5% Giemsa stain for 20 min, washed 2 x 4 ml in water and levels of 
adhesion were quantitated microscopically. Six independent fields per spot were 
counted at 200 x magnification, and calculated to the mean binding per mm2. The 
mean of the three spots per dish for each protein was calculated.
Flow Protein Assays
Microslides were pre-prepared by coating with amino-propyl-tri-ethoxy-silane (APES) 
following nitric acid treatment to allow for protein/cell adherence, then autoclaved. 
Before the experiment a small piece (1.5 cm) of thin wall rubber tubing was attached to 
one end of the microslide, marked to indicate orientation of the coated surface, and 
slides were autoclaved. Slides were then coated with ICAM-1 at 50 pg/ml or 25 pg/ml 
by drawing up 65 pi of solution using a pipette tip connected to the tubing. Protein was 
allowed to adhere to the microslide by incubation in a humid 37°C chamber for 2 hours 
then washed by drawing through 4 x 65 pi of PBS with 1% BSA (PBSBSA). Slides were 
blocked in PBSBSA overnight at 4°C. Parasites were prepared as for static protein 
assay and everything warmed to 37°C before use. The microslide was connected to 
flow apparatus and binding buffer (37°C) flowed through for at least 2 min before the 
experiment started. Prepared parasites were flowed through at pump speed of 0.186 
ml/min to give an appropriate shear stress of 0.05 pascal Pa (Cooke et al., 2002). To
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ensure comparable experiments timings were strictly adhered to. Parasites were 
flowed through for 2 min then image capture was started. 80 images at 1 sec intervals 
were obtained at 10 x magnification over 6 areas of slide. Immediately following this 80 
images were obtained in the same way at 20 x magnification. Parasite flow was 
swapped to binding buffer flow to wash for 2 minutes before counting bound parasites 
over 6 areas of slide. When rolling images were not captured parasite flow culture was 
initiated using a syringe, then flow at the correct rate was timed for 5 min. The slide 
was washed for 2 min with binding buffer to clear the lines and slide of unbound RBC 
before counting stationary adhered parasites. To enable re-use of the slide parasites 
were removed by washing the slide through 2 x 2 ml with water then 2 x 2 ml binding 
buffer. To ensure this had no effect on binding, a positive control was carried out as the 
last run on a slide in each experiment. Slides were not re-used more than 6 times.
Static Cell Assays
Endothelial cells cultured as above were seeded onto 13 mm coverslips coated in 1% 
gelatin in 24 well plates. One confluent T25 flask was trypsinised and used to coat 12 -  
24 coverslips. After leaving overnight for cells to adhere the medium was changed and 
cells cultured until confluent ( 2 - 5  days). Cells were induced with 1 ng/ml TNF for 20 
hours and washed 1 x in culture medium before an assay. Parasites were prepared as 
above to 1% hct and 3% parasitaemia in binding buffer. 0.5 ml of parasite mix was 
applied to each well and incubated at 37°C for 1 hour with gentle resuspension by 
rotating every 10 min. Unbound cells were removed by washing by 2 x 2 sec dips in 
binding buffer followed by 2 x 30 min gravity washes in binding buffer. Bound cells 
were then fixed by incubation in 1% glutaraldehyde in PBS for at least 1 hour. After 
staining with Giemsa for 30 min coverslips were washed in water, air dried and 
mounted using DPX hard set mounting medium. 6 - 1 0  areas of each slide were 
counted under 200 X magnification for the number of bound parasites.
Flow Cell Assays -  Using Microslides
Microslides were prepared as for protein assays then coated with collagen/1% gelatin 
for 45 minutes at 37°C. One confluent T25 flask of endothelial cells was trypsinised and 
was sufficient for 6 microslides. Slides were washed extensively after collagen/gelatin 
coating by aspirating through PBS, and left to dry. Trypsinised cells were resuspended 
in 400 pi of culture medium with the addition of 25 pg/ml gentamicin, and approx 65 pi 
sucked into each microslide ensuring no air bubbles. Cells were allowed to settle for 2 
hours at 37°C then slides connected to a flow system to allow media exchange every 
hour. After overnight growth, TNF (1 ng/ml) was added to confluent cells for 20 hours 
before the assay. Assay conditions were as for the protein flow assay except that slides
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were not re-used, and extra care was taken to ensure no entry of air bubbles into the 
system. See figure 2.3 for schematic of growth and assay conditions.
Flow Cell Assays - Using Chamber Slides
Chamber slides (Permanox Lab-teK chamber slides Nunc #177410) were coated with 
gelatin for 30 min at 37°C. One confluent T25 flask of endothelial cells was trypsinised 
and used to seed 3 (for next day assay) or 6 (For 2-4 days growth before assay) 
chamber flasks. 2.5 ml trypsinised cells were added per flask. After settling overnight 
the medium was changed and cells cultured until confluent. Cells were generally 
stimulated using 1 ng/ml TNF overnight before assays. For assays the medium was 
aspirated off and the chamber removed from the chamber slide flask using the special 
tool. The slide was immediately placed cell side down on the gasket of an 
immunogenetics flow chamber. Vacuum was applied to the chamber to seal the slide 
then flow connected. Buffer was flowed through at a rate of 0.24 ml/min to give a shear 
stress of 0.05 Pa. See figure 2.4 for schematic, and table 2.2 and figure 2.5 for 
comparison of flow assays using microslides or chamber slides.
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Growth and adhesion assay under flow conditions using microslides
Buffer
Chamber
Figure 2.3. Schematic of growth and adhesion under flow conditions using microslides. Cells are 
seeded onto microslides and allowed to adhere for 2 h before connection to the media exchange system. 
Slides are placed in 50 ml medium in an adapted glass petri dish (inset picture), each slide is attached 
using rubber tubing to an outlet connected via tubing to a pump. The pump is on a timer which is active 
every hour to remove enough medium to exchange medium within each microslide. After overnight growth 
TNF can be added as required to the dish. The microslide is placed under a microscope to allow for 
visualisation, imaging and counting of assays. The syringe pump can be set to suitable speed to allow flow 
at appropriate shear stress levels. During the assay the flow can be switched from the parasite or the 
medium reservoirs.
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Growth and assay under flow conditions using chamber slides
Buffer
Chamber
Parasite Chamber
Flow Direction
ChamberSlide
Cells ■
__________________1
Removable Slide is suface for cell growth
ConnectingTubing
Cell coated slide detached 
from chamber upside down 
on gasket
Figure 2.4. Schematic of growth and adhesion assays using chamber slides. Chamber slides act as 
normal tissue culture flasks for cell growth. Once cells have reached confluency and have been stimulated 
for assay the chamber part can be removed by levering away from the slide. This leaves the cells on a flat 
slide which can then be placed cell side down on the Immunetics chamber. A vacuum is applied which 
seals the slide to the gaskets on the chamber then flow can be applied using the syringe pump set to an 
appropriate speed to give desired shear stress levels. During the assay the flow can be switched from the 
parasite or the medium reservoirs.
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Comparison of Flow Binding assays using microslides or flow chamber system
Microslides Flow Chamber
Preparation of slides using acid and APES 
treatment followed by autoclaving required
No pre-treatment of slides required
Slides Cheap to buy Slides relatively expensive to buy
One T25 flask of cells sufficient for 6 slides to be 
confluent the following day
One T25 flask of cells sufficient for 2-3 slides to be 
confluent the following day
Cells will not grow in microslides Cells will grow on flow chamber slides
Need adapted incubator with media exchange 
pump to grow
Can be grown in standard C02 incubator
Flow system attached to microscope required Flow system attached to microscope required as 
well as special flow chamber (immunetics) and 
vacuum pump
Increased risk of infection during culturing due to 
media exchange system
No increased risk of infection during culturing over 
standard culturing
Large volume of medium (>50 ml for 6 slides) 
required
Smaller volume of medium (2.5 ml per slide) 
required
Table 2.2 Comparison of flow assay types.
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Figure 2.5. Adhesion of ItG PRBC under flow conditions to stimulated HUVEC and HDMEC. Results 
show mean + SD bound PRBC per mm2, N=12 for microslides and N=3 for flow chamber for HUVEC. 
HDMEC N=8 microslides and N=2 flow chamber).
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CHAPTER 3 - CYTOADHERENCE OF P. FALCIPARUM  AFTER ANTIMALARIAL 
TREATMENT
3-1 INTRODUCTION
An important aspect of the pathogenesis of severe malaria results from the ability of 
infected red blood cells to sequester in the microvasculature (as described in detail in 
chapter 1). Post-mortem studies of severe malaria show high levels of infected red 
blood cells (PRBC) bound to microvasculature (Taylor et al., 2004, Turner, 1997). The 
involvement of sequestration in pathogenesis could be directly a result of blocking of 
the blood vessels, and/or downstream effects caused by the interaction between PRBC 
and the endothelium, including local inflammatory responses (Chakravorty et al., 
2008).
Cytoadherence is mediated by a parasite protein PfEMP-1 which is a large protein 
comprising several external Duffy-binding-like (DBL) domains, encoded for by var 
genes. P. falciparum has around 60 var genes per genome, of which only one is 
expressed at a time. This process of antigenic variation is a way in which the parasite 
evades recognition by host adaptive antibody immune responses and the large number 
of variants of PfEMP-1 also results in the potential to bind to many different host 
receptors (Kyes et al., 2007b).
ICAM-1 is a host receptor of interest as it is linked to cerebral malaria (Chakravorty & 
Craig, 2005). Patients suffering with cerebral malaria have up-regulated levels of 
ICAM-1 in the brain and parasite isolates from patients suffering from cerebral malaria 
show higher binding to ICAM-1 protein (Turner et al., 1994, Newbold et al., 1997).
It is known that cytoadherence of PRBC induces signalling events in endothelial cells 
(Tripathi et al., 2006, Jenkins et al., 2007a). Some of these signalling responses may 
help protect the host endothelium against damage, as suggested by the down- 
regulation of apoptotic genes in endothelial cells (Chakravorty et al., 2007). However, 
other effects may be damaging. For example, the induction of ICAM-1 expression on 
endothelial cells occurs in response to PRBC (Chakravorty et al., 2007), which could 
lead to further sequestration of PRBC, as well as local leukocyte recruitment, 
amplifying pathology caused by adhesion or local inflammatory responses. There is 
also evidence of induction of apoptosis and leakage in endothelial cells following 
adhesion of PRBC (Medana & Turner, 2007).
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Antimalarial treatments are effective at killing parasites where resistance has not 
developed; however, there is still a high mortality rate associated with severe malaria 
with most deaths occurring in the first 24 h after hospital admission (Marsh et a/., 
1995). It is clear that even after initiation of antimalarial treatment, patients continue to 
show worrying clinical signs (Marsh et al., 1995). It has been suggested that PRBC 
after antimalarial treatment may still continue to cytoadhere -  as observed in cerebral 
ultrastructural studies (Pongponratn et al., 2003). Furthermore a potential mechanism 
for the difference in effectiveness of artesunate versus quinine was suggested to be 
potentially due to activity in preventing sequestration (Dondorp et al., 2005).
It has not previously been shown using in-vitro assays to known receptors what ability 
antimalarial-treated PRBC have to cytoadhere. In this study we investigate the 
hypothesis that non-viable parasites killed by standard antimalarial treatment could 
contribute to disease pathology by their continued ability to cytoadhere. We have 
performed in vitro assays for cytoadherence with drug-treated P. falciparum PRBC to 
ICAM-1 and human endothelium under both static and flow conditions. Using a range 
of antimalarials we show that non-viable P. falciparum PRBC retain the ability to 
cytoadhere at least 24 h after drug administration as a result of the slow rate of 
degradation of the surface protein PfEMP-1.
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3-2 MATERIALS AND METHODS
Parasites
The isogenic parasite isolates ItG and A4 were used as described in methods chapter 
2. Parasites were synchronised at ring stage using sorbitol lysis as described in 
methods chapter 2, and to allow for stage-matched controls for 24 hour drug treatment 
time points parallel cultures were maintained 24 hours apart.
Endothelial Cells
Endothelial cell lines HUVEC and HDMEC were used as described in methods chapter 
2. All assays were performed on confluent monolayers of cells.
Adhesion Assays
Adhesion assays to ICAM-1 protein and to endothelial cells under static conditions 
were performed as described in methods chapter 2. Flow adhesion assays were all 
performed using the microslide system as described in methods chapter 2.
Measurement of PfEMP-1 levels of the surface of P. falciparum  A4 PRBC
PfEMP-1 on the surface of live A4 PRBC was visualised by immunofluorescence using 
BC6 monoclonal primary antibody (1:50 dilution) which specifically recognises an 
exposed epitope of the A4var41 PfEMP-1 (Horrocks et al., 2002). This was followed by 
a secondary rabbit anti-mouse antibody (Serotec) (1:100) followed by Alexa488 
conjugated goat anti-rabbit antibody (Invitrogen) (1:5000). All washes and antibody 
dilutions were in Dulbecco’s PBS with 1% BSA and each incubation was at 37°C for 30 
min. Infected cells were stained with ethidium bromide (1 pg/ml), mounted on a 
microscope slide and analysed by confocal microscopy using Zeiss LSMPascal 
microscope and Zeiss Pascal and Photoshop software (Adobe). For flow cytometry 
analysis staining was carried out as above then infected cells were diluted in PBS and 
500,000 events (red blood cells) acquired on Beckman Coulter FACS XL, gated using 
forward scatter and side scatter to acquire red blood cell populations excluding debris 
and then FL-1 and FL-2 fluorescence intensity measured. Analysis was performed 
using WinMDi software. Region R1 was created for A4var41 positive cells based on 
negative antibody controls. The mean fluorescence intensity (MFI) of region R1 was 
used to quantitate the level of PfEMP-1 on A4var41 positive infected red blood cells. 
The percentage of A4 PRBC that were classed as A4var41 positive remained at ~75- 
85% throughout experiments and was unchanged within an experiment before/after 24 
h artesunate treatment.
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Drug Treatment
The effect of parasite viability on cytoadherence was tested using artesunate, quinine, 
lumefantrine and piperaquine. Final drug concentrations were chosen based on 
published peak plasma levels. These were: 500 nM for artesunate, (Newton et al., 
2006, Simpson et at., 2006), 25 pM for quinine (Akoachere et at., 2005, Le Jouan et a/., 
2005), 15 pM for lumefantrine (McGready et at., 2006, Ashley et al., 2007), and 100 nM 
for piperaquine (Akoachere et al., 2005, Davis et al., 2005). The concentrations of 
drugs used were well above the IC50 determined for each and were confirmed to inhibit 
parasite development as assessed by Giemsa staining. Parasites were confirmed non- 
viable after treatment by continued culture for at least 72 h post-treatment with no 
growth.
IC50 Growth Inhibition Assays
Growth inhibition (IC50) assays were performed on ItG parasites using a standard 
fluorometric assay (Bennett et al., 2004, Smilkstein et al., 2004). A 10 mM stock 
concentration of drug was prepared and 1:3 serial dilution series made (400 pi + 800 
pi) starting at 2000 nM. Drug dilutions were then plated out 50 pi per well in triplicate 
over a 96 well plate including controls with no drug, and control with high concentration 
artemether (1 mM). To each well 50 pi of parasite suspension at 2% rings and 2% Hct 
in normal culture medium was added resulting in a standard final drug dilution series 
ranging from 1000 nM to 0.45 nM. This range was adjusted according to the drug. 
Parasites were incubated under standard culture conditions for 48 hours. Sybr green 
lysis mix consisted of lysis buffer (20 mM Tris.Cl pH 7.5, 5 mM EDTA, 0.008% Saponin 
and 0.08% Triton X-100), with the addition of 0.2 pi Sybr green per 1 ml lysis buffer. 
After 48 hours incubation, 100 pi of Lysis buffer/Sybr green solution was added per well 
and incubated in the dark for 1 hour. Following this incubation the plate was read at 
484 nm excitation 530 nm emission. Percentage growth for each drug concentration 
compared to positive control was calculated, and the IC50 determined using Grafit 
software.
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3-3 RESULTS
Artesunate treatment of ItG
We first assessed the effect of artesunate treatment on parasite development. Unless 
otherwise stated throughout this chapter the P. falciparum isolate ItG was used. 
Addition of 500 nM artesunate to a culture of mid-trophozoite-stage ItG PRBC resulted 
in a rapid growth inhibition of the parasite. The concentration of 500 nM was chosen 
based on published peak plasma concentrations, and is well above the published IC50, 
and the IC50 we determined for ItG (See table 3.1 below) As determined by Giemsa 
staining, parasite growth stopped after 2-4 hours incubation in 500 nM artesunate (Fig. 
3.1) and parasites were not viable for long term culture. Similar results were seen when 
the artesunate was washed out (3 x 10 ml washes) after time periods of 30 min or 
greater. However, when artesunate (500 nM) was washed out after 10 min or less 
incubation time, parasite growth was unaffected.
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Figure 3.1. Giemsa stained smears of ItG over time course of artesunate incubation. (One 
experiment, representative of many independent observations)
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Addition of artesunate to late-stage trophozoites resulted in some lysis of parasites, 
noticeable 24h after addition of drug by the presence of some “free” parasites visible in 
Giemsa stained smears. However, when artesunate was added to younger 
trophozoites there was little observable lysis, and no apparent lysis on addition of drug 
to ring-stage parasites (Fig. 3.2).
7 0
flj
Q .
O
\o
24 h 38 h 42 h
Figure 3.2. Lysis of ItG PRBC after 24h artesunate treatment after addition of drug to parasites at 24, 
38 or 42 hours post-invasion representing young and mature trophozoites, and schizont stages. All 
parasites either free or intraerythrocytic were counted in Giemsa smears and percentage of free or 
intraerythrocytic (but dead) parasites were plotted. (Compiled from two experiments; representative of 
several independent observations).
Cytoadherence of artesunate treated P. falciparum  ItG PRBC to ICAM-1 under 
flow conditions
The effect of artesunate treatment on the ability of PRBC to cytoadhere was first tested 
using flow adhesion assays to ICAM-1. As described in the methods section we used 
ICAM-1 coated microslides and parasite flow at a wall shear stress of 0.05 Pa, as 
widely used to mimic microvascular shear stress (Gray et al., 2003, Cooke et al., 2002) 
(See also materials and methods chapter 2). Mid-trophozoite-stage parasites (24 -  28 
hours post invasion) were treated with 500 nM artesunate in standard culture 
conditions for 24 h. Giemsa stained smears were made at time points after drug 
addiction (Fig. 3.3a) and parasitaemia was adjusted to 3% for ICAM-1 adhesion assays 
under flow conditions. No significant difference in binding was observed for parasites 
exposed to artesunate for 4 h compared to untreated parasites (Fig. 3.3a). Following 8 
h exposure, a slight reduction in binding was seen and following 24 h artesunate 
treatment adhesion to ICAM-1 was reduced to ~30% of control levels (P <0.01, Fig. 
3.3b). Similar binding phenotypes were observed for artesunate concentrations 
ranging from 20 nM to 12.5 pM (Fig. 3.3b). As described above, a 30 minute exposure 
to 500 nM artesunate was sufficient to render parasites non-viable. The adhesion 
phenotype of parasite exposed to artesunate for 30 min to 24 h was assessed. As 
before, 500 nM artesunate was added to mid-trophozoite-stage parasites. Drug was 
washed out after 30 min to 24 h exposure time, and adhesion assayed 24 h after initial 
drug addition. Similar adhesion phenotypes were observed 24 h after initial addition of 
artesunate when it was washed out at various time points of 30 min or longer (Fig. 
3.3c).
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Figure 3.3. Adhesion of artesunate treated PRBC to ICAM-1 under flow conditions. A) Giemsa 
stained smears of PRBC after 0, 4 8, and 24 h 500 nM Art treatment and B) adhesion level to ICAM-1 
protein under flow conditions. C) Adhesion to ICAM-1 under flow after 6h or 24h treatment with a range of 
artesunate concentrations. D) Adhesion to ICAM-1 under flow 24 h after addition of 500 nM artesunate 
then subsequent washing out of drug after 30 min to 24 h. Time points < 30 min had reinvaded to ring 
stage parasites by 24 h following drug addition. * P<0.05 and **P<0.01 as determined by T test compared 
to untreated control.
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Cytoadherence of artesunate treated ItG PRBC to human endothelial cells
Having seen the effect of artesunate treatment on adhesion of PRBC to ICAM-1 
protein, we wanted to confirm whether the same phenotype was observed measuring 
the adhesion to endothelial cells. Adhesion of PRBC to human endothelial cells 
(HUVEC and HDMEC) was assessed under both static and flow conditions following 4, 
8 and 24 h artesunate (500 nM) treatment of trophozoite (24 h post invasion) stage 
parasites.
As described in the Methods section, binding assays were performed with confluent 
monolayers of TNF (1 ng/ml, 18 h) activated endothelial cells. Under these conditions 
HUVEC express the receptor ICAM-1, whereas HDMEC express both CD36 and 
ICAM-1.
Under static conditions, there was no significant difference in the level of binding to 
either HUVEC or HDMEC of PRBC incubated for 4 h with artesunate (500 nM) 
compared to the untreated controls to (Fig. 3.4a,b). Following 8 h exposure, a slight 
reduction in binding was seen and following 24 h artesunate treatment adhesion to 
both HUVEC (P<0.01) and HDMEC (P<0.05) was reduced to ~30% of control levels 
(Fig. 3.4a, b).
Essentially the same binding phenotypes were observed for adhesion measured under 
flow, with up to 8 h exposure to artesunate (500 nM) not significantly affecting adhesion 
to both HUVEC or HDMEC, whilst 24 h exposure to artesunate (500 nM) did reduce the 
levels of binding to both cell types to 25-30% of control levels (Fig. 3.4c,d).
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Figure 3.4. Adhesion of ItG to endothelial cells in static and flow adhesion assays. A) HUVEC static 
B) HDMEC static C) HUVEC Flow D) HDMEC flow. All results are the mean ± SD of three independent 
triplicate experiments. Statistical significance compared to control levels of adhesion (C, untreated 
trophozoites) are indicated * P<0.05, ** P<0.01 as measured by two-tailed independent T test.
Cytoadherence of A4 and CS2 isolates
Similar results to those seen for ItG adhesion after artesunate treatment were also 
seen with two other parasite isolates. A4, like ItG, binds to both ICAM-1 and CD36 but 
generally at lower levels than ItG (Gray et al., 2003). The adhesion of A4 to ICAM-1 
protein under flow and to HDMEC under static conditions was assessed. No significant 
reduction in adhesion was seen after 8 h treatment of trophozoite-stage parasites with 
artesunate (500 nM); however, after 24 hours treatment adhesion was reduced to 25- 
30% of controls (Fig. 3.5a,b). Additionally the CSA binding strain CS2 (Cooke et al., 
1996) was assayed for cytoadherence to CSA protein under flow conditions. No 
reduction in adhesion was seen after 8 h treatment and significant adhesion at around 
25% positive control levels was observed after 24 h treatment (Fig. 3.5c).
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Figure 3.5. Adhesion of A4 and CS2 PRBC. A) Adhesion of A4 PRBC to ICAM-1 under flow conditions 
and B) adhesion of A4 to HDMEC under static conditions. C) Adhesion of CS2 PRBC to chondroitin 
sulphate A (CSA) under flow conditions.
PfEMP-1 distribution on the surface of drug treated P. falciparum  PRBC 
visualised using confocal microscopy
To determine whether the continued ability of non-viable parasites to adhere is due to 
the persistence of the PfEMP-1 complex on the infected erythrocyte membrane the 
distribution of PfEMP-1 on the surface of the A4 PRBC was measured. We used the 
monoclonal antibody mAb BC6 which is specific for the a surface epitope of the 
PfEMP-1 A4var41 variant (Roberts et al., 1992), and used unfixed (i.e. non- 
permeabilised) cells and laser scanning confocal microscopy to observe the A4 PRBC 
surface. The characteristic punctate distribution of PfEMP-1 on the outer erythrocytic 
membrane was observed (Fig. 3.6). Membrane permeant ethidium bromide was used 
to label infected red blood cells, and no BC6 labelling of uninfected cells was observed. 
Similarly, the specificity of the BC6 antibody for the A4var41 PfEMP-1 was such that 
other strains, i.e. ItG, showed no positive labelling (result not shown -  see also flow 
cytometry data below). Qualitatively, the distribution of PfEMP-1 was not observably 
different in A4 PRBC treated for up to 24 h with 500 nM artesunate (Fig. 3.6).
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Figure 3.6. Confocal fluorescence microscopy of PfEMP-1 distribution on the surface of A4 PRBC
after 4 and 24 h artesunate treatment. Panels i and ii show PfEMP-1 labelled with BC6 antibody and 
alexa488 conjugated secondary antibody, top (i) and centre (ii) plane of z-stack sections. Panel Iil shows 
ethidium bromide labelling of parasites, and iv) shows bright field (phase) images. Scale bar (2 pM) shown 
on respective phase images.
Quantitation of PfEMP-1 on the PRBC Surface by Flow Cytometry
PRBC were labelled using immunofluorescence for PfEMP-1 using the BC6 
monoclonal antibody as above and an alexa488 coupled secondary antibody 
detectable using flow cytometry in the FL1 channel. The PRBC could be identified from 
uninfected RBC using ethidium bromide in the FL2 channel. We confirmed that 75-85% 
of A4 PRBC used in these experiments expressed detectable levels of A4var41 
PfEMP-1 (Fig. 3.7). The specificity of the BC6 antibody for the A4var41 PfEMP-1 was 
confirmed as there was no staining visible on uninfected RBC, or the antigenically 
distinct ItG isolate (Fig 3.7).
Following treatment with artesunate (500 nM, 24 h), the mean fluorescence of PfEMP-1 
surface positive PRBC was reduced to approximately 65% the level of untreated cells 
(P < 0.01, n=3, Fig. 3.8). This is based on the geometic mean of those cells falling the 
upper right quadrant as illustrated in figure 3.7. During an experiment there was no
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change in the percentage of PRBC that expressed PfEMP-1 (i.e. as illustrated in figure 
3.7, the number of cells falling in the upper right quadrant (Ethidium bromide positive 
and PfEMP-1 positive) compared with upper left (Ethidium bromide positive but PfEMP- 
1 negative)). Notably, PfEMP-1 could still be detected on PRBC surface after 4 days 
treatment (data not shown).
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Figure 3.7. Density plots of flow cytometry experiments for surface PfEMP-1 measurement. Cells 
were immunolabeled for A4var41 specific PfEMP-1 using BC6 primary antibody and an alexa488 coupled 
secondary antibody. PRBC were labelled using ethidium bromide. Fluorescence in the FL1 channel (Alexa 
488, PfEMP-1) is indicated on the x axis, and FL2 (ethidium bromide, indicating parasitized cells) on the Y 
axis. RBC populations were gated to exclude debris and cell clumps on a forward scatter/side scatter plot 
before analysis of FL1/FL2 levels. Result representative of several independent experiments. Each plot is 
the analysis of at least 100,000 RBC. Quadrant lines are identical for each plot, and the values indicate the 
percentage of the population falling within each quadrant.
Cells in each quadrant can be described as follows:
Lower Left -  Uninfected RBC, A4var41 PfEMP-1 Negative 
Lower Right -  Uninfected RBC, A4var41 PfEMP-1 Positive 
Upper Left -  PRBC, A4var41 PfEMP-1 Negative 
Upper Right -  PRBC, A4var41 PfEMP-1 Positive
The top row shows uninfected RBC only, the middle row ItG infected PRBC culture, and bottom row A4 
infected PRBC culture. Left column shows no staining, middle shown ethidium bromide, and alexa 
conjugated antibody staining and right column shows staining including primary BC6 antibody.
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Figure 3.8. PfEMP-1 levels by flow cytometry after artesunate treatment. A) Representative histogram 
of FL1 mean fluorescence intensity of control (solid) and 24h artesunate treated cells (open black). Gated 
on ethidium bromide positive population (quadrant upper left and upper right as in figure 3.7). B) mean 
fluorescence intensity of PfEMP-1 positive populations (quadrant upper right as in figure 3.7) after 24h 
artesunate treatment, mean ± SD three independent experiments. **P<0.01 as determined by T test 
compared to untreated control.
Use of other antimalarials -  Determination of IC50 values
Other antimalarials were chosen to assess cytoadherence of non-viable P. falciparum. 
The IC50 for each chosen antimalarial was assessed on ItG using a standard 
fluorometric (Sybr Green) assay (Bennett et al., 2004, Smilkstein et al., 2004). The IC50 
values determined for ItG were within the range previously reported for each drug, and 
the concentration chosen for use was based on previously published peak plasma 
concentrations (see methods section for references) and were mostly well above the 
IC50 value (Table 3.1). Figure 3.9 show representative IC50 curves.
Drug IC(50) on ItG Concentration
Mean of three assays +/- SD Used
Artesunate 1.6 nM +/-1.5 500 nM
Quinine 382.48 nM +/-140 25 pM
Lumefantrine 233.29 nM 15 pM
Piperaquine 52.4 nM +/-8.16 100 nM
Table 3.1. IC50 values calculated on ItG. Similar results were seen for A4 (not shown). Mean IC50 for 
each is the mean of three independent triplicate experiments. (*lumefantrine two experiments)
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Figure 3.9. Representative IC50 curves on ItG. Y axis shows percentage fluorescence (representing 
growth) compared to untreated control, and x axis indicates concentration of drug (nM). Each point 
represents the mean of triplicate values.
Cytoadherence to ICAM-1 after treatment of TROPHOZOITE-stage PRBC with a 
range of antimalarials
Adhesion of PRBC to ICAM-1 protein under flow was assayed following 4, 8 and 24 h 
drug treatment of trophozoite (24 h post invasion) stage parasites. The antimalarial 
drugs tested were artesunate (500 nM), quinine (25 pM), lumefantrine (15 pM) and 
piperaquine (100 nM).
The binding phenotypes for all treatments were observed to be very similar, with no 
significant difference in binding observable after 4 h drug exposure (Fig. 3.10a). As 
observed previously, a small reduction in binding was observed for parasites exposed 
to 8 h artesunate (Fig. 3.10b) but no significant difference relative to control cells was 
observed for all other drugs (Fig. 3.10b). A significant reduction in PRBC binding was 
observed following 24 h exposure to all of the drugs, with binding ~30% of control 
levels (Fig. 3.10c).
8 0
Treatment
Figure 3.10. Adhesion of drug-treated trophozoite-stage ItG PRBC to ICAM-1 under flow conditions.
Adhesion shown as bound PRBC/mm2 to ICAM-1 under flow conditions after 4 h (A), 8 h (B), and 24 h (C) 
treatment of trophozoites stage parasites with artesunate (art) 500 nM, quinine (Quin) 25 pM, lumefantrine 
(Lum) 15 pM, and piperaquine (Pip) 100 nM or untreated trophozoite stage PRBC (C). * P<0.05 and 
**P<0.01 as determined by T test compared to untreated control.
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Cytoadherence to ICAM-1 after treatment of RING-stage PRBC with a range of 
antimalarials
As the antimalarial drugs used in this study have different pharmacodynamic 
properties, especially in regards to cell cycle specificity, binding experiments to ICAM-1 
under flow conditions were repeated as described above but drug exposure was 
performed on ring-stage (12 h post invasion) parasite cultures. These younger ring 
stage parasites represent the pre-cytoadherent circulating population.
Adhesion to ICAM-1 protein under flow, was determined after 24 h exposure of ring- 
stage PRBC to artesunate (500 nM), quinine (25 pM), lumefantrine (15 pM) and 
piperaquine (100 nM) relative to untreated control cells. Significant differences were 
observed between the various treatments. Artesunate treated parasites were unable to 
mature to trophozoites and non-viable ring parasites were observed after 24 h 
exposure (Fig. 3.11a), whilst quinine and lumefantrine treated parasites matured to late 
trophozoites before dying and appearing pyknotic (Fig. 3.11a). Piperaquine treated 
parasites appeared to show an intermediate amount of development to late ring/early 
trophozoite before becoming non-viable. Binding experiments revealed that control 
parasites allowed to develop for 24 h from ring stage parasites to trophozoites 
displayed characteristic levels of adhesion whilst control ring-stage parasites, as 
expected, displayed a very low level of cytoadherence (Fig. 3.11b). Artesunate treated 
parasites, which had failed to mature showed little cytoadherence, whilst quinine and 
lumefantrine treated parasites displayed high levels of adhesion comparable to control 
trophozoite-stage PRBC (Fig. 3.11b). Treatment of parasites with piperaquine resulted 
in intermediate levels of binding, ~50% of control levels (Fig. 3.11b).
82
- Drug Oh 24 h Art 24 h QN 24 h Lum 24 h Pip
•|« J ria p r
¡parai
L  _ . .
J l j
C (Troph) C (Ring) Art Quin Lum Pip
Treatment
Figure 3.11. Adhesion to ICAM-1 after addition of drugs to ring stages A) Giemsa stained smear of 
parasites at time of assay, 24h after administration of drug to RING-stage parasites. B) Adhesion to ICAM- 
1 under flow conditions 24h after administration of drugs to RING stage parasites (Ring stage control is 
alternate day culture (highlighted by dashed outline), Troph control is 24 h -  drug). Mean ± SD three 
independent triplicate experiments.
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3-4 DISCUSSION
We have assessed the ability of non-viable parasites killed by antimalarial treatments 
to cytoadhere, and our data demonstrate that P. falciparum PRBC are capable of 
cytoadherence for at least 24 h after lethal dosages of a range of antimalarial drugs. 
The antimalarial drugs tested in this study were artesunate, quinine, lumefantrine and 
piperaquine at clinically relevant concentrations, chosen to mimic peak plasma drug 
levels. The cytoadherence phenotype of PRBC was measured using both static and 
flow assays and using a range of parasite strains (ItG, A4 and CS2) against purified 
receptor proteins and endothelial cells (HUVEC and HDMEC).
These observations are consistent with observations from a previous ultrastructural 
analysis of brains from patients with cerebral malaria (Pongponratn et al., 2003) which 
suggested that they observe morphologically damaged parasites adhered to cerebral 
endothelium, consistent with parasite death in-situ and maintained ability to adhere.
Consistent with the continued ability to cytoadhere, we observed the characteristic 
punctate distribution of PfEMP-1 on the surface of P. falciparum PRBC following 24 h 
antimalarial treatment, as shown in figure 3.6. For the measurement of PfEMP-1 levels 
the A4 isolate was used (rather than the ItG isolate as used for the majority of the 
adhesion assays) due to the availability of the specific antibody for the A4var41 
PfEMP-1. Importantly this antibody, BC6, recognises an external epitope of the PfEMP- 
1 protein. The ItG isolate was originally used in adhesion assays due to the generally 
higher level of binding seen to ICAM-1 compared to A4 (Gray et al., 2003). In adhesion 
assays after drug treatment of A4 the effect of drug treatment on adhesion levels was 
comparable to the result that we had seen with ItG (Fig 3.5a).
These data illustrate the stability of the changes made to the red blood cell by the 
parasite such that the remodelling of the infected red blood cells is maintained after the 
parasite is rendered non-viable. Nevertheless, quantification of the PfEMP-1 levels on 
PRBC surface showed some reduction after drug treatment, consistent with a degree 
of degradation/loss of the protein. This reduction in PfEMP-1, combined with potential 
degradation of other cytoadherence-related parasite proteins, i.e. KAHRP, could 
explain the reduced levels of cytoadherence seen after 24 h treatment. This could be 
comparable to that seen when mutations are present in haemoglobin, i.e. haemoglobin 
C (HbC), and sickle haemoglobin (HbS). In these cases infected erythrocytes show a
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slightly reduced and abnormal display of PfEMP-1 and concurrently reduced 
cytoadherence (Cholera et al., 2008).
Testing a selection of antimalarial drugs showed that the effect on mature trophozoite 
cytoadherence was not drug specific; the same level of adhesion was seen after 24 h 
treatment with all of the antimalarials tested.
Previously published data has implied that antimalarial drugs including quinine, 
halofantrine, artesunate and artemether reduce cytoadherence and/or rosetting in P. 
falciparum (Udomsangpetch et al., 1996). In the Udomsangpetch et al. study, 
parasites (presumably ring stage circulating parasites) were exposed to antimalarial 
drugs for 2 to 24 h, washed and grown in culture until control parasites (no drug 
exposure) were at late trophozoite/early schizont stage. Depending on the drug 
treatment these authors reported a range of binding phenotypes, most notably 
parasites exposed to artesunate and artemether were reported to result in >50% 
inhibition of both cytoadherence (static assay) and rosetting. It was concluded by 
these authors that the observed differences between the various drugs on parasite 
adhesion probably reflected differences in the susceptibility of asexual stage parasites 
to antimalarials.
We show a similar effect when drug treatment is added to ring stage (young) parasites. 
As shown in figure 3.11, the various antimalarials used inhibited parasite growth at 
different stages of the asexual cycle. This is consistent with previous 
pharmacodynamic data on the mode of action of these drugs, with artesunate known to 
be active against young ring stage parasites (Skinner et al., 1996, O'Neill & Posner, 
2004). The activity of lumefantrine, quinine and piperaquine, however, is based on the 
disruption of haem detoxification (Biagini et al., 2003, Biagini et al., 2005) occurring 
later in development during haemoglobin digestion by trophozoite stage parasites 
(Skinner et al., 1996, Hempelmann et al., 2003, O'Neill et al., 2006). The 
pharmacodynamic differences of these drugs when administered to ring stage 
parasites results in mismatched comparisons of binding phenotypes. Essentially the 
assays measured the adhesion of dead ring stage parasites for the artesunate treated 
group, against the adhesion of dead trophozoite stage parasites for the quinine, 
lumefantrine and piperaquine treated groups. The significant reduction in adhesion 
seen by artesunate treated parasites in figure 3.11 and in the Udomsangpetch et al., 
study (Udomsangpetch et al., 1996) reflect that these groups consist of ring stage 
parasites that have insufficient levels of binding proteins, i.e. PfEMP-1, exported to the 
erythrocyte membrane surface at that stage.
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The significance of this difference between ring-stage acting artemisinin based 
treatments and treatments that only act on mature parasites (i.e. quinine), has also 
been discussed in the context of the SEAQUAMAT trial. This trial compared artemisinin 
and quinine for the treatment of severe malaria in adults and showed an advantage for 
artesunate over quinine, particularly in groups with high parasitaemia (Dondorp et al., 
2005). The authors suggest that this advantage may stem from the mechanism of 
action of artesunate on immature parasites thereby preventing the next round of 
sequestration. Our in vitro results support this hypothesis.
The significant observation of our study is that dead parasites retain the ability to 
cytoadhere irrespective of the antimalarial treatment administered. However, we can 
hypothesise that administration of fast, ring stage acting antimalarials such as 
artesunate will result in a reduction of de novo cytoadherence when administered in 
vivo due to the ability to prevent maturation of parasites to mature cytoadherent stages. 
The persistence of cytoadherence for many hours after treatment, despite rapid effects 
on parasite viability fits with, and may in part explain, the clinical observation of a high 
mortality rate in first 24 hours after hospital admission after initiation of antimalarial 
treatment (Marsh et al., 1995). Even though treatment is killing the parasites rapidly, 
we show that they would still be able to cytoadhere 24 h following treatment, potentially 
still contributing to disease pathology.
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3-5 LIMITATIONS AND FURTHER WORK
We have shown that the PfEMP-1 exported to the surface of the RBC by the parasite is 
still present for many hours following antimalarial treatment, illustrating the permanent 
nature of the changes made to the red blood cell by the parasite. In chapter 4 we 
further investigate the issue of RBC remodelling by the parasite and the effect of 
antimalarial treatment by looking at the reduced deformability of the PRBC.
A major limitation of this work is that we have been unable to look at the effect of 
antimalarial treatment on the adhesion of already bound PRBC. We have treated 
trophozoite stage parasites and then assessed for adhesion up to 24 hours following 
treatment. In vivo these trophozoite-stage PRBC would already be expected to be 
sequestered in microvasculature. We have been able to show that PRBC are still 
capable of adhesion after up to 24 hours treatment, but we have not been able to show 
whether already bound PRBC would stay adhered. A long term co-culture model would 
need to be developed to enable us to perform these experiments. We would expect, 
however, that having shown PRBC are still capable of binding, the interaction between 
already bound PRBC and endothelium would be maintained to at least the same 
degree of binding ability that we have seen.
It is conceivable that the predicted continued sequestration of non-viable P. falciparum 
PRBC in patient microvasculature may be targeted by adjuvant therapies designed to 
prevent or ideally reverse cytoadherence. Indeed, studies have recently been 
performed with Levamisole, which was shown to reduce sequestration of P. falciparum 
in patients by inhibition of CD36 dephosphorylation (Dondorp et al., 2007). The 
potential for adjunct therapies to reverse cytoadherence (specifically ICAM-1 mediated 
cytoadherence) is investigated in chapter 6.
An important consequence of adhesion to host endothelium is signalling events within 
endothelial cells that may contribute to pathogenesis (Chakravorty et al., 2008). It has 
been shown that adhesion of PRBC to endothelial cells induces signalling pathways, 
one example of which results in induction of ICAM-1 on the surface of the endothelial 
cell (Chakravorty et al., 2007, Tripathi et al., 2006). Preliminary experiments to address 
whether non-viable PRBC were able to stimulate adhesion molecule expression in a 
similar way suggested dead PRBC elicited the same response as viable PRBC, 
however, in our experiments the basal level of simulation by live PRBC was very low
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resulting in little confidence when trying to detect differences between live and dead 
PRBC (results not shown).
Similarly the stimulation of MAP kinase signalling pathways has been shown by 
endothelial cells in response to cytoadherence (Jenkins et al., 2007b), however, in our 
experiments the difference between uninfected RBC and PRBC signalling was very 
small resulting in little confidence in detecting differences (or stating none) between 
signalling events induced by live PRBC or dead PRBC (results not shown).
Another widely discussed consequence of adhesion to endothelial cells is the induction 
of apoptosis in the endothelial cells. There are three ways in which endothelial cell 
apoptosis may be stimulated in malaria. It has been shown that soluble parasite 
derived factors can induce apoptosis in endothelial cells (Wilson et al., 2008). Host 
derived inflammatory factors may influence apoptosis (Combes et al., 2006, Wassmer 
et al., 2006a, Wassmer et al., 2006b, Hemmer et al., 2005), and there is also evidence 
suggesting that cytoadherence of PRBC can directly induce apoptosis. However, all 
published data showing in vitro evidence for cytoadherence-induced apoptosis is based 
on assays using human lung endothelial cells (Toure et al., 2008, Pino et al., 2003, 
Siau et al., 2007). Our adhesion experiments performed on endothelial cells of different 
origins, HUVEC and HDMEC (and HBEC, not shown), do not result in superficial 
evidence for endothelial cell disruption in conditions used for our experiments. Indeed, 
it has been suggested that there is upregulation of pathways protective against 
apoptosis following cytoadherence in HUVEC (Chakravorty et al., 2007). We have not 
attempted to assay for apoptosis after adhesion, but suggest that established models 
for induction of apoptosis, i.e. lung endothelial cells would have to be used to compare 
the ability of live and antimalarial-treated PRBC to induce any potential cytoadherence- 
related apoptosis.
We would hypothesise that there would be no difference in the cytoadherence-related 
signalling between live or dead PRBC adhesion. This would strengthen an argument 
for an adjunct therapy to prevent or reverse sequestration since it may also prevent 
endothelial cell damage resulting from cytoadherence related signalling events.
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3-6 CONCLUSIONS
In summary, this study has assessed the cytoadherence capability of drug-killed P. 
falciparum PRBC. We demonstrate that non-viable parasites, irrespective of treatment 
retain the ability to cytoadhere for up to 24 h. This phenomenon is due to the stability 
of the changes made to the host red blood cell by the parasite, as illustrated by the 
continued presence of PfEMP-1 on the surface of PRBC after loss of parasite viability. 
The continued capacity for cytoadherence, and presence of surface PfEMP-1 indicates 
that the remodelling of the red blood cell is stable.
The continued capacity for cytoadherence could contribute to disease pathology 
following treatment. It is hypothesised that fast and ring stage acting antimalarials such 
as the endoperoxides may be therapeutically more favourable by their ability to prevent 
de novo adhesion, but adjunctive therapy strategies that can also reverse 
cytoadherence may also be advantageous in addressing the high mortality seen in 
severe malaria early after hospital admission.
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CHAPTER 4 - LORCA ANALYSIS OF THE DEFORMABILITY OF PRBC AFTER 
ANTIMALARIAL TREATMENT
4-1 INTRODUCTION
The many modifications that a parasite makes to the host RBC are described in detail 
in chapter 1. As well becoming able to cytoadhere and sequester in microvasculature a 
PRBC is much more rigid, i.e. less deformable than an uninfected RBC (Cooke et al., 
2001, Cranston et al., 1984). The reduction in deformability of PRBC could lead to 
reduced flow through small vessels contributing to the severe pathologies of malaria. In 
support of this, a correlation between a lack of deformability and clinical severity has 
been shown (Dondorp et al., 1997, Dondorp, 2008). Decreased rigidity of PRBC is a 
particular problem in microvasculature already partially blocked by cytoadherent PRBC. 
Whereas deformable RBC can squeeze through partially blocked vessels more rigid 
PRBC are less able to do so and more likely to lead to obstructions (Shelby et al., 
2003, Dondorp et al., 2008).
A major determinant of the reduced deformability of a PRBC is the increased 
membrane cytoskeleton rigidity, which results both from modification of host proteins, 
and insertion of parasite proteins into the membrane. The role of knobs in the 
increased rigidity of PRBC has been shown using knobless clones (Paulitschke & 
Nash, 1993), and using micropipette techniques the involvement of two knob- 
associated proteins KAHRP and PfEMP-3 has been demonstrated (Glenister et al., 
2002). Other possible contributors to the decreased deformability of a PRBC include 
the physical presence of the parasite as well as a potential increased cytoplasmic 
viscosity, partly due to increased solute uptake via NPP (Cooke et al., 2001, Cranston 
et al., 1984). Cytoplasmic viscosity has been suggested to contribute to the 
determination of deformability of uninfected RBC along with membrane stiffness 
(Mohandas et al., 1980, Kon etal., 1987).
It has been suggested that there is a decreased deformability of uninfected RBC from 
malaria patients (Dondorp et al., 1997, Griffiths et al., 2001), or RBC that have been in 
contact with parasite derived factors (Naumann et al., 1991). However, other studies 
did not see this (Paulitschke & Nash, 1993, Glenister et al., 2002). These differences 
may reflect both the different techniques used to measure the deformability of PRBC, 
and differences between in vivo, and in vitro studies.
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It is widely thought that it is the increased rigidity of P. falciparum PRBC that is 
responsible for the ability of the spleen to recognise and clear PRBC, either through 
destruction of the PRBC, or through removal of the parasite by the mechanical process 
of pitting (Engwerda et al., 2005, Chotivanich et al., 2002, Angus et al., 1997, Safeukui 
et al., 2008). Sequestration in the microvasculature is a mechanism by which the rigid 
PRBC can escape from circulation and avoid passage through, and destruction by, the 
spleen. P. vivax PRBC are not known to cytoadhere, so remain in peripheral circulation 
during intraerythrocytic development. However, P. vivax infection does not lead to 
increased rigidity of the PRBC. It has been suggested that the P. vivax PRBC are more 
deformable than uninfected RBC (Suwanarusk et al., 2004). An alternative mechanism 
for avoidance of splenic clearance of P. vivax PRBC has been proposed based on 
adhesion of P. vivax PRBC to barrier cells in the spleen preventing entry into the 
spleen and subsequent clearance (del Portillo et al., 2004), but there is little (or no) 
evidence to support this.
In chapter 3 we were interested in the effect of antimalarial treatment on the ability of 
PRBC to cytoadhere. Since deformability of PRBC has also been correlated with 
severity of disease (Dondorp et al., 1997, Dondorp, 2008), we were interested in 
looking at the effect that antimalarial treatment of trophozoite stage PRBC may have on 
deformability. The effect of antimalarial treatment on the deformability of PRBC has 
been looked at in one previous study (Chotivanich et al., 2000), where it was 
suggested that treatment of ring-stage parasites with artesunate restricted further 
decreases in deformability, while quinine had a more limited effect. However, this 
study assessed deformability of PRBC after addition of drugs to ring stage parasites. 
We sought to extend this study by analysing the effect of antimalarial treatment on the 
already remodelled trophozoite-stage PRBC, to see whether, as with cytoadherence, 
the phenotype is maintained after the parasite is rendered non-viable by antimalarial 
treatment.
Methods to Study Deformability
Three main techniques have been used to study deformability of RBC/PRBC. 
Micropipette studies can be used to measure the elasticity of the cell membrane, which 
is determined by the membrane cytoskeleton (Nash et al., 1989). This is calculated by 
measuring the shear elastic modulus, the length of membrane that can be aspirated 
into a micropipette (1 -1 .5  pm diameter) with a given pressure (Fig 4.1 a) (Glenister et 
al., 2002).
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Figure 4.1 a. Determination of membrane shear elastic modulus by micropipette aspiration.
(Figure taken from Glenister 2002 (Glenister et al., 2002)) Bright-field digitally captured images of a typical 
micropipette (1.3 pm internal diameter) used for determination of the shear elastic modulus of (A) an 
uninfected RBC and (B) an RBC infected with a mature P. falciparum parasite. A portion of the RBC 
membrane aspirated into the pipette can be visualized clearly, shown here at a pressure of 2.0mm H20 
(A) and 4.0 mm H20 (B). Scale bar, 5 pm.
Microfluidics methods measure ability of cells to pass through narrow constrictions in 
channels (Fig. 4.1 b) (Shelby et al., 2003). Video capturing of cells passing through 
microfluidic channels of 2 to 8 pm allow visualisation of channel blockage by PRBC at 
different stages.
Figure 4.1 b. Schematic of a microchannel. (Figure taken from Shelby 2003 (Shelby et al., 2003))
Schematic illustrating the geometry of the microchannel. The constricted segment of the channel (width 
denoted by w) was sized at 8, 6, 4, and 2 pm. The white arrow represents the direction of fluid flow. (Upper 
lnsef)A differential interference contrast image of normal (smooth) and infected RBCs. (Lower Left Insef) A 
normal RBC passing through a 2-pm constriction. (Lower Right Insef) Infected RBCs blocking a 6-pm 
constriction.
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The method that we have used to measure deformability is an ektacytometry based 
method (Mohandas et al., 1980, Dondorp et al., 1997) using a Laser-assisted Optical 
Rotational Cell Analyzer (Lorca)
(http://www.mechatronics.nl/products/lorrca/index.htm). In this technique, erythrocytes 
are placed in a narrow gap between two concentric cylinders and the outer cylinder 
rotates to create a defined shear force on the red blood cells. A camera connected to a 
computer allows images to be taken, each image being a composite of 500 cells. The 
elongation index of the red blood cells, the ratio of length to width, is calculated on a 
composite image of the 500 cells and used as the measure of deformability at a given 
shear stress (Fig. 4.1c). Deformability is generally measured over a range of shear 
stress from 0.5 Pa to 30 Pa, and at each shear stress the mean of 50 calculations is 
used.
Whereas micropipette studies generally measure the deformability of the cell 
membrane/membrane cytoskeleton of individual cells, Lorca enables measurement of 
the deformability of the whole cell. Microfluidics based studies also measure the 
deformability of the cell as a whole. However, microfluidics studies show the effect of 
the deformability changes of individual cells since relatively few rigid cells in a 
population will be sufficient to block the microfluidic channels. Lorca enables the study 
of the deformability of the whole population of RBC and allows us to quantitate the 
deformability changes based on a large number of RBC.
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Figure 4.1 c. Laser-assisted Optical Rotational Cell Analyzer (Lorca).
A thin layer of red blood cell suspension is sheared between two concentric cylinders. The rotation of the 
outer cylinder (cup) causes deformation (elongation) of the red blood cells. The laser-beam diffraction 
pattern Is detected with a video camera and analyzed by a computer.
(http://www.mechatronics.nl/Droducts/lorrca/index.htm).
In this study our main aim was to investigate the rigidity of PRBC after treatment with 
antimalarials. This is a continuation of work presented in chapter 3 which looked at 
cytoadherence after antimalarial treatment. The chapter is split into three main parts; 
first, controls to establish our use of Lorca to measure PRBC rigidity; second, the effect 
of antimalarial treatment on deformability; and finally, we have attempted to dissect the 
relative contributions of the various changes in the erythrocyte brought on by parasite 
infection, i.e. changes to cytoplasmic viscosity and membrane changes.
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4-2 MATERIALS AND METHODS
Strains and Culture conditions
P. falciparum was maintained under standard conditions as described in chapter 2. 
Most experiments were performed using the A4 isolate, and some repeated using ItG 
as described in chapter 2. The KAHRP deletion strain 1C10 was also used. This isolate 
originates from A4 but has a truncation on chromosome 2 resulting in a deletion of the 
KAHRP gene and a knobless phenotype (Horrocks et al., 2005). This phenotype was 
confirmed by assessing the (lack of) ability to float on Plasmagel. Parasite cultures 
were regularly synchronised at ring stage using sorbitol lysis, however this was shown 
to affect the deformability of cells for up to 2 days post treatment so synchronisation 
using this technique was carried at least 3 days before experiments.
Enrichment for Trophozoite stage parasites
Since Lorca measures the deformability of a population of RBC, PRBC were generally 
enriched to 50% parasitaemia. In order to enrich a culture either Plasmagel flotation or 
magnetic separation method was used as described in methods chapter 2. After 
enrichment using either method PRBC were washed three times in incomplete 
medium, parasitaemia was checked and PRBC diluted to usually 50% using matched 
cultured uninfected red blood cells. Final parasitaemia achieved was checked before 
experiments.
LORCA (Laser assisted optical rotational cell analyser)
A 12.5 pi pellet of packed RBC at 50% parasitaemia was diluted with 12.5 pi of serum 
free medium and mixed gently into 5 ml of polyvinylpyrrolidone (PVP) at 37°C. Before 
taking readings the Lorca was washed twice with 1 ml sample. 1 ml sample was then 
added to the Lorca and measurements taken over 9 shear stress levels from 0.5 Pa to 
30 Pa. The cup was washed once more with 1 ml sample before a second reading was 
taken. All measurements were taken at 37°C. Control uninfected red blood cells were 
measured along with each experiment. Plasmagel treatment was shown to have no 
effect on the deformability of red blood cells (data not shown), however, in all 
experiments control RBC were exposed to Plasmagel as for PRBC before deformability 
assays.
Uninfected cell experiments
To assess the deformability of uninfected cells in a culture, a culture at 12% 
parasitaemia at mid-trophozoite stage was cleared of infected cells by magnetic
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purification using the VarioMacs magnet and column as described in methods chapter 
2. Unbound cells were collected from the magnet and the process repeated 2 - 4  
times. This resulted in cultures containing <2% infected cells, and remaining infected 
cells were usually infected with early stage parasites (as determined by Giemsa 
stained smear).
Drug Treatment
Artesunate was made up to a 10 mM stock solution in dimethylsufoxide (DMSO) 
immediately prior to the experiment. Drug was added to mid-trophozoite stage cultures 
into normal culture medium to 500 nM. Furosemide and quinine stocks were made to 
100 mM stock solution and used at 100 pM concentrations. For long drug incubations 
drugs were added to normal culture parasitaemia (8 -12%) and cultures Plasmagel 
enriched at appropriate time points before Lorca analysis. For short time course 
furosemide experiments parasites were enriched prior to drug addition, and drug was 
added to the enriched culture. The untreated control was from the same enrichment.
Sorbitol Lysis
As a control for the activity of furosemide the ability of sorbitol to lyse trophozoite-stage 
PRBC was quantitated by measuring absorbance at 546 nm. A 20 pi sample of cells at 
50% haematocrit and 50% parasitaemia was mixed with 180 pi 5% sorbitol, or 180 pi 
5% sorbitol plus 100 pM furosemide, or incomplete medium. Uninfected red blood cells 
were used as controls in the same way. At 5 minute time points a 30 pi sample was 
taken, centrifuged at 5000 rpm for 1 min in an Eppendorf centrifuge and 25 pi of the 
supernatant diluted with 475 pi of appropriate buffer and transferred to a cuvette. 
Absorbance at 546 nm was measured compared to relevant blank.
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4-3 RESULTS
Part I - Deformability of PRBC
Deformability of PRBC is reduced compared to uninfected red blood cells
We first confirmed that we could use Lorca to detect deformability changes in PRBC. 
Unless otherwise stated we have used the A4 P. falciparum isolate. We could detect 
the reduced deformability of un-enriched PRBC cultures at a parasitaemia of 12%, as 
well as on Plasmagel enriched cultures at 50% parasitaemia (Fig. 4.2a).
To determine whether parasites alter the deformability of uninfected cells within a 
culture, a culture at 12% parasitaemia mid-trophozoite stage was cleared of infected 
cells using magnetic separation, and deformability of these parasite-exposed but 
uninfected RBC were measured against a control RBC “culture” that had been 
maintained in parallel. PRBC from this culture measured at 50% parasitaemia after 
magnetic enrichment showed a significant reduction in deformability compared to 
control RBC. Uninfected RBC from within the culture were no less deformable than the 
control RBC (Fig. 4.2b). Results are shown for A4 PRBC, showing the mean and 
standard error of three experiments in separate batches of blood. The same result was 
obtained using the KAHRP deletion isolate 1C10 in two experiments (data not shown).
In figure 4.2a we established that we could detect reduced deformability at a 
parasitaemia as low as 12%, although the difference was clearer at higher 
parasitaemia. To detect deformability of a culture from ring through to schizont stages 
we used a culture at a relatively high parasitaemia but that still enabled healthy growth, 
in this case we used a culture at 17% parasitaemia. Deformability of a culture of PRBC 
measured (un-enriched) at 17% parasitaemia over the 48 hour parasite growth cycle 
showed increasing rigidity of red cells as the parasite matures (Fig. 4.2c). When 
comparing freshly washed RBC with RBC that had been stored washed at 4°C for > 1 
week it was apparent that stored washed RBC become more rigid with time, (see also 
Fig. 4.5c). However, over the time course of the experiments (< 48h), there was no 
appreciable difference in the deformability of RBC maintained under culture conditions 
(Fig. 4.2d).
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Figure 4.2. Deformability of PRBC A) A4 PRBC measured at 12% parasitaemia and 50% parasitaemia 
are less deformable than uninfected red cells. Y axis indicates deformability measured as an Elongation 
index (El). B) Uninfected RBC that have been exposed to PRBC (Uninfected) are not detectably different 
to red cells from control culture (RBC). Mean ±SE of three independent experiments. C) Deformability of 
parasite culture reduces as parasites mature. Time indicates hours post-invasion from 8h (rings) to 42h 
(mature schizonts). Measured on an un-enriched culture at 17% parasitaemia. Representative of two 
independent experiments D) Deformability of control RBC “cultured” in parallel is unchanged over the 
experimental time course.
These results indicate that we can use Lorca to detect the expected increase in PRBC 
rigidity during parasite maturation, and suggest that the changes we are measuring in a 
population are due to parasite induced changes to the infected red blood cells only.
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Part II - Deformability of Drug-treated PRBC
Deformability of PRBC after 24 hours antimalarial treatment is slightly reduced 
compared to the culture before treatment
The deformability of mature trophozoite stage PRBC (28-30h post invasion) was 
measured before addition of artesunate (500 nM) to the culture. After 24 hours the 
original culture with no artesunate had matured and reinvaded to ring stage parasites, 
however, as expected, the artesunate treated parasites were dead and pyknotic (as 
determined by Giemsa stained smears, not shown). PRBC could still be enriched using 
Plasmagel after 24h artesunate treatment indicating maintenance of knob structures. 
The deformability of uninfected red blood cells was not affected by 24 hours artesunate 
treatment, and the deformability of artesunate treated PRBC was slightly reduced at 
most shear stress compared to the 0 h time point (Fig. 4.3a). Figure 4.3 a shows the 
mean and standard error of three independent experiments. Deformability of stage- 
matched (mature trophozoite) untreated PRBC at the 24 hour time point was not 
significantly different to the 0 h time point (not shown).
The apparent increase in the deformability of PRBC at very low shear stress is most 
likely an artefact due to the presence of free parasites in the culture resulting from low 
levels (< 10%) lysis of PRBC after artesunate treatment.
Artesunate and quinine were next added to young trophozoites (~18 h post invasion) 
and deformability assessed after 24 hours with or without treatment. The artesunate 
treated parasites had become slightly more rigid than the starting culture but had not 
progressed to become as rigid as the untreated PRBC now matured to schizonts. 
Quinine treated PRBC showed a similar result, although had become slightly more rigid 
(Fig. 4.3b). The same result was seen in two independent experiments, figure 4.3b 
shows one representative experiment.
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Figure 4.3. Effect of antimalarials on PRBC deformability A) A4 PRBC after 24 hour incubation with 
artesunate (500 nM) (treated at mid-trophozoite stage) show a slight reduction in deformability when 
compared to untreated PRBC, mean ± SE of three independent duplicate experiments. A4 - represents 
mean of both the Oh culture and 24h stage matched untreated alternate culture which were not 
significantly different. B) Deformability of artesunate (Art 24h) or quinine treated (QN 24 h) PRBC 24 hours 
after addition of drug to young trophozoites (0 h Small troph) compared with untreated PRBC which had 
matured to schizonts (24h Schizont).
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Part III - Determinants of PRBC rigidity
KAHRP deletion strain appears to be more deformable than A4
To confirm the role of parasite induced membrane cytoskeletal changes in the 
increased rigidity of PRBC we used a knobless strain. The KAHRP deletion strain 1C10 
(Horrocks et al., 2005) was used as an isolate with a compromised membrane 
cytoskeletal structure. This isolate is a derivative of A4 with a truncation of 
chromosome 2 that knocks out KAHRP and therefore knobs, resulting in reduced 
membrane rigidity compared to wild type PRBC (Horrocks et al., 2005, Glenister et al., 
2002, Paulitschke & Nash, 1993). The 1C10 KAHRP deletion PRBC (PRBCakahrp) 
showed virtually no ability to float on Plasmagel when compared directly over 30 
minutes with wild type A4 PRBC (PRBCA4), an observation that is consistent with the 
lack of knobs. The PRBCakahrp were less rigid than PRBCA4. Over several independent 
Lorca experiments the difference between PRBCA4 and PRBCakahrp deformability at 
mid-trophozoite stage was confirmed (Fig. 4.4). Figure 4.4 a illustrates the deformability 
of PRBCA4 and PRBCakahrp at mature trophozoite stage (~ 28 h post invasion) 
compared to uninfected RBC, shown is the mean and standard error of three 
independent experiments. Figure 4.4 b illustrates Giemsa stains pictures of PRBC used 
from one experiment. As seen with PRBCA4, the PRBCakahrp did not affect the 
deformability of uninfected cells within a culture (two experiments, data not shown).
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Figure 4.4. Effect of KAHRP deletion on deformability of PRBC A) Comparison of A4 and KD at mid­
trophozoite stage. Mean of results from three independent experiments (six readings) Error bars show 
standard error. B) Giemsa stained smears illustrating stage matched mid-trophozoite PRBC after 
Plasmagel enrichment. i)A4 and ii) KAHRP deletion PRBC 1C10 (KD)
Furosemide blocks NPP and Inhibits Solute Uptake in PRBC
The increased uptake of solutes through parasite induced new permeability pathways 
(NPP) in PRBC could be responsible for an altered cytoplasmic viscosity (Kirk et al., 
1994), which could contribute to the increased rigidity of PRBC (Cooke et al., 2001). 
Furosemide is a diuretic that has been suggested to lead to a slight reduction in RBC 
mean cell volume (MCV) (Biagini unpublished) (although this has not been seen in 
other studies (Hasler & Reinhart, 1998)), but is also known to block NPP in PRBC
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(Kirk et al., 1994). To test the effect of NPP on overall PRBC deformability we used 
furosemide to inhibit NPP then assayed deformability of PRBC using Lorca.
The activity of furosemide on PRBC was confirmed by the blocking of sorbitol lysis of 
PRBCA4. Sorbitol lysis of mature PRBC selectively is dependent on the NPP which 
allow uptake of sorbitol normally excluded from RBC, and result in the lysis of PRBC. 
This lysis can be quantitated by measuring haemoglobin release through its absorption 
at 545 nm. On addition of 5% sorbitol to mid-trophozoite stage PRBCA4 a rapid lysis of 
the PRBC could be measured (Fig. 4.5a). However on addition of furosemide this lysis 
was almost completely inhibited showing that furosemide can inhibit NPP as measured 
by the ability to inhibit osmotic lysis due to sorbitol uptake.
Figure 4.5. Effect of furosemide on RBC and PRBC A) Inhibition of sorbitol lysis of PRBC by 100 |jM 
furosemide. Lysis measured by absorbance of released haemoglobin at 456 nm (y axis). B) Reduction in 
mean cell volume (MCV) measured in fl (y axis) of RBC incubated in furosemide for 15 min. Comparison of 
fresh and mock-cultured RBC. Mean +- SD of three readings. C) Deformability of RBC after incubation in 
varying concentrations, 0 to 500 pM, of furosemide for 15 min. D) Deformability of fresh and mock-cultured 
RBC after incubation with or without 100 pM furosemide for 15 min.
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Furosemide does not affect RBC deformability
To determine whether furosemide affected RBC, furosemide was added in 
concentrations from 10 to 500 |jM for 15 minutes. We first measure the mean cell 
volume (MCV) and found a very slight reduction in MCV after 15 min exposure to 
between 10 pM and 100 pM furosemide (figure 4.5b). The same effect on MCV was 
seen after 2 h incubation (not shown). However, no effect on deformability of RBC was 
observed (Fig. 4.5c). The same result was seen with the 100 pM furosemide at time 
points of 2h, 4h and 24 hours (not shown). We found that cultured RBC were smaller 
and less deformable than fresh RBC (Fig 4.5c and d). However, the effect of 
furosemide treatment on RBC in terms of MCV and deformability was the same for 
both fresh and “cultured” cells.
Furosemide does not affect the deformability of A4 PRBC
The deformability of PRBCA4 was not affected by treatment with furosemide for 15 
minutes (Fig. 4.6 a). This was consistent in four independent experiments, and also at 
longer time points (up to 4 hours). After 24 hours incubation in furosemide parasites 
had developed to schizonts but not burst and showed low deformability consistent with 
the mature schizont stage (not shown).
Furosemide reduces the rigidity of KAHRP deletion PRBC
Interestingly 15 min incubation with 100 pM furosemide did lead to a reduction in the 
rigidity of PRBCakahrp. This was consistent in three independent experiments, shown in 
figure 4.6a is one representative experiment and figure 4.6b shows the mean and SD 
of the relative change in El for for furosemide treated compared to untreated control for 
three independent experiments. A third parasite isolate, ItG which, like A4, has knobs, 
showed similar results to that seen with A4.
This showed that as well as being initially more deformable than the wild type PRBC, 
the PRBC with a compromised membrane structure were more sensitive to furosemide 
treatment, resulting in an even further reduced rigidity compared to wild type PRBC.
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Figure 4.6. Effect of furosemide on A4 and KD PRBC A) Representative experiment comparing A4 
(A4) and the KAHRP Deletion strain 1C10 (KD) PRBC after furosemide treatment. B) Relative 
deformability compared to untreated control for a range of shear stress for A4 and KAHRP deletion PRBC 
mean ± SD for three independent experiments.
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4-4 DISCUSSION
As the increased rigidity of PRBC compared to uninfected RBC is thought to be a 
contributory factor to severe disease we looked at these changes, and the effect that 
antimalarial treatment may have on the deformability of PRBC. Our significant result is 
that the deformability of PRBC remains reduced compared to uninfected RBC for long 
after the administration of antimalarial treatment.
There are three main parts to this chapter that will be discussed: firstly, the series of 
controls that established Lorca as a tool to measure the deformability of PRBC. 
Secondly, the main aim of the study which was to determine the effect of antimalarial 
treatment on PRBC; and finally some insights into the contributory factors to the 
increased rigidity of PRBC.
Part I -  Use of Lorca to measure PRBC Deformability 
Deformability of A4 PRBC compared to uninfected RBC
The first results presented in this chapter were controls to establish that we could use 
Lorca to detect the expected deformability changes in PRBC. As Lorca measures the 
mean rigidity of the whole population of RBC it was important that we established at 
what parasitaemia we could detect the changes in the PRBC resulting from parasite 
infection. We could easily detect these changes at 50% parasitaemia after enrichment 
for trophozoites, but this could also be detected even with fewer parasites present, in 
cultures at only 12% parasitaemia (Fig. 4.2a). This enabled us to look at the changes in 
rigidity through parasite development from young ring stages which cannot be easily 
enriched for, through to schizonts. We were able to show that PRBC became 
increasingly rigid as the parasites matured (Fig. 4.2c). We had also observed that 
washed RBC stored at 4°C became increasingly rigid with storage (Fig. 4.6d) so a 
control “culture” of uninfected red blood cells was always maintained in parallel with the 
PRBC culture to ensure matched RBC controls. These “cultured” RBC were diluted 
with fresh RBC in parallel with the PRBC culture and maintained in the same culture 
conditions. Over the time course of experiments (<48 hours) there was no measurable 
change in the deformability of uninfected RBC (Fig. 4.2d). For many of the 
experiments we were enriching for trophozoite-stage PRBC using Plasmagel so we 
also confirmed that this treatment had no effect on the deformability of uninfected RBC.
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Deformability of uninfected RBC from parasite culture
Some previous studies on the deformability of PRBC have also shown that uninfected 
RBC that have been in contact with PRBC, or exposed to parasite derived factors also 
show increased rigidity compared to normal uninfected RBC (Dondorp et al., 1997, 
Naumann et al., 1991). However, other studies have not seen this (Paulitschke & Nash, 
1993, Glenister et al., 2002). To test this in our cultures we used the magnetic 
separation technique to clear a culture of PRBC. After two clearings on the magnet 
RBC were ~98% uninfected, and the remaining infected cells contained younger 
parasites.
This cleared culture was compared to uninfected RBC that had been “cultured” in 
parallel (as described above). Using Lorca we could not detect a significant difference 
in the deformability of uninfected RBC from the culture, compared to the control 
uninfected RBC. This was shown over the whole shear stress range from 0.5 Pa to 30 
Pa, in several independent experiments and with two parasite isolates (Fig. 4.2 b).
The reduction in deformability of uninfected RBC previously reported could have 
several explanations. Deformability of uninfected PRBC from patients has been shown 
(Dondorp et al., 1997, Griffiths et al., 2001) . However, our study is in-vitro so no host- 
factors are involved. Host responses to infection, including fever (Marinkovic et al., 
2008), could cause an increase in rigidity of all RBC, including uninfected.
Changes in deformability of uninfected cells due to 4-hydroxynonenal (HNE) adducts 
from haemozoin were shown to be detectable (Skorokhod et al., 2007). However, the 
compound is insoluble so not expected to diffuse to affect a large number of RBC. Only 
uninfected RBC in close contact with PRBC would likely to be affected by this. If 
relatively few individual RBC are affected by compounds such as HNE we would not 
detect this on our system which measures an average deformability of the whole cell 
population. For the purposes of our experiments, this result, i.e. that we cannot detect 
changes to uninfected RBC, allows us to say that all the changes that we are 
measuring using Lorca in our experiments are due to parasite-induced changes to 
infected PRBC only.
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Part II -  The effect of antimalarial treatment on the deformability of PRBC
Increased rigidity of PRBC over RBC is maintained after antimalarial treatment
As the increased rigidity of PRBC is possibly linked to the pathophysiology of severe 
disease we wanted to determine whether the rigidity of PRBC was reversed or 
maintained after antimalarial treatment. In chapter 3 we established that cytoadherence 
of PRBC can continue for several hours after antimalarial treatment, and showed that 
the remodelling of PRBC, including factors responsible for cytoadherence including 
knobs and PfEMP-1, were maintained after loss of parasite viability. This suggested 
that the remodelling of the parasite was stable even after loss of parasite viability, and 
to test this hypothesis further we wanted to determine the effect of antimalarial 
treatment on the rigidity of the PRBC.
We observed a maintained reduction in deformability of PRBC for 24 hours after 
artesunate treatment (Fig. 4.3). This result is consistent with a permanent remodelling 
of the RBC by the parasite, and corresponds well to the results presented in chapter 3 
showing the prolonged cytoadherent ability of drug treated parasites.
Artesunate is known to have a very rapid effect on the parasites, and very short 
exposure times are sufficient to kill parasites (chapter 3). However, the parasites are 
not immediately affected by the drug (ter Kuile et al., 1993), and as determined by 
Giemsa staining appear to mature slightly before dying and becoming increasingly 
pyknotic (as shown in chapter 3, figure 3.1a). By comparing a time course of growing 
parasite cultures with an artesunate killed culture we suggest that the decrease in 
deformability seen in drug killed cultures is consistent with a small amount of 
development of the parasites after treatment. There was little further change in 
deformability of PRBC if the same culture was compared after 4h and 24h treatment 
(result not shown), suggesting that no further changes in the parasite deformability 
occurred after parasite death.
Similar results were seen after treatment with quinine suggesting that the deformability 
of the PRBC after artesunate treatment remains consistent with the developmental 
stage of the parasite when the parasite was killed. After drug treatment PRBC remain 
more rigid than uninfected RBC for at least 24 hours after parasite death. This is 
consistent with cytoadherence results seen after antimalarial treatment (chapter 3), and 
confirms that the changes made to the RBC by the parasite are stable for long after the 
parasite has been killed.
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Any pathophysiological effects resulting from the increased rigidity could be occurring 
for many hours after administration of antimalarials, however, it is also the increased 
rigidity of PRBC that makes them a target for clearance by the spleen. It has been 
suggested that mature, circulating PRBC are retained by the spleen for either parasite 
removal, a mechanical process known as pitting, or for destruction. Furthermore it has 
recently been shown that a subset of ring-stage PRBC can also be retained by the 
spleen (Angus et al., 1997, Safeukui et al., 2008). There is also evidence for circulating 
dead PRBC after artesunate treatment in splenectomised patients (Chotivanich et al., 
2002). The increase in the number of observed dead PRBC in patients with no spleen 
suggests a role for the spleen in destroying PRBC or removing parasites that may be 
dead and circulating after antimalarial treatments. The maintained increase in PRBC 
rigidity explains how non-viable PRBC after antimalarial treatment are a target for 
clearance by the spleen. Although we have shown that cytoadherence can also 
continue after antimalarial treatment, if desequestration could be achieved releasing 
PRBC into circulation, (see chapter 6) these remodelled PRBC could still potentially be 
cleared by the spleen.
Part III -  Determinants of increased rigidity of PRBC
As discussed in the introduction there are three main types of technique used to 
measure deformability of RBC, each giving slightly different information, and having 
different limitations. One of the advantages of Lorca is that it provides information 
about the RBC deformability as a whole, whereas micropipette studies are generally 
restricted to the deformability (or elasticity) of the cell membrane alone. We sought to 
take advantage of this property of the technique to investigate how different factors 
contribute to the increased rigidity of the PRBC. While it is known that the increased 
rigidity of PRBC membrane is an important factor in the increased rigidity of the cell 
(Paulitschke & Nash, 1993, Glenister et al., 2002), the contribution of other factors, 
such as the presence of the parasite and the change in composition of the RBC 
cytoplasm (Cooke et al., 2001, Cranston et al., 1984), has not been previously 
investigated. The aim of the last series of results presented in this chapter was to 
determine whether factors other than the increased membrane rigidity are contributing 
to the observed increase in rigidity of PRBC.
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Effect of inhibition of NPP on deformability of infected Red Blood cells.
The lack of organelles in an uninfected RBC, along with a simple cytoplasm comprising 
mainly of haemoglobin results in a low cytoplasmic viscosity. The viscosity of the 
cytoplasm of an uninfected RBC is determined by the concentration of haemoglobin 
(Gennaro et al., 1996), and it has been shown that the internal viscosity of the RBC 
cytoplasm does contribute to the overall deformability of the RBC (Mohandas et al., 
1980, Kon et al., 1987). PRBC take up more solutes than uninfected RBC (Kirk et al., 
1994), much of this increased uptake is through the as-yet poorly characterised NPP. 
The NPP are also responsible for the removal of waste products, including amino acids 
from the haemoglobin breakdown by the parasite. It is possible that a result of the 
haemoglobin breakdown by the parasite is a decrease in cytoplasmic viscosity. 
However, it has been hypothesised that the increased solute concentration in the 
PRBC cytoplasm leads to an increased cytoplasmic viscosity when compared to 
uninfected RBC (Cooke et al., 2001).
In order to try to determine the contribution of cytoplasmic viscosity to the increased 
rigidity of PRBC we used furosemide. Furosemide inhibits NPP in infected red blood 
cells. It is a diuretic drug that is known to act on channels in other cell types, and there 
is some evidence that it also acts on uninfected red blood cells. As the cytoplasmic 
viscosity of PRBC is thought to be increased because of uptake of solutes through 
NPP, by inhibiting this solute uptake into the PRBC cytoplasm cytoplasmic viscosity 
might be reverted to a native state, as seen in uninfected RBC.
We found that furosemide had a very slight effect on reducing the mean cell volume 
(MCV) of uninfected red blood cells (Biagini, unpublished and figure 4.5b) suggesting it 
has some effect on uninfected RBC. However, the deformability of uninfected red blood 
cells appeared to be not significantly affected by the drug.
Before testing the effect of furosemide on deformability of PRBC we used its effect on 
sorbitol lysis as a control that furosemide was indeed inhibiting NPP in PRBC. Sorbitol 
lyses PRBC due to it being taken up though NPP, which are only present in mature 
infected RBC. Uninfected RBC and PRBC containing young rings do not have NPP 
activity and do not take up sorbitol -  hence are not osmotically lysed by sorbitol. As 
furosemide can block NPP the addition of furosemide to trophozoite-stage PRBC 
blocks lysis by sorbitol. This effect was observed indicating that in our experiments the 
furosemide was inhibiting NPP.
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However, the deformability of A4 PRBC was not changed after furosemide treatment, 
suggesting that inhibition of NPP did not affect the overall deformability of A4 PRBC as 
we could measure by Lorca.
Effect of Cytoplasmic Viscosity and Cytoskeletal Changes -  using a KAHRP 
deletion mutant
To further test the possible contributions of increased cytoplasmic viscosity in PRBC 
we used the KAHRP deletion (therefore knobless) parasite isolate 1C10 (Horrocks et 
al., 2005). As expected, we were unable to enrich this isolate using Plasmagel flotation 
-  indicative of a lack of knobs. For these experiments a magnetic separation method 
was used to enrich for trophozoite-stage parasites. Consistent with previously 
published results this strain also showed reduced rigidity compared to wild type 
parasites, although deformability was not restored to the level of uninfected RBC (Fig. 
4.4). These results confirm that the cytoskeletal changes to the RBC by parasites, 
including knob formation involving KAHRP contribute to the overall reduced 
deformability seen in PRBC (Glenister et al., 2002).
Using furosemide as for A4 above, we found that the KAHRP deletion strain showed a 
significant increase in deformability when NPP were inhibited. One possible 
explanation could be the contribution of an increased cytoplasmic viscosity in PRBC 
resulting from increased solute uptake through NPP. When NPP are inhibited in the 
KAHRP deletion strain the cytoplasmic viscosity is again reduced resulting in a more 
deformable cell. In our model, the increased cytoplasmic viscosity in PRBC compared 
to RBC does contribute to the increased rigidity of PRBC. However, in WT PRBC such 
as A4 the overriding contribution to the reduced deformability is that of the rigidification 
of the cytoskeleton. When the cytoskeletal rigidity is compromised as seen in the 
KAHRP deletion isolate the contribution of the cytoplasmic viscosity can be seen. This 
potential model is illustrated in figure 4.7.
These results have implications for any adjunct therapy potentially aimed at reducing 
the rigidity of PRBC with the aim of improving circulation. Therapies aimed at reducing 
rigidity by affecting cytoplasmic viscosity would be unlikely to have a significant effect in 
the presence of a wild-type P. falciparum membrane cytoskeletal modifications. To 
result in an observable reduction in PRBC rigidity the membrane cytoskeletal 
modifications would have to be targeted.
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Figure 4.7. Possible model for cytoplasmic and cytoskeletal determinants of rigidity in PRBC
• Uninfected red blood cells have an elastic membrane cytoskeleton (thin blue box) and low viscosity 
cytoplasm (pale pink). This results in them being highly deformable and able to elongate under shear 
stress.
• PRBC contain a parasite within its parasitophorous vacuole (solid blue), contain more solutes in the 
RBC cytoplasm increasing the viscosity (dark pink) and have a modified cytoskeleton (Thick blue box). 
This results in the parasite being able to withstand shear stress without elongating.
• The KAHRP deletion PRBC as with WT infected red blood cells contain a parasite, and have an 
increased solute content of RBC cytoplasm leading to increased viscosity. While modified to some 
extent, the membrane cytoskeleton is less rigid than that of WT PRBC. These cells deform more than 
WT (A4) PRBC under shear stress but remain more rigid than uninfected RBC.
• When treated with furosemide there is no effect on uninfected RBC which remain deformable.
• The WT (A4) PRBC lose cytoplasmic viscosity to a nearer uninfected state, but there is no change in 
deformability observed due to the rigid cytoskeleton
• The KAHRP deletion strain (1C10), when treated with furosemide loses cytoplasmic viscosity and the 
effect of this on whole cell rigidity can be observed as there is no reinforcing rigid cytoskeleton.
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4-5 LIMITATIONS AND FURTHER WORK
There are many limitations to this work regarding the contribution of an altered 
cytoplasmic viscosity to the rigidity of PRBC. Firstly, the conclusions are drawn based 
on the comparison of one knobless and one knobby strain, although in one experiment 
ItG (knobby) gave the same result as the A4 strain (not shown). Also the knobless 
strain used is lacking in KAHRP due to a chromosomal truncation resulting in 
potentially other deletions that may be relevant. Confirmation of the result using other 
deletion strains, and specific (KAHRP) mutations would be essential to confirm the 
results.
A major limitation is that this interpretation is based on an assumption that the 
cytoplasmic viscosity of PRBC is increased compared to RBC, and importantly, that the 
inhibition of NPP using furosemide results in a reduction of the cytoplasmic viscosity. 
Furosemide is a broad ranging inhibitor of transport channels, and may act on host 
RBC channels (as indicated by the possible loss of MCV in RBC) as well as plasmodial 
NPP and plasmodial folate transporters (Wang et al., 2007). Also, the NPP are not yet 
completely characterised. As a result we are unable to predict the effect that 
furosemide would have on PRBC cytoplasmic viscosity. Our model assumes that 
inhibition of NPP inhibits uptake of solutes to result in a loss of PRBC cytoplasmic 
viscosity. Should this not be the case then the differences between the two isolates 
may be due to more subtle differences in the interaction of furosemide with the PRBC. 
It is possible that, for example, the KAHRP knock out strain has changes in the NPP 
channels that are affected by furosemide resulting in the differences seen.
Our model could be tested in several ways. The involvement of NPP specifically could 
be tested by using chymotrypsin to effectively turn off the NPP (Baumeister et al., 
2006), or use other inhibitors more specific for NPP i.e. 5-nitro-2-(3-phenylpropylamino) 
benzoic acid (NPPB) (Kirk et al., 1994). The increased viscosity of the PRBC 
cytoplasm over uninfected RBC cytoplasm could be measurable as an increased 
osmotic fragility. This is seen by lysis of mature trophozoite PRBC earlier in a series of 
lysis buffers of increasing relative tonicity (Lew et al., 2003). An effect of furosemide on 
this change in osmotic fragility could easily be tested for. A return to a reduced osmotic 
fragility as seen in uninfected RBC after furosemide treatment would support the model 
that furosemide is leading to a reduction in PRBC cytoplasmic osmolarity. However, a 
complication is that the cytoplasmic viscosity may not be directly related to the 
osmolarity as many solutes may contribute to cytoplasmic viscosity without affecting 
osmolarity.
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4-6 CONCLUSIONS
In summary, we have shown that the observed rigidity of PRBC is due to changes in 
the RBC membrane cytoskeleton structure made by the parasite. Our hypothesis from 
this work is that the increased cytoplasmic viscosity of a PRBC also has a role in the 
increased rigidity, however, this effect can only be seen when membrane cytoskeleton 
integrity is compromised.
Increased rigidity of PRBC is maintained after the parasite has been killed -  indicative 
of the permanent remodelling of the RBC by the parasite. This is significant as it 
implies that any pathophysiological features resulting from the increased rigidity of the 
PRBC can potentially still be continuing long after antimalarial treatment has been 
administered. However, it also indicates that if PRBC were to be released from 
sequestration the increased rigidity of the cells would still make them a potential target 
for splenic clearance.
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CHAPTER 5 - REDUCED CYTOADHERENCE TO ENDOTHELIAL CELLS EXPOSED 
TO FEVER
5-1 INTRODUCTION
An important symptom of P. falciparum malaria is fever, which may occur as classically 
predicted fever peaks recurring every 48 hours, or a more general raised temperature 
as commonly observed in acute malaria (Peters, 1995) [www.who.int].
Febrile temperatures may have an effect on the growth, and cytoadherence capacity of 
P. falciparum parasites. There is some evidence that trophozoite stage parasites are 
sensitive to higher temperatures (Oakley et al., 2007, Kwiatkowski, 1989), resulting in 
inhibition of growth and loss of viability of parasites, while the young ring stage 
parasites may mature quicker at febrile temperatures (Long et al., 2001, Kwiatkowski, 
1989, Pavithra et al., 2004). This has been suggested to result in an increased 
synchronicity of cultures.
It has been shown by Udomsangpetch et al. (Udomsangpetch et al., 2002), that the 
ability of PRBC to cytoadhere may be increased after growth at febrile temperatures, 
possibly due to increased PfEMP-1 trafficking at higher temperatures. However, other 
studies have shown no evidence for increased levels of PfEMP-1 on the surface of 
PRBC matured under febrile conditions (Oakley et al., 2007). However, the 
Udomsangpetch et al. study only looked at the effect of fever on PRBC, and not the 
effect that fever may have on the host endothelial cells to which the PRBC adhere.
Host endothelial cells respond to febrile temperatures, and as described in chapter 1, 
there are differences between the responses to febrile temperatures and heat shock 
(Hasday & Singh, 2000, Park et al., 2005). We define febrile, or fever-range 
temperatures as physiologically relevant temperatures generally between 39°C and 
41 °C, whereas heat shock temperatures are non-physiological temperatures over 
42.5°C (up to 55°C was used in one study (Zhou et al., 2007)). Some studies have 
reported that exposure to febrile temperatures increase the response to cytokines such 
as TNF (Chen et al., 2006), whereas other studies have seen the opposite, i.e. fever 
exposure reduces the response to cytokines (Hasday et al., 2001). Some of these 
differences are due to differences between different endothelial cell types. One relevant 
phenotype of increased ICAM-1 expression in response to febrile temperatures 
appears limited to the specialized High Endothelial Venule (HEV) endothelial cells 
(Chen et al., 2006).
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There have been more studies looking at the effect of non-physiological heat shock 
conditions on endothelial cells but again varying results have been seen with some 
studies showing a stimulatory effect of heat shock (Lefor et al., 1994), whereas others 
show a reduced response to cytokines in cells exposed to heat shock (Nakabe et al., 
2007, Kohn et al., 2002).
One expected response to heat shock is the induction of the heat shock response 
pathway. This is a stress pathway that is well known to be induced in many cell types in 
response to a range of environmental stresses, including heat shock. The response is 
characterised by the activation of a transcription factor, HSF-1, which induces 
transcription of several genes, mainly those encoding heat shock proteins, including 
HSP70. Heat shock proteins include several families of proteins with mainly chaperone 
functions that may exist to protect against deleterious effects of fever on protein folding 
(Lindquist & Craig, 1988, Hartl, 1996).
Antipyretic (fever-reducing) treatment is standard adjunct therapy for malaria 
(Winstanley & Ward, 2006), however, studies assessing the effects of antipyretic 
treatment on disease have not shown evidence (in terms of parasite clearance time or 
disease outcome) for an advantage of giving antipyretic treatment (Meremikwu et al., 
2000). In one study paracetamol led to a significantly increased time to parasite 
clearance when compared to mechanical antipyresis alone (Brandts et al., 1997). 
Similar results were seen with other antipyretics metamizol and naproxen, where a 
slight difference in parasite clearance time was observed but this could not be linked to 
any significant difference in fever reduction compared to controls (Lell et al., 2001).
As fever is a universal symptom in malaria, knowing whether fever affects 
cytoadherence could have implications for symptom management, as well as being 
interesting in terms of host-pathogen interactions. From available literature it is not 
clear how endothelial cells respond to febrile temperatures with respect to phenotypes 
relevant for cytoadherence, i.e. adhesion receptor expression. Since there have been 
some studies looking at the effect of febrile temperatures on parasites, we focus on the 
possible cytoadherence-related effects of fever on endothelial cells. In order to simply 
look at effects on endothelial cells in this study we expose only the endothelial cells to 
physiologically relevant febrile temperatures and assess effects on subsequent PRBC 
cytoadherence. We have found that exposure of endothelial cells to febrile 
temperatures results in a reduction in cytoadherence, illustrating the protective nature 
of host responses.
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5-2 MATERIALS AND METHODS
Parasites
Parasite isolates used were C24, ItG, A4, JDP8 as described in Methods chapter 2 and 
the patient isolate 8146 described in chapter 6. All were maintained at 37°C throughout 
and used at mid-trophozoite stage for assays.
Endothelial Cells
HUVEC and HDMEC were obtained from Promocell and maintained as described in 
Methods chapter 2. In addition, individual isolates of HUVEC were used which were 
obtained by Neil Jenkins in Kilifi (N. Jenkins PhD Thesis 2007, LSTM. Ethics were 
approved locally for HUVEC isolation (Kilifi), and cells were cultured before shipment to 
LSTM). These were maintained as described in methods chapter 2 for Promocell 
HUVEC. The human pulmonary microvascular (Lung) endothelial cell line (HLEC) were 
obtained from Sciencell and maintained as for HDMEC as described in chapter 2. The 
transformed brain microvascular endothelial cell line HB13 (Tripathi et al., 2006) was a 
gift from M. Stins. HB13 were maintained in DMEM (high glucose with sodium 
bicarbonate, without L-Glutamine and sodium pyruvate) (Gibco) with 10% (vol/vol) 
foetal bovine serum (Sigma) and supplemented with 2 mM L-glutamine, 10 ng/ml 
epidermal growth factor (EGF), 1 pg/ml hydrocortisone. Cells were incubated at 37°C 
in 5% C02 in a humidified incubator and trypsinisation for passage was carried out on 
sub-confluent cells as described for HUVEC/HDMEC. HUVEC, HDMEC and HLEC 
were used at passage number 3 - 6  and HB13 were used at passage number 12-15.
Immunofluorescence and Flow Cytometry
ICAM-1 expression on endothelial cells was measured by flow cytometry after 
immunofluorescence staining using and anti-ICAM-1 monoclonal antibody mAb 15.2 
conjugated to FITC, as described in methods chapter 2. For fluorescent confocal 
microscopy cells were grown to confluence on 13 mm permanox cover slips (Nunc) 
and exposed to TNF/fever conditions as appropriate. Cells were washed in PBS with 
1% BSA (PBSBSA) and incubated with primary anti-ICAM-1 antibody (mAb 15.2) 1:50 
dilution in PBSBSA for 45 min at 37°C. After washing with PBSBSA secondary FITC- 
conjugated anti-mouse secondary antibody at 1:50 dilution was incubated in the cells in 
the dark for 45 min at 37°C. Cells were then fixed in 4% paraformaldehyde for 30 min. 
The cells were then permeabilised with PBSBSA with this addition of 0.1% triton X-100 
for 30 min, then washed before incubation with Rhodamine Phalloidin at 1:50 dilution 
along with 1:1000 dilution DAPI in PBSBSA with 0.005% triton for 45 min. Cells were
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washed with PBSBSA, then washed with PBS and mounted in vector shield and 
sealed. Analysis was using a Zeiss LSM Pascal confocal microscope and Zeiss pascal 
software. Minor image processing carried out using Adobe Photoshop was performed 
in the same way for all experimental conditions.
Adhesion Assays
Static adhesion assays to endothelial cells were performed at 37°C as described in 
chapter 2. Flow adhesion assays to endothelial cells were performed at 37°C using the 
chamber slide system as described in chapter 2.
Fever Treatment
Confluent cells were incubated at febrile temperatures of 39.5°C or 41 °C in an identical 
5% C02 humidified incubator as the control cells (37°C) (Heraeus incubator). Actual 
temperature was monitored using a thermometer on the same shelf as the cells in each 
incubator and was found to be ± 0.5°C expected temperature. For most experiments 
fever exposure was for 16 hours, however other exposure times were used in some 
cases as described in the text. Controls maintained at 37°C were included in every 
experiment.
Heat Shock Treatment
Heat shock (as opposed to “fever”) was performed by incubating endothelial cells in a 
sealed (parafilm) 24 well plate in a water bath carefully measured to be at 42.5°C for 1 
hour. Control cells were incubated in the same way in a water bath at 37°C. After 1 h 
incubation the plates were unsealed and returned to the 37°C C02 incubator for 4 h 
recovery time before experiment.
Protein Samples
Whole cell lysates were obtained from confluent cells in one well of a 24 well plate. 
Cells were washed twice with dPBS then incubated in 40 pi 2 X SDS sample buffer for 
30 seconds before harvesting by scraping with a yellow pipette tip. Samples were 
boiled for 4 min before use and 5-10 pi loaded on sodium dodecyl sulfate (SDS) gels 
for Coomassie staining or western analysis. Comparable protein concentration in each 
sample was confirmed by analysing a coomassie stained gel.
SDS-PAGE and Western Blotting
For Western blotting, 5 - 10 pi samples of whole cell lysate (0.5 -  1 x 104 cell 
equivalents) were separated on a 10% SDS gel according to standard procedures
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(Sambrook et. al) before transfer onto Hybond-P membrane (Amersham) using Bio-rad 
mini-protean transfer kit (using a Tris-Glycine transfer buffer as standard procedures 
Amersham/Bio-rad). Low or High molecular weight protein markers (Amersham) were 
loaded alongside. After transfer the membrane was blocked in 5% Marvel Low fat milk 
in TBST (Tris-buffered saline solution with 0.1% Tween20) overnight at 4°C. Primary 
anti-HSP70 antibody (A gift of Yang Wu) was used at 1:50,000 dilution in TBST for 1 h 
at room temperature. After washing for 1 h at room temperature with 4 x changes of 
TBST a horseradish peroxidase (HRP)-coupled secondary antibody was incubated at 
1:5000 for 1 h at room temperature. The membrane was washed 1 h at room 
temperature with at least 4 changes of buffer and visualised using ECL system 
(Amersham) and exposure to X-ray film (Pierce). After exposure blots were stripped 
with 2 x 5  min washes in 0.2N NaOH followed by 2 x washes in dH20  before re­
blocking with 5% marvel as above. For loading control the blot was then probed with [3- 
Actin antibody (Abeam) used at 1:5000 dilution and proceeded as above.
Viability Assay
The Cell-Titer Blue metabolic assay (Promega) was used to determine endothelial cell 
viability. The assay is based on the ability of living cells to convert a redox dye 
(resazurin) into a fluorescent end product (resorufin). Nonviable cells will have lost 
metabolic capacity and therefore will not generate the fluorescent signal. From 
trypsinisation of 1 x confluent T25 flask cells were counted and two-fold serial dilutions 
of endothelial cells were seeded from 1 x 104 cells/well to 625 cells/well, in triplicate 2X 
in a 96 well plate. After settling for two hours medium was replaced with 150 pi/ well of 
growth medium and cells grown overnight. Controls included wells containing no 
endothelial cells and dead endothelial cells treated with sodium azide before addition of 
reagent. After overnight growth at 37°C or fever temperature, in triplicate with/without 1 
ng/ml TNF cells were incubated in 100 pi of a 1:20 dilution of cell-titer blue reagent in 
HUVEC medium for 4 h at 37°C. Fluorescence at 560/590 nm was measured and 
plotted after subtraction of background (medium alone negative control).
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5-3 RESULTS
Part I -  Effect of Febrile Temperatures on Cytoadherence
Adhesion of ItG to fever treated and stimulated HUVEC is reduced
To examine the effect that exposure of endothelial cells to fever had on cytoadherence, 
we first used Human endothelial umbilical vein endothelial cells (HUVEC). We chose a 
modest febrile temperature of 39.5°C which is within physiologically relevant fever 
range. We initially exposed cells to fever for 16h which would be relevant for 
observations of generally raised temperatures during acute infection, or corresponds to 
the maximum length of fever peaks in a classical model of P. falciparum malaria febrile 
episodes.
A confluent monolayer of HUVEC was incubated at a fever temperature of 39.5°C or 
standard temperature of 37°C for 16 h. Resting HUVEC do not express ICAM-1, so 
TNF (1ng/ml) was used in most experiments to induce expression of ICAM-1 on these 
cells. Since it has been shown that fever peaks and TNF levels coincide in malaria 
infection, TNF (when used) was added concurrently with fever exposure for the 
stimulation of ICAM-1 adhesion receptor expression. Adhesion of parasite isolates to 
these cells was then assayed. Parasites had been maintained at 37°C and assays 
were carried out at 37°C in order to only assess the affect of fever on the endothelial 
cells.
The P. falciparum isolate C24 which is not expected to adhere to HUVEC showed very 
low levels of binding in static assays, and this was the same regardless of overnight 
incubation temperature or TNF exposure (Fig. 5.1a). ItG showed low levels of adhesion 
to non-stimulated HUVEC and significantly increased levels of adhesion to TNF 
stimulated cells. However, adhesion to fever treated TNF stimulated HUVEC was lower 
than that seen to control HUVEC maintained at 37°C (Fig. 5.1b). A similar reduction in 
adhesion to fever treated HUVEC was seen in assays under flow conditions where 
<50% adherent PRBC were present on fever treated cells compared to those 
maintained at 37°C (Fig. 5.1c).
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Figure 5.1. Adhesion to HUVEC exposed to 16 h 39.5°C fever. A,B) Static adhesion assays. Adhesion 
of C24 PRBC (a) and ItG PRBC (b) to HUVEC with or without 16h 1 ng/ml TNF and concurrent 16h 37°C 
or 39.5°C fever exposure in static adhesion assays. Results shown are bound PRBC/mm2 ± SD from 3 
(C24) or 6 (ItG) Independent experiments. C) Flow adhesion assay ItG to HUVEC stimulated with 1 ng/ml 
TNF concurrent with/without 16 h 39.5°C fever. Result shown as bound PRBC/mm2 ± SD from 3 
independent experiments
ICAM-1 Expression levels are the same after fever treatment
The first explanation we considered for the reduction in adhesion seen to HUVEC after 
fever exposure was the possibility of reduced levels of ICAM-1 stimulation. We first 
showed that, as predicted, there was no induction of ICAM-1 expression on 
unstimulated cells after fever treatment, as measured by flow cytometry after 
immunofluorescence for ICAM-1 (Fig. 5.2a solid lines). Following TNF exposure ICAM- 
1 was strongly stimulated, and this level of stimulation did not appear to be affected by 
exposure to febrile temperatures (Fig. 5.2 a dashed lines).
HUVEC Viability is unaffected by fever treatment
To exclude that the reduced cytoadherence observed was due to reduced cell viability 
we used a resorufin-based assay Cell-titer blue (Promega) to determine viability of 
HUVEC after exposure to fever temperatures. Cells were seeded at a range of 
densities in a 96 well plate in order to distinguish between any potential cell death or 
reduced growth phenotype in case of differences in viability observed. There was no
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significant difference in viability after incubation at 39.5°C compared to control 37°C 
with viability at all seeding densities being >90% of control (Fig. 5.2b).
Figure 5.2. ICAM-1 expression and viability of HUVEC after 16h fever. A) ICAM-1 expression on the 
surface of HUVEC measured by flow cytometry. Result is representative of three independent 
experiments. B) Viability of HUVEC measured by resorufin assay at different cell seeding densities. Mean 
of three independent experiments.
Addition of TNF to HUVEC after fever exposure results in protection against 
cytoadherence
It could be possible that the reduced adhesion seen is due to reduced efficacy of TNF 
when it is added at higher temperature, conceivably simply due to reduced stability of 
TNF at the higher temperatures. To control for this we added TNF independently of 
fever treatment. HUVEC were exposed to 39.5°C fever for 16 h in the absence of TNF, 
then cells were returned to 37°C and TNF was added at 10 ng/ml for 5 h after fever 
exposure before static adhesion assays. As discussed later, this is probably less 
physiologically relevant than addition of TNF and fever concurrently, but may also 
reveal clues to the mechanism of protection.
These preliminary experiments showed a reduction in adhesion to fever exposed cells 
compared to that seen to cells maintained at 37°C when TNF was added after fever 
exposure (Fig. 5.3a), similar to the protection shown in figure 5.1b when TNF and fever 
were added together. However, when cells were exposed to fever after TNF stimulation 
no effect on adhesion was seen (Fig. 5.3a). The reduced adhesion to overnight fever 
exposed cells was similar after a 30 min, or 6 h recovery time (Fig. 5.3b). Exposure of 
HUVEC to fever for < 6h did not appear to affect adhesion levels (not shown).
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Figure 5.3. Adhesion if ItG to HUVEC after different fever/TNF exposure conditions. Static adhesion 
assays. A) Adhesion levels after exposure of HUVEC to 16 h fever either before addition of 10 ng/ml TNF 
for 6 h (first column), or exposure to 10 ng/ml TNF for 6 h before exposure to 16 h fever (second column). 
B) Recovery time at 37°C after exposure to fever and TNF (1 ng/ml) for 16 h.
Febrile temperatures of 41 °C result in protection against cytoadherence
Adhesion of ItG to HUVEC after exposure to a fever temperature of 41 °C also showed 
a reduction in adhesion compared to that seen on HUVEC maintained at 37°C. (Fig. 
5.4a). The level of reduction in adhesion was similar to that seen after exposure to a 
39.5°C fever, and similarly ICAM-1 expression levels were unaffected (Fig 5.4b). 
Although cell morphology appeared generally unaffected (Fig. 5.4c) viability was 
slightly reduced to ~85-90% of control cells maintained at 37°C (Fig. 5.4d).
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Figure 5.4. Effect of 41 °C fever on HUVEC. A) adhesion of ItG to HUVEC after either overnight fever 
with 1 ng/ml TNF (column 1) or after 16 h fever followed by 10 ng/ml TNF (column2) Mean + SD of 3 or 2 
independent triplicate experiments. B) Expression of ICAM-1 after exposure to fever at 41 °C 16 h with 1 
ng/ml TNF. C) Giemsa staining morphology of HUVEC after adhesion assay. D) Viability of HUVEC after 
exposure to 41 °C fever. Mean ± SD of two independent experiments.
ICAM-1 Distribution on HUVEC
Although levels of ICAM-1 appeared the same in flow cytometry analysis we used 
fluorescence microscopy to analyse the distribution of ICAM-1 on the surface of 
HUVEC. ICAM-1 expression in HUVEC was visualised by immunofluorescence 
staining on live (unfixed) cells (to ensure surface staining only), using mAb 15.2 and a 
FITC conjugated secondary antibody and counter stained with rhodamine conjugated 
phalloidin to stain filamentous actin (f-actin) cytoskeleton, and DAPI stain for nuclear 
DNA. With no primary anti-ICAM-1 antibody there was no visible background in the 
FITC channel (not shown). In the absence of TNF there was minimal visible staining of
HUVEC for ICAM-1 (Fig. 5.5a, c). The ICAM-1 distribution on TNF stimulated HUVEC
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was an uneven patchy distribution over the surface of the cell which was unchanged 
after ItG adhesion assays (Fig. 5.5b,d).
Immunofluorescence Analysis of HUVEC after fever Treatment
Immunofluorescence staining for ICAM-1 and f-Actin was carried out as above on 
HUVEC that had been exposed to 16 h 39.5°C. The pattern of ICAM-1 expression and 
the phalloidin staining appeared no different between cells maintained at 37°C and 
those exposed to 39.5°C fever for 16h (Fig. 5.6). Similar results were seen when 
staining was carried out after ItG adhesion assay and no ICAM-1 expression was 
visible in unstimulated cells (not shown).
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Figure 5.5. Immunofluorescence labelling of ICAM-1 on HUVEC. DAPI stain for nuclear DNA (row 1), 
Surface labelling of ICAM-1 on HUVEC using mAb 15.2 followed by FITC conjugated secondary antibody 
prior to fixation (row 2). F-Actin staining using rhodamine phalloidin after paraformaldehyde fixation and 
permeabilisation (row 3), and merged images (row 4). Cells were stimulated with TNF (1ng/ml 16h) (b,d) or 
without stimulation (a,c). Immunofluorescence procedure were carried out before (a,b) or after (c,d) ItG 
adhesion assay.
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Figure 5.6. ICAM-1 Immunofluorescence on HUVEC after 16h 39.5°C fever. DAPI stain for nuclear 
DNA (row 1), Surface labelling of ICAM-1 on HUVEC using mAb 15.2 followed by FITC conjugated 
secondary antibody prior to fixation (row 2). F-Actin staining using rhodamine phalloidin after 
paraformaldehyde fixation and permeabilisation (row 3), and merged images (row 4). Cells were stimulated 
with TNF (1 ng/ml 16 h) along with treatment (16 h) at 37°C (left column) or 39.5°C (right column).
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Part II - Heat Shock Response Pathway Activation
The next series of experiments attempt to determine something of the mechanism of 
the observed protection against cytoadherence. We have not seen any evidence of 
changes to the endothelial cells in response to fever, so we next assessed the 
stimulation of the heat shock response pathway. We have used HSP70 which is 
expressed in response to heat shock temperatures and other environmental stresses to 
analyse whether heat shock pathways are activated in response to our fever 
conditions. As a control we used standard heat shock conditions of a 42.5°C heat 
shock for 1 hour followed by 4 h recovery at 37°C to allow for protein expression. 
These conditions, as expected, showed strong HSP70 stimulation in HUVEC (Fig. 5.7 
lanes 5-8).
Heat Shock Response Pathway is activated in response to 16 h 39.5°C fever
HSP70 was seen to be strongly stimulated in response to standard heat shock 
conditions (42.5°C for 1 h followed by a 4 h recovery at 37°C to allow for protein 
expression) (Fig. 5.7 lanes 5-8). HSP70 was also strongly induced by exposure of 
HUVEC to our fever conditions of 39.5°C for 16 h (Fig. 5.7 lanes 1-4). The presence of 
1 ng/ml TNF had no effect on HSP70 level stimulation.
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Figure 5.7. Induction of HSP70 in HUVEC. Western blot probed for HSP70 of HUVEC samples after 
exposure to heat shock conditions (right) or febrile temperatures (left). Coomassie stained membrane 
(bottom panel) used as indication of loading. Amersham high range molecular weight markers were run 
alongside, approximate position of 66 kDa marker is indicated.
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Individual HUVEC isolates have similar HSP70 activation and adhesion assay 
phenotypes
All experiments we have presented so far have been performed on pooled HUVEC 
from one commercial supplier (Promocell). To ensure that our observations were not 
unusual to these cells we used HUVEC isolates obtained from individuals (Neil 
Jenkins, Liverpool/Kilifi) as opposed to pooled batches from Promocell. We assayed 
individual isolates both for adhesion phenotype after fever exposure, and HSP70 
expression. Four isolates tested and compared in parallel with Promocell HUVEC 
showed similar results.
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Figure 5.8. Effect of fever on individual HUVEC isolates. A) Induction of HSP70 in individual HUVEC 
isolates after exposure to 39.5C for 16h. The same blot was probed for b-actin as a loading control. B) 
Adhesion of ItG to different HUVEC isolates after exposure to 39.5’C 16h (grey bars) compared to 
maintained at 37’C (black bars). Adhesion expressed as a percentage of 37’C control and mean + SD of 
two slides. All assays and protein extraction were carried out at the same time.
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All isolates showed HSP70 induction after exposure to 16h 39.5°C (Fig. 5.8a). Although 
actual numbers of adherent PRBC varied between isolates, all isolates showed 
reduced levels of adhesion to cells exposed to 16h 39.5°C compared with controls 
maintained at 37°C (Fig. 5.8b).
Adhesion to HDMEC is not affected by exposure to fever
HDMEC express CD36 constitutively as well as ICAM-1 after TNF stimulation, and 
adhesion of ItG PRBC to stimulated HDMEC is known to use both receptors. In 
contrast to the reduced adhesion seen to stimulated fever-exposed HUVEC, adhesion 
of both C24 and ItG PRBC to both unstimulated and stimulated HDMEC was relatively 
unaffected by 16 h exposure to 39.5°C temperatures (Fig. 5.9a). Similarly, under flow 
conditions there was no difference in adhesion of ItG to stimulated HDMEC (Fig. 5.9b).
To separate out CD36 mediated adhesion and ICAM-1 mediated adhesion a 
monoclonal antibody which blocks adhesion to CD36 was used. As shown in figure 
5.9c, after inhibiting CD36 mediated adhesion there was a reduced level of adhesion 
which was slightly, but not significantly, reduced after exposure to 16 h 39.5°C fever 
(Fig. 5.9c +block). Without blocking treatment adhesion was ~85% of 37°C control, 
however after CD36 blocking, adhesion was ~70% of control.
After blocking of ICAM-1 adhesion using the anti-ICAM-1 monoclonal antibody 
mAb15.2 we could see that febrile temperature exposure had no effect on the CD36 
mediated adhesion (result not shown) even after TNF stimulation, suggesting that only 
ICAM-1 mediated adhesion is affected by febrile temperatures (Fig. 5.9d).
To further investigate this, a different parasite isolate, JDP8, which favours ICAM-1 
adhesion and shows comparatively little adhesion to CD36 was used (Chattopadhyay 
et al., 2004). JDP8 PRBC showed the expected higher adhesion than ItG to stimulated 
HDMEC with mean adhesion of 995 PRBC/mm2, whereas CD36 mediated adhesion to 
unstimulated HDMEC was lower than ItG at 215 PRBC/mm2. JDP8 showed a subtle 
reduction in adhesion to stimulated HDMEC (Fig. 5.9e), a mean adhesion of 71% 
compared to 37°C controls was observed (Fig. 5.9e) but again this was not statistically 
significant.
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As seen with HUVEC there was no difference in the level of ICAM-1 after exposure to 
16 h 39.5°C fever (Fig. 5.9f). These experiments indicate that there is much less 
response of HDMEC to febrile temperatures than we previously observed with HUVEC, 
with no reduction in adhesion being statistically significant although some reduced 
binding was observed in most experiments. The results also hint that any possible 
reduction in adhesion seen is due to ICAM-1 mediated adhesion only.
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Figure 5.9. Adhesion to HDMEC after fever exposure. A) Adhesion of ItG to HDMEC in static assays. 
Bound PRBC/mm2, mean + SD three independent experiments. B) Adhesion of ItG to TNF stimulated 
HDMEC in flow adhesion assays. Expressed as bound PRBC/mm2, mean ± SD of two independent 
duplicate experiments. C) Adhesion of ItG to TNF stimulated HDMEC in static assays. Bound PRBC/mm2 
mean + SD of two independent duplicate experiments. D) Adhesion of ItG to TNF stimulated HDMEC in 
static assays with blocking of ICAM-1 adhesion using mAb 15.2. E) Adhesion of JDP8 to HDMEC in static 
assays. Percent of 37°C control binding, mean + SD four independent duplicate experiments. F) 
Expression of ICAM-1 on HDMEC
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Adhesion to HBEC but not HLEC is reduced by fever
Human pulmonary vein (lung) endothelial cells (HLEC) express CD36 and ICAM-1 after 
TNF stimulation (Muanza et al., 1996). These cells showed very similar adhesion 
behaviour to HDMEC. There was no difference in the adhesion to unstimulated HLEC 
after fever exposure, representing mainly CD36 mediated adhesion. (Fig. 5.10a), and 
there was a slight effect on adhesion to TNF stimulated HLEC after exposure to 16h 
39.5°C fever (Fig. 5.10a). The brain endothelial cell line HB13 is a transformed cell line 
derived from human brain microvascular endothelial cells. These cells have been 
shown to express ICAM-1 after TNF stimulation, however have very low levels of CD36 
expression (Tripathi et al., 2006). Preliminary experiments with these cells have 
indicated that the response to fever is more similar to that seen with HUVEC, i.e. a 
reduction in cytoadherence of ~ 50% is seen.
HLEC-TNF HLEC + TNF 37°C 39.5°C
Figure 5.10. Adhesion of ItG to HLEC and HBEC. Showing bound PRBC/mm2to a) HLEC, mean + SD 
two independent duplicate experiments, and b) HBEC mean + SD of triplicate experiment.
Adhesion of A4 to fever-exposed HUVEC is reduced
Preliminary experiments suggest that the adhesion of A4 to fever-exposed HUVEC 
shows a similar pattern to that seen with ItG, i.e. a reduction in adhesion to cells 
exposed to 16 h 39.5°C compared to those maintained at 37°C.
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Figure 5.11. Adhesion of A4 to HUVEC. Mean of triplicate experiment. + SD.
HDMEC show a reduced HSP response to fever compared to HUVEC
The ability of febrile temperatures to induce heat shock response pathways in HUVEC 
and HDMEC was compared. The level of HSP70 induction was measured over a time 
course of incubation at 39.5°C. Samples were taken from both cell lines at the same 
time, and were run on the same gel to ensure equivalent blotting and antibody 
exposure conditions. The results suggest that HDMEC show a lower level of HSP70 
expression in response to febrile temperature, suggesting lower levels of heat shock 
response pathway activation (Fig. 5.12). The same result was seen in two independent 
experiments.
Time (h) 
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Figure 5.12. Western blot for HSP70 as a marker of heat shock pathway activation after exposure to 
febrile temperatures. Representative of two independent experiments. Upper panel, membrane probed for 
HSP70, and membrane was stripped and re-probed for beta-actin as a loading control (lower panel). 
HUVEC and HDMEC samples were taken at the same time, processed in the same way and run on the 
same gel.
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The role of the heat shock response pathway in response to fever
In order to determine whether the heat shock response pathway was important in the 
observed protection against fever we sought to inhibit the activation of this pathway. 
Two chemical inhibitors of the heat shock pathway induction were used, quercetin and 
KNK437 (Powers & Workman, 2007, Dokladny et al., 2008, Nagai et al., 1995, 
Hosokawa et al., 1992). Quercetin was shown to reduce the level of heat shock 
pathway following fever treatment by western blotting for HSP70 protein levels (Fig. 
5.13a). At the higher concentrations of quercetin 10 pM, 50 pM and 100 pM cellular 
morphology was disrupted, and extensive cell death appeared to have occurred at 50 
pM and 100 pM concentrations. No effect was seen at equivalent maximum 
concentration of DMSO solvent. Quercetin has previously been reported to also affect 
the TNF stimulation of ICAM-1 expression (Kobuchi et al., 1999), so we measured 
ICAM-1 levels on quercetin treated HUVEC. There was a slight reduction in ICAM-1 
level of quercetin treated HUVEC compared to untreated (Fig. 5.13b,c). After overnight 
quercetin treatment of HUVEC adhesion was significantly reduced (Fig. 5.13c) 
although again at higher concentrations of quercetin (50 pM and 100 pM) cells were 
visibly affected by the treatment. The effect of 2 pM quercetin on fever- exposed 
HUVEC was assessed (Fig. 5.13d) but the effect of quercetin on basal adhesion levels 
masks any effect related to heat shock response pathway. At the concentration of 
KNK437 recommended for use (10 pM) there was a slight reduction in ICAM-1 level 
(80% of control, not shown) but cells were visibly affected by the treatment so any 
effect on binding phenotype (not shown) could not be directly attributed to effect on 
heat shock pathway over general cell death effects.
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Figure 5.13. Effect of quercetin treatment of HUVEC on HSP induction, ICAM-1 expression and 
cytoadherence. A) Western blot for HSP70 Induction by 16h 39.5°C fever with addition of Quercetin at 
0-10 pM concentration. 0 pM quercetin represents DMSO solvent only compared to -  indicates no 
treatment. Blot was stripped and reprobed for p-actin as a loading control (lower panel). B) Geometric 
mean quantitation of ICAM-1 expression after 16 h TNF (1ng/ml) stimulation with 2 pM quercetin. And C) 
FACS trace of ICAM-1 levels after 16h TNF (1 ng/ml). D) Effect of quercetin at concentrations of 0.4 to 100 
pM on ItG adhesion. Mean +SD 1-3 independent experiments expressed as a percentage of control 
(untreated) adhesion. E) Adhesion of ItG to HUVEC treated with quercetin 2 pM and 16 h 39.5°C fever. 
Bound PRBC/mm2, mean + SD two independent triplicate experiments.
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5-4 DISCUSSION
We have assessed the response of endothelial cells to fever in terms of PRBC 
cytoadherence. The striking result that we have shown is that host endothelial cells 
respond to fever in a way that is protective against ICAM-1 cytoadherence. All assays 
were performed at 37°C using parasites that had been maintained at 37°C in order to 
only analyse the effect that febrile temperatures had on the host endothelial cell.
The first observation was that fever had no stimulatory effect on adhesion. C24 which 
is known not to bind to HUVEC showed very low levels of adhesion to HUVEC that had 
been exposed to fever either with or without TNF stimulation. This suggested that fever 
was not making the endothelial cells “stickier” in any non-specific way. Similarly, 
HUVEC not exposed to TNF stimulation are known to support only very low levels of 
ItG cytoadherence, and this was not increased on fever exposure.
After TNF stimulation under febrile conditions, adhesion of ItG PRBC to HUVEC was 
reduced compared to adhesion to TNF stimulated cells maintained at 37°C. In 
individual experiments the degree of adhesion varied between 30% and 80% of 
controls. This variability could be explained by variations in the temperature of the 
incubators, both of which were found to vary by ± 0.5°C. Alternatively previous 
exposure of cells to fever or heat shock is known to confer protection against 
subsequent exposures, thermotolerance, it is possible that batches of cells may have 
been exposed to slightly raised temperatures at some point during growth or expansion 
which affected their response.
Although cell morphology appeared unaffected by fever, (as determined by 
observations of cell monolayers during adhesion assays), we used a resazurin based 
metabolic assay to quantitate cell viability. This showed that HUVEC exposed to 
39.5°C fever for 16 h were still >90% viable compared to controls maintained at 37°C. 
Furthermore, analysis of cells using fluorescence microscopy to look at cell 
cytoskeleton showed no gross morphological changes and an intact monolayer of cells 
remained despite fever treatment.
A second explanation for the reduced adhesion that we considered was the possibility 
of a reduction in the level of ICAM-1 induced by the TNF stimulation. Flow cytometry
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analysis of surface ICAM-1 levels suggested equivalent ICAM-1 stimulation in fever 
treated cells compared to those maintained at 37°C.
A reduction in the response to TNF could conceivably be due to increased degradation 
of TNF at the higher temperature resulting in an effectively lower concentration. 
Although this appeared not to be the case as ICAM-1 levels were equivalent, a second 
control for this involved adding TNF separately from the fever exposure. We found that 
cells exposed to fever then stimulated with TNF at 37°C showed a similar phenotype to 
those exposed to fever and TNF simultaneously, i.e. there was a reduction in adhesion 
to the fever exposed cells compared with those maintained at 37°C. Interestingly, 
preliminary experiments suggested that the converse was not true. Cells stimulated 
with TNF before fever exposure did not show a reduced binding phenotype. This hints 
at the possibility that the reduction in adhesion seen could be due to effects on newly 
synthesised proteins resulting from TNF stimulation under fever conditions or after 
fever exposure.
We also looked at ICAM-1 distribution across the surface of HUVEC. Initial 
experiments looked at ICAM-1 distribution before and after ItG adhesion assay, as well 
as without / with TNF stimulation. Before TNF stimulation there was very little ICAM-1 
staining visible, and controls with no primary antibody showed no background 
fluorescence from secondary antibody alone (result not shown). After the ItG assay few 
PRBC were remaining after wash steps so any potential redistribution of ICAM-1 to 
PRBC adhesion sites would be difficult to analyse. This is probably due to the use of 
mAb 15.2 which is known to inhibit PRBC cytoadherence, and as we describe in 
chapter 6 can also reverse binding of already adherent parasites. Phalloidin staining of 
the actin cytoskeleton revealed possible hints of cytoskeletal changes to HUVEC (and 
HDMEC, not shown) after parasite adhesion (Fig. 5.5 phaloidin panel), however, this is 
under investigation elsewhere (Srabasti Chakravorty).
The distribution of ICAM-1 across the surface of HUVEC appeared broadly unaffected 
by fever exposure, similarly there was no evidence for effects on the F-actin network 
after exposure to fever. We also looked at HUVEC (and HDMEC) after adhesion 
assays on both control cells and those exposed to fever (not shown) and, similarly, 
there was no difference between cells exposed to fever and those maintained at 37°C.
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We then chose to investigate the heat shock response pathway. This is a stress 
response pathway present in all mammalian cells which activates protective responses 
in response to environmental stresses including heat shock and heavy metal exposure 
(Wagner et al., 1999). Standard heat shock conditions involve a short (1h) exposure to 
heat shock temperature generally between 42°C and 43°C followed by a recovery 
period at 37°C for around 4h to allow for protein synthesis. Under these conditions in 
HUVEC we could see significant upregulation of the heat shock response protein 
HSP70. This was the same whether TNF was absent or present. After exposure to our 
fever conditions of 39.5°C for 16 h we found that HSP70 was also induced, and again 
expression was unaffected by the presence of TNF. Upregulation of HSP70 in HUVEC 
could first be detected by western blotting after 4 h exposure to 39.5°C. This showed 
that exposure even to physiological range temperatures induces this stress response in 
endothelial cells.
HUVEC from different sources were shown to behave similarly in terms of 
cytoadherence phenotype and heat shock response after fever exposure (Fig. 5.8), 
however, significant differences could be seen between different types of endothelial 
cells. Whereas there was a clear reduction in adhesion to fever-exposed HUVEC, there 
was much less effect of fever on adhesion to HDMEC. This could be in part explained 
by the adhesion to constitutively expressed CD36 on the HDMEC. C24 adhesion to 
CD36 on HDMEC, and ItG binding to CD36 (after blocking of ICAM-1 adhesion) on 
HDMEC appeared unaffected by fever treatment (Fig. 5.9). When the CD36 mediated 
adhesion was blocked using the monoclonal antibody some further reduction in 
adhesion was seen after fever treatment -  but the adhesion seen was still ~70% of 
controls compared with the <50% of control adhesion seen with HUVEC.
We also observed a reduced heat shock pathway response in HDMEC compared to 
HUVEC. This lesser response may explain this discrepancy in adhesion after fever, 
and hints at a role for the heat shock response pathway (or subsequent downstream 
effects) as having a role in the protection observed in HUVEC. Differences between 
different endothelial cell types are not unexpected as have been seen in previous 
studies looking at responses of endothelial cell to fever and heat shock (Ketis et al., 
1988). A specific example of this is the upregulation of ICAM-1 expression in 
specialised HEV cells (Chen et al., 2006), whereas, as we show, other endothelial cell 
types show little response (Hasday et al., 2001).
We assessed heat shock response pathway activation by looking at the stress 
response protein HSP70 which is known to be upregulated in response to heat stress
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through the Heat Shock Transcription Factor (HSF-1). HSF-1 is a protein that in a 
resting state is complexée! with HSP90. On exposure to heat stress HSF-1 becomes 
dissociated from HSP90 and trimerises, autophosphorylâtes and becomes an active 
transcription factor able to stimulate transcription of other heat shock pathway proteins, 
including HSP70 (Morimoto, 1998).
To determine the role of this pathway in protection against cytoadherence in HUVEC 
chemical inhibitors of the heat shock response pathway were used. Quercetin is a 
flavonoid which is found in onions, apples, tea and red wine, and can reach peak 
plasma concentrations of up to 2 pM from dietary intake (Moon et al., 2008). It can 
inhibit heat shock response by inhibiting trimérisation and activation of HSF-1 (Nagai et 
al., 1995). However, quercetin has wide ranging inhibitory properties and has been 
shown to inhibit JNK pathways (Nagai et al., 1995), as well as TNF stimulation of NF- 
kB and conversely NF-kB pathway induced upregulation of TNF (Nair et al., 2006). We 
found that the chemical appeared slightly toxic to HUVEC at concentrations previously 
published to be effective against HSF-1 activation, even in the absence of heat stress.
Quercetin alone in the absence of heat stress appeared able to significantly reduce 
levels of adhesion. The ability of this readily available dietary chemical alone to exert 
significant protective effects against cytoadherence may in itself be interesting. 
However, as a result of this effect on cytoadherence we were unable to use quercetin 
to help determine the importance of the heat shock response pathway in response to 
fever.
The downstream effector of the protection against cytoadherence was not elucidated. 
There are several possibilities which are described below and illustrated in figure 
5.14b.
We have hints that the protective effect is seen only on adhesion to ICAM-1 newly 
synthesised in the presence of heat shock response proteins. This was evidenced by 
the lack of reduction in adhesion following fever when TNF stimulation, and therefore 
ICAM-1 production, preceded fever exposure (Fig. 5.3a). While when ICAM-1 was 
stimulated concurrently with fever, or following fever exposure, adhesion levels were 
reduced. Many of these proteins are chaperones which are involved in the folding of 
newly synthesised proteins. It is conceivable that the presence of one of more of these 
chaperones (i.e. HSP70) could result in subtly different folding of newly synthesised 
ICAM-1 resulting in a different display of the PfEMP-1 adhesion site on ICAM-1 (Fig. 
5.14b).
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Alternatively there may be effects of heat shock response pathway proteins inhibiting 
adhesion. HSP70 can be localised on the surface of cells after heat shock (although 
this has mainly been demonstrated in tumour cells (Multhoff et al., 1995)) -  this (or 
other proteins) could be providing direct inhibition of adhesion to ICAM-1 (Fig. 5.14d).
ICAM-1 dimerisation and clustering may be important for adhesion of the endogenous 
ligand LFA-1 (Miller et al., 1995, Yang et al., 2004, Jun et al., 2001a), and could also 
be important for optimal adhesion of PRBC. The presence of heat shock pathway- 
activated proteins in the cell membrane i.e. small HSPs (sHSPs) such as HSP17 
(Tsvetkova et al., 2002) could be reducing the fluidity of the cell membrane (Fig. 5.14c).
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Heat Shock resjronses lead to 
insertion of proteins in the endothelial 
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reduced fluidity Leads to less 
dimérisation and/or clustering of 
ICAM-1 and red uced adhesion
Heat Shock res[>onses lead to subtle 
differences in K .AM -1. A ) Differences 
inavailablityof PfEMP-1 adhesion site 
or B) conformation differences in 
other domains Heading to reduced 
dimérisation and/or clustering
Heat Shock respionses lead to 
inhibitory proteins on the surface of 
the cell membrane sterically inhibiting 
adhesion, or b) additional or modified 
carbohydrategiroups on ICAM 1 or 
other proteins w hich sterically inhibit 
adhesion
Figure 5.14. Model of possible mechanisms for the reduction in ICAM-1 cytoadherence after fever.
Illustration of suggested mechanisms, as described In the text, for the protection against cytoadherence 
observed after exposure of endothelial cells to febrile temperatures.
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5-5 LIMITATIONS AND FURTHER WORK
One limitation of this work is that most assays were carried out using just one P. 
falciparum isolate, ItG. To further confirm the observations in this chapter, this work 
needs to be extended by using further parasite isolates as it is known that different 
isolates have slightly different mechanisms of adhesion to ICAM-1 (Tse et al., 2004). 
Preliminary results suggested that the JDP8 and A4 P. falciparum isolates, both of 
which are known to adhere to ICAM-1, showed the same behaviour as the ItG. 
However, further repeats should confirm this, and the use of fresh patient isolates 
would be important to show that the phenomenon is not unusual to established 
laboratory isolates. The availability of new ICAM-1 binding patient isolates from a 
separate project (Lucy Ochola and Tadge Szestak), as used in chapter 6, will be 
advantageous.
Our results using HDMEC have suggested that the reduced adhesion following fever 
exposure in our experiments was limited to ICAM-1 binding, as there was no apparent 
effect on CD36 mediated adhesion. Whether this is due to CD36 being constitutively 
expressed, or that the febrile temperatures are specifically affecting ICAM-1 is not 
clear. Further work could be carried out to determine this, and the effect on adhesion to 
other receptors could also be determined.
Further experiments to elucidate how fever exposure is protecting against PRBC 
cytoadherence need to be carried out to distinguish between the possibilities illustrated 
in figure 5.14. These could include using a range of conformation sensitive ICAM-1 
antibodies to detect potential subtle differences in ICAM-1. Adhesion of other ICAM-1 
ligands, i.e. LFA-1 could show how general the effect is or whether it is limited to PRBC 
adhesion. Detection of changes in cellular membrane fluidity using FRAP of a GFP- 
labelled ICAM-1 protein (Yang et al., 2006) could show whether ICAM-1 is less mobile 
within the membrane after fever exposure. A general screen for differences in protein, 
or carbohydrate content of the membranes of fever treated compared to untreated 
endothelial cells might reveal differences that prove to be the effector in the protection 
against cytoadherence. A 2-d DIGE approach combined with mass-spec identification 
of spots could be employed.
We suggest that the heat shock response pathway may play a role in the protection, 
although we were unable to provide any evidence for this. The use of chemical 
inhibitors of the heat shock response pathway was not successful. An RNAi knockdown
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of the effecter transcription factor, HSF-1 (Zhao & Shen, 2007), could be attempted. 
RNAi has been increasingly used in HUVEC, and RNAi of HSF-1 has been 
successfully achieved in other endothelial cell types.
The opposite approach to determining whether heat shock response pathway was 
having a role in protection was also considered. Stimulation of heat shock response 
pathways in two alternative ways to the 16h 39.5°C fever was attempted. This first 
involved exposure to heavy metals (Wagner et al., 1999), however at concentrations 
around those previously reported to stimulated heat shock response pathways negative 
effects on cellular integrity were observed. Similarly, using heat shock (42.5°C, 1 h) to 
stimulate heat shock response pathways there was a fine line between just stimulating 
heat shock response pathways and reducing cellular integrity. Careful optimisation of 
these types of experiments would be required for any conclusions to be made.
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5-6 CONCLUSIONS
We have provided evidence for the protective nature of natural host responses against 
cytoadherence. Specifically, we have shown that exposure of endothelial cells to 
physiologically relevant febrile range temperatures can protect against subsequent 
ICAM-1 mediated PRBC adhesion. Future work will determine what the mediator of this 
protective response is, and whether the heat shock response pathway plays any role in 
the protection.
1 44
CHAPTER 6 - BLOCKING AND REVERSAL OF ICAM-1 CYTOADHERENCE
6-1 INTRODUCTION
Cytoadherence of PRBC to endothelium is thought to have an important role in the 
pathogenesis of malaria, and as shown in chapter three this cytoadherence could be 
continuing for long after the initiation of antimalarial treatment. If this continued 
sequestration of PRBC is contributing to the continuation of disease symptoms, i.e. 
coma in the case of cerebral malaria, then it could be advantageous to reverse the 
cytoadherence interaction.
Although many experiments have addressed inhibition of adhesion, meaning the 
prevention of de-novo adhesion, there have been fewer studies looking at the potential 
to reverse the cytoadherence of already adherent PRBC. Reversal of adhesion, or 
“desequestration” of CSA-binding PRBC to placental sections has, however, been 
achieved by flushing through with CSA (Gysin et al., 1999). Reversal of specific 
adhesion to CD36 has also been previously described. CD36 adhesion was reversed in 
standard static (Baruch et al., 1997) and flow (Cooke et al., 1998) conditions by 
addition of a recombinant protein derived from the CD36 binding region of the CIDR 
domain from PfEMP-1. Under flow conditions reversal of up to 50% was achieved after 
two hours of flow with 2 pM recombinant protein (Cooke et al., 1998). This 
recombinant protein was also shown to be able to reverse around 80% adhesion of 
PRBC to human endothelial cells expressing CD36 in a small number of skin-graft 
mouse models (Yipp et al., 2003a).
Adhesion to ICAM-1 can be inhibited using monoclonal antibodies against ICAM-1 (Tse 
et al., 2004). The monoclonal antibody mAb 15.2 against the L42 loop of domain 1 of 
ICAM-1 is commonly used as a control antibody to inhibit ICAM-1 mediated 
cytoadherence. However, the reversal of adhesion to ICAM-1 has not been previously 
reported. Furthermore, while adhesion to ICAM-1 has been inhibited using antibodies, 
the use of proteins to inhibit adhesion has not been reported. Attempts to inhibit 
cytoadherence using a soluble ICAM-1 protein have been unsuccessful (Craig et al., 
1997) -  although this approach has been used for the inhibition of adhesion of 
rhinovirus to ICAM-1 (Casasnovas & Springer, 1994). A recombinant protein based on 
an ICAM-1 binding domain has not previously been available. However, we were able 
to access a recombinant protein based on the DBL-P domain which was produced as 
part of a project aiming to solve a crystal structure for the ICAM-1 binding DBL-beta
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domain from PfEMP-1 (M. Higgins). This DBL-(3 domain derives from IT4var13 
(Kraemer et al., 2007) which is a DBL-p domain containing var from var group B1 (Ups 
type B1), i.e. in the same var group as known ICAM-1 binders A4var and IT-ICAM (as 
expressed in A4 and ItG).
In this chapter we look at the ability of the recombinant DBL-(3 domain as well as mAb 
15.2 to not only inhibit but to reverse adhesion of PRBC to ICAM-1.
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6-2 MATERIALS AND METHODS
Parasites
P. falciparum isolates A4 and ItG were maintained as described in methods chapter 2. 
The patient isolate 8146 was obtained as part of larger project (Lucy Ochola, Kilifi, 
Kenya. Samples were obtained in Kilifi, Kenya with local ethical approval and parasites 
cultured at for at least 24 h before shipping to LSTM). Parasites were isolated from a 
patient in Kilifi, and after overnight growth to trophozoite-stage were assessed for their 
ability to adhere to ICAM-1 (Lucy Ochola, methods used as described in methods 
chapter 2). Since this isolate had some affinity for ICAM-1 it was maintained in culture 
and subjected to three rounds of selection on ICAM-1 (by Tadge Szestak, selection as 
described in methods chapter 2). All assays were carried out on parasites at mid­
trophozoite stage (26 -  34 h post-invasion). Parasites were used at 3% parasitaemia 
and 1% haematocrit and were washed once then resuspended in binding buffer for 
assays (see methods chapter 2).
DBL Domain Proteins
DBL-|3 and DBL-3x domains were prepared by Matt Higgins (Dept. Biochemistry, 
Cambridge). Both were expressed as His tagged recombinant proteins in E. coli and 
purified using Ni-NTA affinity to a concentration of 10 mg/ml as described in (Higgins, 
2008a). The DBL-p domain used is a 45 kDa fragment from the var gene IT4_var13 
(EF158072) (Kraemer et a!., 2007). The DBL-3X domain is a 37 kDa CSA-binding 
fragment from the var gene var2csa (Higgins, 2008a).
ICAM-1 Proteins
ICAM-1 proteins were prepared by Tadge Szestak (LSTM), as full length FC proteins 
and purified to concentrations of 200 -  700 pg/ml. The wild type, or reference ICAM-1 
(ICAM-1 ref), and two ICAM-1 variants, ICAM-1 Kilifi and ICAM-1 S22A were used. 
Proteins were diluted to 25 pg/ml in Dulbecco’s PBS (dPBS) for use. CD36 protein 
was obtained from R&D systems.
Static Adhesion Assays
Static adhesion assays to protein were carried out as described in methods chapter 2. 
In each dish ICAM-1 ref, (and the mutants ICAM-1 Kilifi and ICAM-1 S22A when used) 
were spotted at a concentration of 25 pg/ml, a CD36 spot was always included at 25 
pg/ml to control for non-specific loss of PRBC binding, and a PBS spot included to 
control for background binding. Triplicate protein spots per dish were used. Counts
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from the PBS spot for each dish were subtracted from each protein count, (however, 
these PBS counts were always very low, in the range of 0 -  6 PRBC/mm2).
Static Adhesion Blocking Assays
Dishes were pre-incubated with 1.5 ml of binding buffer with or without blocking 
antibody or protein, at 37°C for 30 minutes, before proceeding with adhesion assay as 
above. The monoclonal antibody mAb 15.2 was used at 5 pg/ml in binding buffer. DBL- 
(3 domain protein was diluted to 25 pg/ml in binding buffer and serial five-fold dilutions 
were made for concentration dependence assays. Control DBL-3X protein was used at 
25 pg/ml in binding buffer.
Reversal Assays -  Static Protein
For reversal assays controls were always carried out in the same experiment such that 
in a given experiment there were at least 4 conditions (see also schematic figure 6.3a): 
Dishes 1 and 2 were treated as a standard binding / blocking assay (no blocking, mAb 
blocking (and DBL-(3 blocking when used)). Dishes 3 and 4 were treated as a standard 
binding assay along with dishes 1-2 up to the end of 8 x 2 ml binding buffer washes. At 
this point dishes 1-2 were fixed in 1% glutaraldheyde in PBS while dishes 3-4 were 
incubated for a further 1 hour with either binding buffer alone, or mAb 15.2 (5 pg/ml in 
binding buffer), or DBL-P protein when used, with gentle mixing every 10 min. After the 
further incubation dishes were washed 4 X 2 ml binding buffer and fixed in 1% 
glutaraldehyde in PBS. All experiments were carried out with duplicate dishes each 
containing triplicate spots. After overnight fixing at room temperature, dishes were 
stained for 30 min in 5% Giemsa, washed with water and air dried before counting (see 
below).
Reversal Assays -  Static Endothelial Cell
HUVEC were maintained and static cell assays carried out as described in methods 
chapter 2. For reversal assays PRBC were allowed to bind as for normal assay then 
following two dip washes coverslips were placed in a gravity wash for 30 min. After 30 
min coverslips were placed cell-side up into a well containing binding buffer with (and 
control without) mAb 15.2 at 5 pg/ml. After 30 min coverslips were transferred to a 
second gravity wash for 10 min then fixed in 1% glutaraldehyde. As with static protein 
assays, controls were carried out which were fixed before the second incubation. All 
cell assays were carried out in triplicate.
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Reversal Assays -  Under Flow Conditions
Flow reversal assays were carried out on microslides coated in ICAM-1 ref at 50 pg/ml. 
Slides were prepared and assays carried out as described in Methods Chapter 2. 
PRBC at 3% parasitaemia and 1% haematocrit were flowed through the microslide for 
5 min to allow for PRBC adhesion. Flow was continuous throughout the experiment at 
0.05 Pa shear stress. After 5 min PRBC flow, flow was switched to binding medium 
alone to remove unbound PRBC and clear flow lines of PRBC. Timing was started at 
the start of this wash which continued for 2 min before the binding medium was 
swapped for medium containing mAb or DBL-(3 protein. The number of bound cells in 
six fields alone the slide was counted at 2 min, 5 min, 10 min 15 min and 20 min time 
points (see figure 6.7a for schematic). Reversal of adhesion to HUVEC under flow 
conditions was carried out in a similar way on TNF (1 ng/ml 16h) stimulated HUVEC 
grown overnight on microslides.
Counting Static Assays
Static adhesion assays were counted using a macro developed on Image-pro plus by 
Doug Paton as a Masters student project. Images were captured using the X10 
objective on a Nikon microscope using a camera and image pro-plus software. 8 
images for each protein spot were captured and saved as 8 bit grayscale files. Once all 
images from each dish had been captured, files were all opened and the macro 
initiated to count spots from each image. Doug’s work optimised the analysis so that 
the program correctly recognised and counted only PRBC, this was statistically verified 
by comparison with manual counts (Doug Paton, Masters Project 2007).
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6-3 RESULTS
Part I - USE OF PROTEIN TO INHIBIT ADHESION TO ICAM-1
DBL-p protein blocks adhesion of ItG and A4 PRBC to ICAM-1
The ability of the recombinant DBL-p domain protein to bind to ICAM-1 has been 
shown (Tadge Szestak, LSTM, unpublished), suggesting a functional domain. We 
wanted to test the ability of this protein to inhibit adhesion of PRBC to ICAM-1, and first 
tested this using static protein adhesion assays. Adhesion of both ItG and A4 PRBC to 
immobilised ICAM-1 could be blocked with 25 pg/ml of DBL-p protein (Fig. 6.1). 
Blocking compared to control of 84% ± 12% for ItG and 93.4% ± 3% for A4 was 
achieved (P<0.001 (T-test) for both). The monoclonal antibody, mAb 15.2, has been 
previously used to inhibit adhesion, and in these experiments was shown to inhibit 
adhesion by >95% for both isolates (Fig. 6.1).
As a control for the specificity of the blocking by the DBL-p domain we used a DBL-3X 
domain which is a domain known to adhere to CSA but not ICAM-1. The DBL-3X 
protein is a similar size and produced in the same way to the DBL-p protein used 
(Higgins, 2008a). The DBL-3X domain protein did not significantly affect adhesion of 
A4 or ItG PRBC to ICAM-1 (Fig. 6.1). Adhesion to CD36 was not affected by either 
DBL-p or DBL-3X protein (data not shown). Adhesion is expressed as a % of control 
(no blocking) adhesion for each independent experiment, and results show the mean 
and SD of three independent experiments. The mean ± SD of bound A4 PRBC in the 
control dishes was 534 ± 195 PRBC/mm2, whereas ItG PRBC showed higher levels of 
adhesion at 1634 ± 598 PRBC/mm2.
Control 15.2 DBL Beta DBL 3x
Figure 6.1. Adhesion of ItG and A4 to ICAM-1 protein in static assays. Blocking using mAb 15.2 at 5 
pg/ml, DBL-p at 25 pg/ml or DBL-3X at 25 pg/ml. Expressed as a percent of the control binding in each 
experiment. Mean + SD of three independent duplicate experiments
1 50
Concentration Dependence of DBL-(3 blocking of adhesion to ICAM-1 variants
The concentration dependence of this inhibition of adhesion was assessed over a 
range of concentrations from 0.2 pg/ml to 25 pg/ml for both A4 and ItG PRBC. Since 
these two P. falciparum isolates are isogenic, well established laboratory isolate, we 
also used a recent patient isolate, 8146. This strain was isolated from a patient in Kilifi, 
Kenya as part of a larger study (Lucy Ochola). This isolate was tested for adhesion to 
ICAM-1 and since showed some levels of adhesion was then subjected to three rounds 
of selection on ICAM-1 protein (Tadge Szestak, LSTM). We found that the isolate 8146 
was able to adhere to ICAM-1 ref in static assays at similar levels to A4 (not shown).
As illustrated in figure 6.2a, there was clear concentration dependent inhibition of 
adhesion for all three isolates. Curves illustrated the relative inhibition of adhesion, and 
the bar charts for each experiment show adhesion levels of the controls as bound 
PRBC/mm2 (Fig. 6.2). Control adhesion assays with blocking using the DBL-3X domain 
show no inhibition of adhesion, and control inhibition using the mAb 15.2 in each 
experiment showed ~95% inhibition of adhesion (Fig. 6.2a, bar chart). Adhesion to 
CD36 protein was tested in each experiment and was not inhibited by either of the DBL 
domains at any concentration, or by the mAb 15.2 (not shown).
Having shown the ability of DBL-(3 to inhibit adhesion to ICAM-1 ref, we also looked at 
ability of the DBL-(3 protein to block adhesion to ICAM-1 variants. The variant ICAM-1 
Kilifi has a K29M substitution (see introduction chapter 1 figure 1.8). It is known that ItG 
PRBC show similar levels of adhesion to ICAM-1 Kilifi as to the wild type, or reference 
ICAM-1 (referred to as ICAM-1 ref), whereas A4 PRBC do not adhere to ICAM-1 Kilifi. 
A second ICAM-1 variant with a substitution S22A was also used. The adhesion 
phenotypes to ICAM-1 S22A is reversed, with A4 PRBC able to adhere to ICAM-1 
S22A whereas ItG PRBC show no binding to ICAM-1 S22A (Tse et al., 2004). We 
found that the isolate 8146 was able to adhere to ICAM-1 ref at similar levels to A4. It 
was also able to adhere to ICAM-1 Kilifi, and at slightly lower levels to ICAM-1 S22A.
The adhesion of ItG PRBC to the ICAM-1 mutant ICAM-1 Kilifi was inhibited by DBL-p 
in a similar concentration dependent manner to the inhibition of adhesion to ICAM-1 ref 
(Fig. 6.2b). As expected A4 PRBC showed no adhesion to ICAM-1 Kilifi (Fig. 6.2b, bar 
chart). Preliminary experiments showed that the patient isolate 8146 also showed 
adhesion to ICAM-1 Kilifi and this could be inhibited in a similar manner using DBL-0 
(Fig. 6.2b).
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As expected no adhesion of ItG PRBC to ICAM-1 S22A was seen (Fig. 6.2c bar chart). 
However adhesion of both A4 PRBC and 8146 PRBC could be inhibited using DBL-p 
protein (Fig. 6.2c).
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Figure 6.2. Adhesion to ICAM-1 protein variants and concentration dependent inhibition by DBL- 
beta. i) Bar charts show number of PRBC bound per mm2 for controls for assays including untreated 
positive control (i.e. 0 pg/ml DBL-P), DBL-3X at 25 pg/ml, mAb 15.2 at 5 pg/ml and DBL-beta domain at 25 
pg/ml. ii) Curves show plots of relative inhibition of adhesion by DBL-beta protein concentrations 0.2 to 25 
pg/ml. Plotted as relative inhibition of control (untreated) binding where 1 represents complete inhibition of 
adhesion and 0 represents control levels of adhesion. ItG and A4 results represent the mean of three 
independent experiments + SD. Adhesion to: A) ICAM-1 ref, B) ICAM-1 Kilifi and C) ICAM-1 S22A.
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The DBL-3X protein at 25 pg/ml showed no inhibitory effect on adhesion to any of the 
ICAM-1 variants (Fig. 6.2a-c bar charts). As expected, the monoclonal antibody mAb
15.2 strongly inhibited adhesion of all isolates to all ICAM-1 variants, as shown in figure
6.2 bar charts a-c.
The IC50 concentration for DBL-3 blocking represents the concentration at which DBL-(3 
can block 50% of PRBC adhesion. These values varied slightly between isolates, 
which IC50 values highest for the strong ItG PRBC adhesion compared to the moderate 
levels of adhesion of A4 and 8146 PRBC (Table 6.1).
ItG A4 8146
ICAM-1 ref 5.14 0.07 0.435
ICAM-1 Kilifi 11.23 n/a 0.993
ICAM-1 S22A n/a 1.04 0.998
Table 6.1. IC50 concentrations of DBL-p protein for ICAM-1 variants. IC50 value (DBL-P concentration 
pig/ml) calculated using for each isolate ItG, A4 and 8146 on each ICAM-1 variant, ICAM-1 ref, ICAM-1 
Kilifi and ICAM-1 S22A. Values based on three independent experiments (except for 8146 and A4 S22A).
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Part II - REVERSAL OF ADHESION TO ICAM-1
The ability of mAb 15.2 to block adhesion has been shown, and we have established 
that the DBL-(3 domain can also block adhesion. However, the reversal of PRBC 
already bound to ICAM-1 has not been shown. We next test the ability of both the 
monoclonal antibody mAb 15.2 and the DBL-P domain to reverse already adhered 
PRBC.
Reversal of adhesion using Monoclonal Antibody -  Static assays
In conjunction with James Callery as a Masters project (J. Callery 2008) we first 
assessed the ability of the mAb 15.2 to remove PRBC bound to ICAM-1 (Fig. 6.6). 
PRBC were allowed to adhere as for a standard static assay, and unbound cells 
washed off before incubation of the dish with the mAb 15.2 to reverse adhesion (See 
materials and methods and figure 6.3a). In these experiments the mAb 15.2 at 5 pg/ml 
was able to achieve >95% inhibition of adhesion and >80% reversal of ItG adhesion to 
50 pg/ml ICAM-1 (Fig. 6.3). In figure 6.3 the positive control refers to adhesion levels 
with no blocking antibody after the first round of washing, and positive control (2) refers 
to the adhesion levels of control dishes after the second incubation and second round 
of washing, i.e. the reversal step (see also schematic figure 6.3a). It is clear that there 
is some reduction in adhesion in these experiments due to the extra incubations and 
wash steps, however this reversal was greatly increased by addition of the mAb 15.2. 
The value of 80% reversal refers to comparison of adhesion levels after the reversal 
wash steps either with or without mAb 15.2.
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Figure 6.3 (KH & JC). Reversal of adhesion of ItG PRBC to ICAM-1. A) Schematic of assay for reversal 
as described in materials and methods. Each circle represents an assay dish over incubation and wash 
steps (left to right). B) Reversal of adhesion to ICAM-1 in static protein assays using 5 pg/ml mAb 15.2. 
Expressed as bound PRBC/mm2 mean of three independent experiments, error bars indicate 95% 
confidence intervals.
Reversal of Adhesion using mAb 15.2 -  Flow assays
The monoclonal antibody mAb 15.2 was also shown to reverse adhesion to ICAM-1 
under physiologically relevant flow conditions. PRBC were allowed to adhere to ICAM- 
1 under standard flow conditions then washed at the same flow rate with binding buffer 
containing mAb 15.2. Counts of bound parasites showed a reduction in the number of 
adhered PRBC over 20 min flow with mAb 15.2 at either 1 pg/ml or 5 pg/ml 
concentration (Fig. 6.4). A 67% reduction in adhesion was seen when comparing the 
number of adherent PRBC before and after 20 min flow with 5 pg/ml mAb 15.2. Control
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slides washed with binding buffer alone showed that 90% of adhered PRBC remained 
bound after 20 min. The same concentration of antibody was able to block 98% of 
adhesion (not shown).
Time = 0 Count 2 min Count 5 min Count 10 min Count 15 min Count 20 min
Figure 6.4 (KH & JC). Reversal of adhesion of ItG PRBC to ICAM-1 protein in flow assays. A)
Schematic of assay as described in methods. B) Reversal of flow adhesion to ICAM-1 protein using 1 
pg/ml or 5 pg/ml mAb 15.2. Results expressed as bound PRBC/mm2, showing the mean of three 
independent experiments. Error bars indicate 95% confidence intervals.
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Reversal of Adhesion using mAb 15.2 -  HUVEC Static assays
The reversal of ICAM-1 mediated adhesion on endothelial cells was assessed using 
TNF stimulated human umbilical vein endothelial cell (HUVEC). Reversal was achieved 
using mAb 15.2 (Fig. 6.5). A 93% reduction in adhesion was seen after a wash with 5 
pg/ml mAb 15.2 compared to washing in binding buffer alone.
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Figure 6.5 (KH & JC). Reversal of adhesion of ItG to TNF stimulated HUVEC. Monoclonal antibody 
mAb 15.2 at 5 (jg/ml was used to block or reverse adhesion to HUVEC. Results expressed as bound ItG 
PRBC/mm2, showing the mean of three independent experiments. Error bars indicate 95% confidence 
intervals
Reversal of Adhesion using DBL-0 -  Static Assays
The ability of the DBL-p domain protein to reverse adhesion in static protein assays 
was tested in the same way as the monoclonal antibody (as illustrated in schematic 
figure 6.3a). As described in materials and methods the mAb was used in the same 
experiment as a control. We were able to achieve significant reversal of 60% with DBL- 
P at 25 pg/ml compared to binding buffer alone, whereas in these experiments 
treatment with mAb 15.2 resulted in >90% reversal (Fig. 6.9). Adhesion to CD36 was 
not significantly reversed by either the anti-ICAM-1 antibody or DBL-P protein (not 
shown).
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Figure 6.6. Reversal of adhesion of ItG to ICAM-1 protein in static assays using DBL-p. DBL-P 
protein at 25 pg/ml or mAb 15.2 at 5 pg/ml was used to block or reverse adhesion to ICAM-1 protein in 
static assays. Results are expressed as bound PRBC per mm2 showing the mean ± SD of three 
independent duplicate experiments
Reversal of Adhesion using DBL-|S -  Flow Assays
In order to confirm the ability of the DBL-P protein to reverse sequestered PRBC under 
flow conditions we used the same experimental conditions as used for the monoclonal 
antibody (see schematic figure 6.4a). Similarly to mAb 15.2 the DBL-p protein was able 
to inhibit around 95% of adhesion to ICAM-1 under flow conditions (Fig. 6.7 block). 
Reversal of 70% of adherent PRBC to ICAM-1 under flow conditions was achieved 
after 20 min flow with 25 pg/ml DBL-p. (Fig. 6.7).
Wash Time (min)
Figure 6.7. Reversal of adhesion to ICAM-1 protein under flow conditions using DBL-p protein.
Protein used at 25 pg/ml, assay as illustrated in figure 6.3a. Mean of four slides ±95% confidence intervals
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6-4 DISCUSSION
It has been widely discussed that an adjunct therapy which can reverse cytoadherence, 
leading to desequestration of PRBC could be advantageous to improve prognosis in 
severe malaria cases. Our results in chapter 3, which illustrate that PRBC maintain the 
ability to cytoadhere for many hours after administration of antimalarial treatments, 
support the idea that such a therapy, to be administered alongside conventional 
antimalarial treatment, could be beneficial. However, there is little in vitro work showing 
that this is feasible, and no studies have specifically addressed reversal of I CAM-1 
mediated adhesion. We set out to test whether we could reverse specific adhesion to 
ICAM-1 in vitro. We also assessed the ability of a recombinant protein to inhibit and 
reverse adhesion, since most work published has used only monoclonal antibody to 
inhibit ICAM-1 mediated cytoadherence. We have found that both an anti-ICAM-1 
monoclonal antibody, and a DBL-|3 recombinant protein can reverse adhesion of PRBC 
to ICAM-1.
Use of protein to inhibit ICAM-1 adhesion
Monoclonal antibodies have been widely used to inhibit ICAM-1 adhesion. Here, we 
have provided the first evidence of a recombinant protein that can inhibit PRBC 
adhesion to ICAM-1.
Two well characterised, established laboratory P. falciparum isolates were used. ItG 
which is known to have a high binding affinity for ICAM-1 and a moderate ICAM-1 
binder A4. These are isogenic isolates which express antigenically (and phenotypically) 
distinct PfEMP-1 proteins. The expected var or PfEMP-1 expression for each strain 
was confirmed before experiments were carried out (see materials and methods 
chapter 2). In order to confirm that the results seen were not unusual to long- 
established laboratory isolates, a more recent patient isolate was used. The isolate was 
obtained from Kilifi, Kenya as part of a large project to analyse the ICAM-1 binding 
phenotype of patient isolates. The isolate used here, 8146, was shown to adhere to 
ICAM-1, and had undergone three rounds of selection in vitro for adhesion to ICAM-1 
in order to homogenise the population before sequencing of the expressed var gene 
could be carried out (Tadge Szestak).
The three isolates used differ subtly in their binding to ICAM-1. ItG showed the highest 
adhesion to ICAM-1, followed by A4 and 8146 showing similar moderate levels of 
adhesion. However, as well as the difference in affinity for ICAM-1 the three isolates 
show different binding ability to two ICAM-1 variants, ICAM-1 Kilifi which has a K29M
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substitution and the mutant ICAM-1 S22A. As previously shown (Tse et al., 2004), ItG 
showed no binding to the S22A mutant, but high binding to ICAM-1 Kilifi, whereas A4 
showed no binding to ICAM-1 Kilifi but significant adhesion to ICAM-1 S22A. In 
contrast, the new patient isolate, 8146, was able to bind to all three ICAM-1 variants, 
although adhesion to the two mutant ICAM-1 proteins appeared to be at slightly lower 
levels than that seen to ICAM-1 ref (Fig. 6.3).
The recombinant DBL-p protein used to inhibit adhesion was based on a domain from 
a different PfEMP-1 to those expressed by any of the three parasite isolates used. 
However, it was clearly able to inhibit adhesion of all parasite isolates to each of the 
ICAM-1 variants used, including the high levels of adhesion seen of ItG to ICAM-1 ref.
It is known that PRBC expressing different ICAM-1 adhesive DBL-p domains may bind 
slightly differently to ICAM-1, as illustrated by different sensitivity to ICAM-1 mutations 
(Tse et al., 2004). Our use of three parasite isolates, and three ICAM-1 variants 
illustrate that our observed inhibition of ICAM-1 mediated adhesion was not limited to 
one specific PRBC type but could inhibit adhesion of PRBC expressing divergent 
ICAM-1 binding DBL-p domains. We did show, however, that the observed inhibition by 
the protein was specific, and not due to any generic stickiness of the recombinant 
protein. The DBL-p protein, at the highest concentration used, did not inhibit adhesion 
(of any of the tested isolates) to CD36 (data not shown). Furthermore, a DBL-3x 
domain protein produced in a similar way to the DBL-p domain protein did not lead to 
any inhibition of adhesion to either ICAM-1 or CD36.
The concentration dependence of the inhibition of adhesion was slightly different 
between ItG and A4 (Fig. 6.2), reflecting the different strengths of adhesion between 
the two parasite isolates.
Reversal of PRBC adhesion to ICAM-1
We have also shown for the first time the ability to reverse ICAM-1 mediated 
cytoadherence. This was possible using both the monoclonal antibody mAb 15.2 and 
the recombinant DBL-P protein. The antibody used is known to map to the L42 loop in 
the predicted DBL-P binding region of domain 1 of ICAM-1 (see introduction chapter 1, 
figure 1.7), and has previously been used to block ICAM-1 mediated adhesion of PRBC 
(Tse et al., 2004, Chakravorty et al., 2007). Reversal of the strong adhesion of ItG to 
ICAM-1 was possible in static conditions when bound PRBC were incubated in buffer 
containing antibody, and also under flow conditions when the same concentration of
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antibody was flowed at a physiologically relevant shear stress of 0.05 Pa over adhered 
PRBC.
We have also shown that the reversal effect can be achieved under physiologically 
relevant flow conditions, to both ICAM-1 protein and ICAM-1 expressing HUVEC 
endothelial cells. In flow assays the effect of the DBL-(3 protein was rapid with PRBC 
release from the microslide observed as soon as the DBL-(3 containing buffer reached 
the slide (at 4 min).
The ability of both the mAb and the recombinant protein to not only inhibit but to 
reverse adhesion has important therapeutic implications. Results presented in chapter
3 showed that the cytoadherence of PRBC to endothelium can continue for long after 
administration of antimalarial treatment. As we discussed, and has been discussed 
before (Checkley & Whitty, 2007, Dondorp et al., 2005), reversal of these cytoadherent 
parasites has the potential to be highly advantageous. The continued sequestered 
parasite population has the potential to still be contributing to disease severity by 
impeding blood flow and contributing to endothelial damage as well as enhancing local 
inflammatory responses (Chakravorty et al., 2007). Furthermore, we showed in chapter
4 that these antimalarial treated PRBC remain rigid after loss of parasite viability, 
meaning that released PRBC would still potentially be able to be recognised and 
cleared by the spleen.
It has been shown previously that adhesion to CD36 can be reversed to some extent 
using a recombinant protein designed against the CD36-binding CIDR domain of 
PfEMP-1 (Baruch et al., 1997, Cooke et al., 1998, Yipp et al., 2003a). Here we show 
that a recombinant protein derived from the ICAM-1 binding DBL-(3 domain of PfEMP-1 
can reverse ICAM-1 adhesion. Although CD36 adhesion is common to many parasite 
isolates, CD36 is highly expressed in a wide range of endothelial and other cells types 
and is important in many inflammatory processes. The high levels of expression of 
CD36 on a wide range of cell types and the lack of correlation of CD36 adhesion and 
clinical severity may make targeting of CD36 adhesion an inefficient way to remove 
sequestered PRBC populations. Given the proposed link between ICAM-1 adhesion 
and cerebral malaria (Chakravorty & Craig, 2005, Turner et al., 1994) it may be that 
targeting ICAM-1 adhesion may be an efficient way to improve prognosis in this severe 
subset of malaria cases.
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6-5 LIMITATIONS AND FURTHER WORK
Most of the work presented here looks at reversal of adhesion specifically to ICAM-1 
protein. Preliminary experiments suggest that the reversal of adhesion to ICAM-1 on 
endothelial cells would be possible in a similar way. The most physiologically relevant 
in vitro experiment that we could perform would be to assay for reversal of PRBC 
bound to endothelial cells under flow conditions. A potential complication of this would 
be maintaining the health/viability of the endothelial cells during the prolonged flow 
assay process. However, preliminary experiments over a 20 minute reversal suggested 
that a monolayer of generally morphologically healthy looking HUVEC could be 
maintained. This assay revealed that a reversal of over 50% could be achieved from 
HUVEC both with the DBL-(3 domain, and the mAb 15.2 (result not shown). However, 
the much lower levels of adherent PRBC initially may mask larger real differences. 
Significant optimisation of these experiments would be necessary to ensure we were 
working with healthy cells and statistically relevant adhesion levels.
The results presented here show that a 45 kDa recombinant protein derived from a 
previously uncharacterised ICAM-1 binding DBL-[3 domain is an efficient way to inhibit 
and reverse adhesion of even the strong ICAM-1 binding isolate ItG. Further 
knowledge of the mechanism of ICAM-1 adhesion by different variant DBL-P domains 
could allow a targeted development of a protein or peptide with a higher affinity for 
ICAM-1 allowing more efficient reversal of adhesion. A crystal structure of the adhesion 
of DBL-p domains bound to ICAM-1 will be invaluable for establishing the detail of the 
binding interaction. This work is currently in progress and was the reason for the 
availability of the recombinant DBL-(3 protein (M. Higgins, Cambridge). The structure of 
the CSA binding DBL-3X domain has already been solved both alone and in a co­
crystal with CSA (Higgins, 2008b, Singh et al., 2008).
A major limitation is that we are looking at adhesion only to ICAM-1, whereas it is 
known that in vivo adhesion may be mediated by co-operation between more than one 
receptor. We could model a more complicated adhesion process using an alternative 
endothelial cell type, HDMEC which, in addition to ICAM-1 also express CD36. As 
described above optimisation experiments would be necessary, as would inclusion of 
similar experiments using an anti-CD36 antibody or protein. However, since adhesion 
in the brain in cerebral malaria is thought to be mediated at least mainly by ICAM-1 
adhesion, reversal of simple ICAM-1 adhesion could well still be relevant in these 
severe cases.
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The results we have presented are a complete, although simplified analysis of the 
ability of both monoclonal antibody, and DBL-p protein to inhibit and reverse ICAM-1 
adhesion.
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6-6 CONCLUSIONS
We have shown that a monoclonal antibody and a recombinant DBL-(3 domain protein 
can both inhibit and reverse adhesion of different PRBC isolates to ICAM-1 in both 
static and flow conditions. This has significant implications for the viability of an adjunct 
therapy that may be able to reverse sequestration, potentially during the first 24 hours 
of antimalarial therapy while PRBC are still potentially capable of cytoadherence 
(chapter 3). Further development of this work and the development of an optimised 
binding protein based on the DBL-(3:ICAM-1 binding interaction could conceivably lead 
to a viable adjunct therapy that could be administered along with antimalarial treatment 
particularly in cases of cerebral malaria.
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CHAPTER 7 -  SUMMARY
This thesis has focussed on cytoadherence of P. falciparum infected red blood cells to 
endothelial cells, and the potential effects that natural host responses, i.e. fever, as well 
as interventions, i.e. antimalarial drugs, have on this interaction. Within each chapter 
we have discussed our major findings, and their significance and limitations. Here we 
briefly summarise our results.
The first part of the thesis, presented in chapters 3 and 4 addressed the question of 
what happens in terms of cytoadherence after antimalarial treatment. Our main findings 
were that the cytoadherence of PRBC could continue for long periods after 
administration of antimalarial treatment. Consistent with this, the remodelling of PRBC 
could be seen to be maintained after treatment, in terms of both the expression of 
PfEMP-1 on the surface of the PRBC and the increased rigidity of the PRBC. The 
maintained capacity for cytoadherence of PRBC after antimalarial treatment had been 
suggested previously. However we have provided the first evidence using a range of 
cytoadherence assays of the maintained ability of non-viable parasites to cytoadhere.
This work also illustrates that there may be an advantage for antimalarials that act on 
younger, i.e. circulating, ring stage parasites as these prevent the maturation of this 
round of parasites to cytoadherent trophozoite stages. While this result had been 
predicted elsewhere it had not previously been shown. When this stage was treated 
with a range of antimalarials we could show that PRBC treated with drugs that 
prevented maturation to cytoadherent trophozoite stages showed no adhesion 24 h 
following treatment. Ring-stage PRBC treated with drugs that allowed maturation to 
cytoadherence trophozoite stages showed high levels of cytoadherence 24 h following 
treatment, which would be expected to slowly decline over the next 24 + hours.
The maintained capacity for cytoadherence after antimalarial treatment suggests that 
there may be a therapeutic advantage for the administration of anti-adhesive adjunct 
therapies that can not only inhibit, but can reverse cytoadherence. This issue was 
addressed in chapter 6. We have shown that both a monoclonal anti-ICAM-1 antibody, 
and a recombinant protein derived from a PfEMP-1 DBL-(3 domain, can not only inhibit 
but also reverse cytoadherence. This is the first work showing that a recombinant 
protein can not only inhibit but reverse cytoadherence to ICAM-1. The study suggests 
that the development of adjunct therapies to reverse cytoadherence based on the 
PfEMP-1:ICAM-1 interaction could be feasible.
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The second main focus of this thesis was the effect of febrile temperatures on 
cytoadherence. This work arose from the realisation that fever is a major consequence 
of P. falciparum infection, however, most studies on cytoadherence, including our own, 
are carried out under non-febrile conditions at a temperature of 37°C. Since the effect 
of febrile temperatures on parasites has previously been reported, we looked 
specifically at host responses in the endothelial cells, and the effect on cytoadherence. 
The striking result here was that the host response to fever appears to be protective 
against cytoadherence. This could be related to heat shock response pathway 
activation, although we were unable to elucidate an exact mechanism. Revealing the 
mechanisms behind this protection will be a significant undertaking, although we have 
already ruled out simple effects on ICAM-1 levels and cell viability.
Overall our results may contribute to the understanding of why there is still a high 
mortality rate from malaria, especially during the first 24 hours after hospital admission. 
We suggest that continued cytoadherence may contribute to this and indicate the 
feasibility of approaches to reverse this cytoadherence interaction.
1 66
ACKNOWLEDGEMENTS
I’d like to thank my supervisors Alister and Giancarlo for all their help and support over 
the last three years. Thank you to all members of Alister’s group -  Tadge, Srabasti 
and Yang for all their help and support in the lab. Also specific thanks to Tadge for the 
making all the ICAM-1 protein, Matt Higgins for the DBL proteins, members of Steve 
Ward’s group for help with the antimalarial drugs and members of Mike Lehane’s group 
for use of the incubator for fever experiments. Thanks also to project students Doug 
and James for their work and I’d like to wish Khairul good luck continuing the projects.
167
PUBLICATIONS AND PRESENTATIONS
Work in this thesis has been presented for publication, or is in preparation for 
publication, and has been presented at meetings in the following forms:
Publications:
Exported proteins required for virulence and rigidity of Plasmodium falciparum infected 
human erythrocytes. Maier AG, Rug M, O'Neill MT, Brown M, Chakravorty S, Szestak 
T, Chesson J, Wu Y, Hughes K, Coppel RL, Newbold C, Beeson JG, Craig A, Crabb 
BS, Cowman AF. Cell. 2OO8 Jul 11;134(1):48-61.
Host response to cvtoadherence in Plasmodium falciparum.
Chakravorty SJ, Hughes KR, Craig AG. Biochem Soc Trans. 2008Apr;36(Pt2):221-8. Review
Publications in Preparation:
Continued cvtoadherence of Plasmodium falciparum infected red blood cells after 
antimalarial treatment. Hughes KR, Biagini G, Craig AG. Molecular and biochemical 
parasitology 2009 (manuscript accepted subject to minor revisions December 2008)
Reversal of adhesion of Plasmodium falciparum infected red blood cells to ICAM-1 
using antibody and recombinant protein Hughes KR. CalleryJ, Higgins M, Craig AG
Presentations:
Continued cvtoadherence of Plasmodium falciparum infected red blood cells after 
antimalarial treatment. Hughes KR, Biagini G, Craig AG
Has been presented at the following meetings:
Poster presentation Molecular Parasitology Meeting, Woods Hole, September 2007 
Oral Presentation BSP Malaria Meeting, Newcastle, April 2008 
Oral Presentation BioMalPar Meeting, Heidleberg, May 2008
1 68
REFERENCES
Aitcheson, N., S. Talbot, J. Shapiro, K. Hughes, C. Adkin, T. Butt, K. Sheader & G. Rudenko,
(2005) VSG switching in Trypanosoma brucei: antigenic variation analysed using RNAi 
in the absence of immune selection. Mol Microbiol 57:1608-1622.
Akoachere, M., K. Buchholz, E. Fischer, J. Burhenne, W. E. Haefeli, R. H. Schirmer & K. Becker,
(2005) In vitro assessment of methylene blue on chloroquine-sensitive and -resistant 
Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimlcrob 
Agents Chemother 49: 4592-4597.
Alano, P., (2007) Plasmodium falciparum gametocytes: still many secrets of a hidden life. Mol 
Microbiol 66: 291-302.
Angus, B. J., K. Chotivanich, R. Udomsangpetch & N. J. White, (1997) In vivo removal of malaria 
parasites from red blood cells without their destruction in acute falciparum malaria. 
Blood 90: 2037-2040.
Antia, M., T. Herricks & P. K. Rathod, (2007) Microfluidic Modeling of Cell-Cell Interactions in 
Malaria Pathogenesis. PLoS Pathog 3: e99.
Ashley, E. A., K. Stepniewska, N. Lindegardh, R. McGready, A. Annerberg, R. Hutagalung, T. 
Singtoroj, G. Hla, A. Brockman, S. Proux, J. Wilahphaingern, P. Singhasivanon, N. J. 
White & F. Nosten, (2007) Pharmacokinetic study of artemether-lumefantrine given 
once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. 
Trop Med Int Health 12: 201-208.
Barnwell, J. W., A. S. Asch, R. L. Nachman, M. Yamaya, M. Aikawa & P. Ingravallo, (1989) A 
human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a 
cytoadherence ligand on Plasmodium falciparum-infected erythrocytes. J Clin Invest 
84: 765-772.
Barnwell, J. W., C. F. Ockenhouse & D. M. d. Knowles, (1985) Monoclonal antibody OKM5 
inhibits the in vitro binding of Plasmodium falciparum-infected erythrocytes to 
monocytes, endothelial, and C32 melanoma cells. J Immunol 135: 3494-3497.
Baruch, D. I., X. C. Ma, H. B. Singh, X. Bi, B. L. Pasloske & R. J. Howard, (1997) Identification of a 
region of PfEMPl that mediates adherence of Plasmodium falciparum infected 
erythrocytes to CD36: conserved function with variant sequence. Blood 90: 3766-3775.
Baruch, D. I., B. L. Pasloske, H. B. Singh, X. Bi, X. C. Ma, M. Feldman, T. F. Taraschi & R. J. 
Howard, (1995) Cloning the P. falciparum gene encoding PfEMPl, a malarial variant 
antigen and adherence receptor on the surface of parasitized human erythrocytes [see 
comments]. Cell 82: 77-87.
Basco, L. K., J. Bickii & P. Ringwald, (1998) In vitro activity of lumefantrine (benflumetol) 
against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Antimicrob 
Agents Chemother 42: 2347-2351.
Baum, J., A. G. Maier, R. T. Good, K. M. Simpson & A. F. Cowman, (2005) Invasion by P. 
falciparum Merozoites Suggests a Hierarchy of Molecular Interactions. PLoS Pathog 1: 
e37.
Baumeister, S., M. Winterberg, C. Duranton, S. M. Huber, F. Lang, K. Kirk & K. Lingelbach,
(2006) Evidence for the involvement of Plasmodium falciparum proteins in the 
formation of new permeability pathways in the erythrocyte membrane. Mol Microbiol 
60: 493-504.
Bennett, B. J., N. Mohandas & R. L. Coppel, (1997) Defining the minimal domain of the 
Plasmodium falciparum protein MESA involved in the interaction with the red cell 
membrane skeletal protein 4.1. J Biol Chem 272:15299-15306.
Bennett, T. N., M. Paguio, B. Gligorijevic, C. Seudieu, A. D. Kosar, E. Davidson & P. D. Roepe, 
(2004) Novel, rapid, and inexpensive cell-based quantification of antimalarial drug 
efficacy. Antimicrob Agents Chemother AS: 1807-1810.
169
Berendt, A. R., A. McDowall, A. G. Craig, P. A. Bates, M. J. Sternberg, K. Marsh, C. I. Newbold & 
N. Hogg, (1992) The binding site on ICAM-1 for Plasmodium falciparum-infected 
erythrocytes overlaps, but is distinct from, the LFA-l-binding site. Cell 68: 71-81.
Bertonati, C. & A. Tramontano, (2007) A model of the complex between the PfEMPl malaria 
protein and the human ICAM-1 receptor. Proteins 69: 215-222.
Biagini, G. A., P. M. O'Neill, P. G. Bray & S. A. Ward, (2005) Current drug development portfolio 
for antimalarial therapies. Curr Opin Pharmacol 5: 473-478.
Biagini, G. A., P. M. O'Neill, A. Nzila, S. A. Ward & P. G. Bray, (2003) Antimalarial chemotherapy: 
young guns or back to the future? Trends Parasltol 19: 479-487.
Biswas, A. K., A. Hafiz, B. Banerjee, K. S. Kim, K. Datta & C. E. Chitnis, (2007) Plasmodium 
falciparum uses gClqR/HABPl/p32 as a receptor to bind to vascular endothelium and 
for platelet-mediated clumping. PLoS Pathog 3:1271-1280.
Blythe, J. E., T. Surentheran & P. R. Preiser, (2004) STEVOR--a multifunctional protein? Mol 
Blochem Parasltol 134:11-15.
Borst, P., W. Bitter, R. McCulloch, F. Van Leeuwen & G. Rudenko, (1995) Antigenic variation in 
malaria. Cell 82:1-4.
Brandts, C. H., M. Ndjave, W. Graninger & P. G. Kremsner, (1997) Effect of paracetamol on 
parasite clearance time in Plasmodium falciparum malaria [see comments]. Lancet 
350: 704-709.
Bray, P. G., R. E. Martin, L. Tilley, S. A. Ward, K. Kirk & D. A. Fidock, (2005) Defining the role of 
PfCRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol 56: 323-333.
Bull, P. C., M. Berriman, S. Kyes, M. A. Quail, N. Hall, M. M. Kortok, K. Marsh & C. I. Newbold, 
(2005) Plasmodium falciparum Variant Surface Antigen Expression Patterns during 
Malaria. PLoS Pathog 1: e26.
Bull, P. C., B. S. Lowe, M. Kortok, C. S. Molyneux, C. I. Newbold & K. Marsh, (1998) Parasite 
antigens on the infected red cell surface are targets for naturally acquired immunity to 
malaria. Nat Med 4: 358-360.
Casasnovas, J. M. & T. A. Springer, (1994) Pathway of rhinovirus disruption by soluble 
intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-1 is bound 
and RNA is released. J. Virol. 68: 5882-5889.
Casasnovas, J. M., T. Stehle, J. H. Liu, J. H. Wang & T. A. Springer, (1998) A dimeric crystal 
structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc 
Natl Acad Sei U S A 95: 4134-4139.
Chakravorty, S. J. & A. Craig, (2005) The role of ICAM-1 in Plasmodium falciparum 
cytoadherence. EurJ Cell Biol 84:15-27.
Chakravorty, S. J., C. Carret, G. B. Nash, A. Ivens, T. Szestak & A. Craig, (2007) Altered 
phenotype and gene transcription in endothelial cells induced by Plasmodium 
falciparum - infected red blood cells: pathogenic or protective? Int. J. Parasitol. 37: 
975-987.
Chakravorty, S. J., K. R. Hughes & A. G. Craig, (2008) Host response to cytoadherence in 
Plasmodium falciparum. Biochem Soc Trans 36: 221-228.
Chattopadhyay, R., T. Taneja, K. Chakrabarti, C. R. Pillai & C. E. Chitnis, (2004) Molecular 
analysis of the cytoadherence phenotype of a Plasmodium falciparum field isolate that 
binds intercellular adhesion molecule-1. Mol Biochem Parasltol 133: 255-265.
Checkley, A. M. & C. J. Whitty, (2007) Artesunate, artemether or quinine in severe Plasmodium 
falciparum malaria? Expert Rev Anti Infect Ther 5:199-204.
Chen, Q., D. T. Fisher, K. A. Clancy, J. M. Gauguet, W. C. Wang, E. Unger, S. Rose-John, U. H. von 
Andrian, H. Baumann & S. S. Evans, (2006) Fever-range thermal stress promotes 
lymphocyte trafficking across high endothelial venules via an interleukin 6 trans­
signaling mechanism. Nat Immunol 7:1299-1308.
Cholera, R., N. J. Brittain, M. R. Gillrie, T. M. Lopera-Mesa, S. A. Diakite, T. Arie, M. A. Krause, A. 
Guindo, A. Tubman, H. Fujioka, D. A. Diallo, O. K. Doumbo, M. Ho, T. E. Wellems & R.
1 70
M. Fairhurst, (2008) Impaired cytoadherence of Plasmodium falciparum-infected 
erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci USA  105: 991-996.
Chotivanich, K., R. Udomsangpetch, A. Dondorp, T. Williams, B. Angus, J. A. Simpson, S. 
Pukrittayakamee, S. Looareesuwan, C. I. Newbold & N. J. White, (2000) The 
mechanisms of parasite clearance after antimalarial treatment of Plasmodium 
falciparum malaria. J Infect Dis 182: 629-633.
Chotivanich, K., R. Udomsangpetch, R. McGready, S. Proux, P. Newton, S. Pukrittayakamee, S. 
Looareesuwan & N. J. White, (2002) Central role of the spleen in malaria parasite 
clearance. J Infect Dis 185:1538-1541.
Cockburn, I. A., M. J. Mackinnon, A. O'Donnell, S. J. Allen, J. M. Moulds, M. Baisor, M. Bockarie, 
J. C. Reeder & J. A. Rowe, (2004) A human complement receptor 1 polymorphism that 
reduces Plasmodium falciparum rosetting confers protection against severe malaria. 
Proc Natl Acad Sci USA  101: 272-277.
Combes, V., N. Coltel, D. Faille, S. C. Wassmer & G. E. Grau, (2006) Cerebral malaria: role of 
microparticles and platelets in alterations of the blood-brain barrier. Int J Parasltol 36: 
541-546.
Comeaux, C. A. & M. T. Duraisingh, (2007) Unravelling a histone code for malaria virulence. 
Mol Microbiol 66:1291-1295.
Cooke, B. M., A. R. Berendt, A. G. Craig, J. MacGregor, C. I. Newbold & G. B. Nash, (1994) 
Rolling and stationary cytoadhesion of red blood cells parasitized by Plasmodium 
falciparum: separate roles for ICAM-1, CD36 and thrombospondin. Br J Haematol 87: 
162-170.
Cooke, B. M. & G. B. Nash, (1995) Plasmodium falciparum: characterization of adhesion of 
flowing parasitized red blood cells to platelets. Exp Parasitol 80:116-123.
Cooke, B. M., S. J. Rogerson, G. V. Brown & R. L. Coppel, (1996) Adhesion of malaria-infected 
red blood cells to chondroitin sulfate A under flow conditions. Blood 88: 4040-4044.
Cooke, B. M., C. L. Nicoll, D. I. Baruch & R. L. Coppel, (1998) A recombinant peptide based on 
PfEMP-1 blocks and reverses adhesion of malaria-infected red blood cells to CD36 
under flow. Mol Microbiol 30: 83-90.
Cooke, B. M., N. Mohandas & R. L. Coppel, (2001) The malaria-infected red blood cell: 
structural and functional changes. Adv Parasitol 50:1-86.
Cooke, B. M., R. L. Coppel & G. B. Nash, (2002) Analysis of the adhesive properties of 
Plasmodium falciparum-infected red blood cells under conditions of flow. Methods 
Mol Med 72:561-569.
Cox-Singh, J., T. M. Davis, K. S. Lee, S. S. Shamsul, A. Matusop, S. Ratnam, H. A. Rahman, D. J. 
Conway & B. Singh, (2008) Plasmodium knowlesi malaria in humans is widely 
distributed and potentially life threatening. Clin Infect Dis 46:165-171.
Crabb, B. S., B. M. Cooke, J. C. Reeder, R. F. Waller, S. R. Caruana, K. M. Davern, M. E. Wickham, 
G. V. Brown, R. L. Coppel & A. F. Cowman, (1997) Targeted gene disruption shows that 
knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. 
Cell 89: 287-296.
Craig, A. G., R. Pinches, S. Khan, D. J. Roberts, G. D. Turner, C. I. Newbold & A. R. Berendt, 
(1997) Failure to block adhesion of Plasmodium falciparum-infected erythrocytes to 
ICAM-1 with soluble ICAM-1. Infect Immun 65: 4580-4585.
Craig, A. & A. Scherf, (2001) Molecules on the surface of the Plasmodium falciparum infected 
erythrocyte and their role in malaria pathogenesis and immune evasion. Mol Biochem 
Parasitol 115:129-143.
Crandall, I., K. M. Land & I. W. Sherman, (1994) Plasmodium falciparum: pfalhesin and CD36 
form an adhesin/receptor pair that is responsible for the pH-dependent portion of 
cytoadherence/sequestration. Exp Parasitol 78: 203-209.
Cranston, H. A., C. W. Boylan, G. L. Carroll, S. P. Sutera, J. R. Williamson, I. Y. Gluzman & D. J. 
Krogstad, (1984) Plasmodium falciparum maturation abolishes physiologic red cell 
deformability. Science 223: 400-403.
171
Davis, T. M., T. Y. Hung, I. K. Sim, H. A. Karunajeewa & K. F. Ilett, (2005) Piperaquine: a 
resurgent antimalarial drug. Drugs 65: 75-87.
del Portillo, H. A., M. Lanzer, S. Rodriguez-Malaga, F. Zavala & C. Fernandez-Becerra, (2004) 
Variant genes and the spleen in Plasmodium vivax malaria. Int J Parasitol 34: 1547- 
1554.
Diamond, M. S., D. E. Staunton, S. D. Marlin & T. A. Springer, (1991) Binding of the integrin 
Mac-1 (CDllb/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and 
its regulation by glycosylation. Cell 65: 961-971.
Dokladny, K., D. Ye, J. C. Kennedy, P. L. Moseley & T. Y. Ma, (2008) Cellular and molecular 
mechanisms of heat stress-induced up-regulation of occludin protein expression: 
regulatory role of heat shock factor-1. Am J Pathol 172: 659-670.
Dondorp, A. M., B. J. Angus, M. R. Hardeman, K. T. Chotivanich, K. Silamut, R. Ruangveerayuth, 
P. A. Kager, N. J. White & J. Vreeken, (1997) Prognostic significance of reduced red 
blood cell deformability in severe falciparum malaria. Am J Trop Med Hyg 57: 507-511.
Dondorp, A. M., P. A. Kager, J. Vreeken & N. J. White, (2000) Abnormal blood flow and red 
blood cell deformability in severe malaria. Parasitol Today 16: 228-232.
Dondorp, A., F. Nosten, K. Stepniewska, N. Day & N. White, (2005) Artesunate versus quinine 
for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717-725.
Dondorp, A. M., K. Silamut, P. Charunwatthana, S. Chuasuwanchai, R. Ruangveerayut, S. 
Krintratun, N. J. White, M. Ho & N. P. Day, (2007) Levamisole inhibits sequestration of 
infected red blood cells in patients with falciparum malaria. J Infect Dis 196: 460-466.
Dondorp, A. M., (2008) Clinical significance of sequestration in adults with severe malaria. 
Transfus Clin Biol 15: 56-57.
Dondorp, A. M., C. Ince, P. Charunwatthana, J. Hanson, A. van Kuijen, M. A. Faiz, M. R. 
Rahman, M. Hasan, E. Bin Yunus, A. Ghose, R. Ruangveerayut, D. Limmathurotsakul, K. 
Mathura, N. J. White & N. P. Day, (2008) Direct in vivo assessment of microcirculatory 
dysfunction in severe falciparum malaria. J Infect Dis 197: 79-84.
Duraisingh, M. T., T. S. Voss, A. J. Marty, M. F. Duffy, R. T. Good, J. K. Thompson, L. H. Freitas- 
Junior, A. Scherf, B. S. Crabb & A. F. Cowman, (2005) Heterochromatin silencing and 
locus repositioning linked to regulation of virulence genes in Plasmodium falciparum. 
Cell 121:13-24.
Dzikowski, R., F. Li, B. Amulic, A. Eisberg, M. Frank, S. Patel, T. E. Wellems & K. W. Deitsch,
(2007) Mechanisms underlying mutually exclusive expression of virulence genes by 
malaria parasites. EMBO Rep 8: 959-965.
Eda, S., J. Lawler & I. W. Sherman, (1999) Plasmodium falciparum-infected erythrocyte 
adhesion to the type 3 repeat domain of thrombospondin-1 is mediated by a modified 
band 3 protein. Mol Biochem Parasitol 100:195-205.
Engwerda, C. R., L. Beattie & F. H. Amante, (2005) The importance of the spleen in malaria. 
Trends Parasitol 21: 75-80.
Freitas-Junior, L. H., R. Hernandez-Rivas, S. A. Ralph, D. Montiel-Condado, O. K. Ruvalcaba- 
Salazar, A. P. Rojas-Meza, L. Mancio-Silva, R. J. Leal-Silvestre, A. M. Gontijo, S. Shorte & 
A. Scherf, (2005) Telomeric heterochromatin propagation and histone acetylation 
control mutually exclusive expression of antigenic variation genes in malaria parasites. 
Cell 121: 25-36.
Fried, M., F. Nosten, A. Brockman, B. J. Brabin & P. E. Duffy, (1998) Maternal antibodies block 
malaria [letter]. Nature 395: 851-852.
Fried, M. & P. E. Duffy, (2002) Two DBLgamma subtypes are commonly expressed by placental 
isolates of Plasmodium falciparum. Mol Biochem Parasitol 122: 201-210.
Gamain, B., A. R. Trimnell, C. Scheidig, A. Scherf, L. H. Miller & J. D. Smith, (2005) Identification 
of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene 
transcribed in CSA-binding parasites. J Infect Dis 191:1010-1013.
Gaur, D., D. C. Mayer & L. H. Miller, (2004) Parasite ligand-host receptor interactions during 
invasion of erythrocytes by Plasmodium merozoites. IntJ Parasitol 34:1413-1429.
172
Gennaro, A. M., A. Luquita & M. Rasia, (1996) Comparison between internal microviscosity of 
low-density erythrocytes and the microviscosity of hemoglobin solutions: an electron 
paramagnetic resonance study. Biophys J 71: 389-393.
Glenister, F. K., R. L. Coppel, A. F. Cowman, N. Mohandas & B. M. Cooke, (2002) Contribution of 
parasite proteins to altered mechanical properties of malaria-infected red blood cells. 
Blood 99: 1060-1063.
Glushakova, S., D. Yin, T. Li & J. Zimmerberg, (2005) Membrane transformation during malaria 
parasite release from human red blood cells. Curr Biol 15:1645-1650.
Gnant, M. F., E. M. Turner & H. R. Alexander, Jr., (2000) Effects of hyperthermia and tumour 
necrosis factor on inflammatory cytokine secretion and procoagulant activity in 
endothelial cells. Cytokine 12: 339-347.
Gravenor, M. B. & D. Kwiatkowski, (1998) An analysis of the temperature effects of fever on 
the intra-host population dynamics of Plasmodium falciparum. Parasitology 117: 97- 
105.
Gray, C., C. McCormick, G. Turner & A. Craig, (2003) ICAM-1 can play a major role in mediating 
P. falciparum adhesion to endothelium under flow. Mol Biochem Parasitol 128: 187- 
193.
Greenwood, J., C. L. Amos, C. E. Walters, P. O. Couraud, R. Lyck, B. Engelhardt & P. Adamson, 
(2003) Intracellular domain of brain endothelial intercellular adhesion molecule-1 is 
essential for T lymphocyte-mediated signaling and migration. J Immunol 171: 2099- 
2108.
Griffiths, M. J., F. Ndungu, K. L. Baird, D. P. Muller, K. Marsh & C. R. Newton, (2001) Oxidative 
stress and erythrocyte damage in Kenyan children with severe Plasmodium falciparum 
malaria. Br J Haematol 113: 486-491.
Guerra, C. A., P. W. Gikandi, A. J. Tatem, A. M. Noor, D. L. Smith, S. I. Hay & R. W. Snow, (2008) 
The limits and intensity of Plasmodium falciparum transmission: implications for 
malaria control and elimination worldwide. PLoS Med  5: e38.
Gysin, J., B. Pouvelle, N. Fievet, A. Scherf & C. Lepolard, (1999) Ex vivo desequestration of 
plasmodium falciparum-infected erythrocytes from human placenta by chondroitin 
sulfate A [In Process Citation]. Infect Immun 67: 6596-6602.
Hanssen, E., R. Sougrat, S. Frankland, S. Deed, N. Klonis, J. Lippincott-Schwartz & L. Tilley,
(2008) Electron tomography of the Maurer's cleft organelles of Plasmodium 
falciparum-infected erythrocytes reveals novel structural features. Mol Microbiol 67: 
703-718.
Hartl, F. U., (1996) Molecular chaperones in cellular protein folding. Nature 381: 571-579.
Hasday, J. D., D. Bannerman, S. Sakarya, A. S. Cross, I. S. Singh, D. Howard, B. E. Drysdale & S. E. 
Goldblum, (2001) Exposure to febrile temperature modifies endothelial cell response 
to tumor necrosis factor-alpha. J Appl Physiol 90: 90-98.
Hasday, J. D. & I. S. Singh, (2000) Fever and the heat shock response: distinct, partially 
overlapping processes. Cell Stress Chaperones 5: 471-480.
Hasler, C. R. &. W. H. Reinhart, (1998) No influence of furosemide on human erythrocyte shape 
and volume and blood viscosity in vitro. Clin Hemorheol Microcirc 18: 43-46.
Helmby, H., L. Cavelier, U. Pettersson & M. Wahlgren, (1993) Rosetting Plasmodium 
falciparum-infected erythrocytes express unique strain-specific antigens on their 
surface. Infect Immun 61: 284-288.
Hemmer, C. J., H. A. Lehr, K. Westphal, M. Unverricht, M. Kratzius & E. C. Reisinger, (2005) 
Plasmodium falciparum Malaria: reduction of endothelial cell apoptosis in vitro. Infect 
Immun 73:1764-1770.
Hempelmann, E., C. Motta, R. Hughes, S. A. Ward & P. G. Bray, (2003) Plasmodium falciparum: 
sacrificing membrane to grow crystals? Trends Parasitol 19: 23-26.
Higgins, M. K., (2008a) Overproduction, purification and crystallization of a chondroitin sulfate 
A-binding DBL domain from a Plasmodium falciparum var2csa-encoded PfEMPl 
protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 64: 221-223.
173
Higgins, M. K., (2008b) The Structure of a Chondroitin Sulfate-binding Domain Important in 
Placental Malaria. J. Biol. Chem. 283: 21842-21846.
Ho, M., T. Schollaardt, X. Niu, S. Looareesuwan, K. D. Patel & P. Kubes, (1998) Characterization 
of Plasmodium falciparum-infected erythrocyte and P- selectin interaction under flow 
conditions. Blood 91: 4803-4809.
Ho, M. & N. J. White, (1999) Molecular mechanisms of cytoadherence in malaria. Am J Physiol 
276: C1231-1242.
Ho, M., H. L. Hoang, K. M. Lee, N. Liu, T. MacRae, L. Montes, C. L. Flatt, B. G. Yipp, B. J. Berger, 
S. Looareesuwan & S. M. Robbins, (2005) Ectophosphorylation of CD36 regulates 
cytoadherence of Plasmodium falciparum to microvascular endothelium under flow 
conditions. Infect Immun 73: 8179-8187.
Horrocks, P., R. Pinches, S. Kyes, N. Kriek, S. Lee, Z. Christodoulou & C. I. Newbold, (2002) Effect 
of var gene disruption on switching in Plasmodium falciparum. Mol Microbiol 45:1131- 
1141.
Horrocks, P., R. Pinches, Z. Christodoulou, S. A. Kyes & C. I. Newbold, (2004) Variable var 
transition rates underlie antigenic variation in malaria. Proc Natl Acad Sei U S A  101: 
11129-11134.
Horrocks, P., R. A. Pinches, S. J. Chakravorty, J. Papakrivos, Z. Christodoulou, S. A. Kyes, B. C. 
Urban, D. J. Ferguson & C. I. Newbold, (2005) PfEMPl expression is reduced on the 
surface of knobless Plasmodium falciparum infected erythrocytes. J Cell Sei 118: 2507- 
2518.
Hosokawa, N., K. Hirayoshi, H. Kudo, H. Takechi, A. Aoike, K. Kawai & K. Nagata, (1992) 
Inhibition of the activation of heat shock factor in vivo and in vitro by flavonoids. Mol 
Cell Biol 12: 3490-3498.
Hughes, K., M. Wand, L. Foulston, R. Young, K. Harley, S. Terry, K. Ersfeld & G. Rudenko, (2007) 
A novel ISWI is involved in VSG expression site downregulation in African 
trypanosomes. EMBOJ 26: 2400-2410.
Jenkins, N., Y. Wu, S. Chakravorty, O. Kai, K. Marsh & A. Craig, (2007a) Plasmodium falciparum 
intercellular adhesion molecule-l-based cytoadherence-related signaling in human 
endothelial cells. J Infect Dis 196: 321-327.
Jenkins, N., Y. Wu, S. J. Chakravorty, O. Kai, K. Marsh & A. Craig, (2007b) Plasmodium 
falciparum ICAM-l-based cytoadherence-related signalling in human endothelial cells. 
J. Infect. Dis. 196: 321-327.
Jensen, J. B., (1978) Concentration from Continuous Culture of Erythrocytes Infected with 
Trophozoites and Schizonts of Plasmodium Falciparum. Am J Trop Med Hyg 27: 1274- 
1276.
Jolly, C., Y. Usson & R. I. Morimoto, (1999) Rapid and reversible relocalization of heat shock 
factor 1 within seconds to nuclear stress granules. Proc Natl Acad Sel U S A 96: 6769- 
6774.
Jun, C. D., C. V. Carman, S. D. Redick, M. Shimaoka, H. P. Erickson &. T. A. Springer, (2001a) 
Ultrastructure and function of dimeric, soluble intercellular adhesion molecule-1 
(ICAM-1). J Biol Chem 276: 29019-29027.
Jun, C. D., M. Shimaoka, C. V. Carman, J. Takagi & T. A. Springer, (2001b) Dimerization and the 
effectiveness of ICAM-1 in mediating LFA-l-dependent adhesion. Proc Natl Acad Sei U 
SA 98: 6830-6835.
Ketis, N. V., R. L. Hoover & M. J. Karnovsky, (1988) Effects of hyperthermia on cell survival and 
patterns of protein synthesis in endothelial cells from different origins. Cancer Res 48: 
2101-2106.
Kirk, K., H. A. Horner, B. C. Elford, J. C. Ellory & C. I. Newbold, (1994) Transport of diverse 
substrates into malaria-infected erythrocytes via a pathway showing functional 
characteristics of a chloride channel. J Biol Chem 269: 3339-3347.
Kirk, K., (2001) Membrane transport in the malaria-infected erythrocyte. Physiol Rev 81: 495- 
537.
1 74
Kobuchi, H., S. Roy, C. K. Sen, H. G. Nguyen & L. Packer, (1999) Quercetin inhibits inducible 
ICAM-1 expression in human endothelial cells through the JNK pathway. Am J Physiol 
277: C403-411.
Kohn, G., H. R. Wong, K. Bshesh, B. Zhao, N. Vasi, A. Denenberg, C. Morris, J. Stark & T. P. 
Shanley, (2002) Heat shock inhibits tnf-induced ICAM-1 expression in human 
endothelial cells via I kappa kinase inhibition. Shock 17: 91-97.
Kon, K., N. Maeda & T. Shiga, (1987) Erythrocyte deformation in shear flow: influences of 
internal viscosity, membrane stiffness, and hematocrit. Blood 69: 727-734.
Kraemer, S. M., L. Gupta & J. D. Smith, (2003) New tools to identify var sequence tags and 
clone full-length genes using type-specific primers to Duffy binding-like domains. Mol 
Biochem Parasltol 129: 91-102.
Kraemer, S. M., S. A. Kyes, G. Aggarwal, A. L. Springer, S. O. Nelson, Z. Christodoulou, L. M. 
Smith, W. Wang, E. Levin, C. I. Newbold, P. J. Myler & J. D. Smith, (2007) Patterns of 
gene recombination shape var gene repertoires in Plasmodium falciparum: 
comparisons of geographically diverse isolates. BMC Genomics 8: 45.
Kwiatkowski, D., (1989) Febrile temperatures can synchronize the growth of Plasmodium 
falciparum in vitro. J Exp Med 169: 357-361.
Kwiatkowski, D., M. E. Molyneux, S. Stephens, N. Curtis, N. Klein, P. Pointaire, M. Smit, R. Allan, 
D. R. Brewster, G. E. Grau & et al., (1993) Anti-TNF therapy inhibits fever in cerebral 
malaria [see comments]. Q J Med  86: 91-98.
Kwiatkowski, D., C. A. Bate, I. G. Scragg, P. Beattie, I. Udalova & J. C. Knight, (1997) The malarial 
fever response-pathogenesis, polymorphism and prospects for intervention. Ann Trop 
Med Parasitol 91: 533-542.
Kyes, S. A., J. A. Rowe, N. Kriek & C. I. Newbold, (1999) Rifins: a second family of clonally 
variant proteins expressed on the surface of red cells infected with Plasmodium 
falciparum. Proc Natl Acad Sci USA  96: 9333-9338.
Kyes, S., R. Pinches & C. Newbold, (2000) A simple RNA analysis method shows var and rif 
multigene family expression patterns in Plasmodium falciparum. Mol Biochem 
Parasitol 105: 311-315.
Kyes, S., Z. Christodoulou, R. Pinches, N. Kriek, P. Horrocks & C. Newbold, (2007a) Plasmodium 
falciparum var gene expression is developmentally controlled at the level of RNA 
polymerase ll-mediated transcription initiation. Mol Microbiol 63:1237-1247.
Kyes, S. A., S. M. Kraemer & J. D. Smith, (2007b) Antigenic variation in Plasmodium falciparum: 
gene organization and regulation of the var multigene family. Eukaryot Cell 6: 1511- 
1520.
Lawler, J. & R. O. Hynes, (1986) The structure of human thrombospondin, an adhesive 
glycoprotein with multiple calcium-binding sites and homologies with several different 
proteins. J Cell Biol 103:1635-1648.
Le Jouan, M., V. Jullien, E. Tetanye, A. Tran, E. Rey, J. M. Treluyer, M. Tod & G. Pons, (2005) 
Quinine pharmacokinetics and pharmacodynamics in children with malaria caused by 
Plasmodium falciparum. Antlmicrob Agents Chemother 49: 3658-3662.
Lefor, A. T., C. E. Foster, 3rd, W. Sartor, B. Engbrecht, D. F. Fabian & D. Silverman, (1994) 
Hyperthermia increases intercellular adhesion molecule-1 expression and lymphocyte 
adhesion to endothelial cells. Surgery 116: 214-220; discussion 220-211.
Lei I, B., M. Sovric, D. Schmid, D. Luckner, K. Herbich, H. Y. Long, W. Graninger & P. G. Kremsner, 
(2001) Effect of antipyretic drugs in children with malaria. Clin Infect Dis 32: 838-841.
Lew, V. L., T. Tiffert & H. Ginsburg, (2003) Excess hemoglobin digestion and the osmotic 
stability of Plasmodium falciparum-infected red blood cells. Blood 101: 4189-4194.
Lindquist, S. & E. A. Craig, (1988) The heat-shock proteins. Annu Rev Genet 22: 631-677.
Long, H. Y., B. Lell, K. Dietz & P. G. Kremsner, (2001) Plasmodium falciparum: in vitro growth 
inhibition by febrile temperatures. Parasitol Res 87: 553-555.
Lopez-Rubio, J. J., A. M. Gontijo, M. C. Nunes, N. Issar, R. Hernandez Rivas & A. Scherf, (2007a) 
5' flanking region of var genes nucleate histone modification patterns linked to
175
phenotypic inheritance of virulence traits in malaria parasites. Mol Microbiol 66: 1296- 
1305.
Lopez-Rubio, J. J., L. Riviere & A. Scherf, (2007b) Shared epigenetic mechanisms control 
virulence factors in protozoan parasites. CurrOpin Microbiol 10: 560-568.
Lucas, J. Z. & I. W. Sherman, (1998) Plasmodium falciparum: thrombospondin mediates 
parasitized erythrocyte band 3-related adhesin binding. Exp Parasitol 89: 78-85.
Luchavez, J., F. Espino, P. Curameng, R. Espina, D. Bell, P. Chiodini, D. Nolder, C. Sutherland, K. 
S. Lee & B. Singh, (2008) Human Infections with Plasmodium knowlesi, the Philippines. 
Emerg Infect Dis 14: 811-813.
Lustigman, S., R. F. Anders, G. V. Brown & R. L. Coppel, (1990) The mature-parasite-infected 
erythrocyte surface antigen (MESA) of Plasmodium falciparum associates with the 
erythrocyte membrane skeletal protein, band 4.1. Mol Biochem Parasitol 38: 261-270.
Magowan, C., R. L. Coppel, A. O. Lau, M. M. Moronne, G. Tchernia & N. Mohandas, (1995) Role 
of the Plasmodium falciparum mature-parasite-infected erythrocyte surface antigen 
(MESA/PfEMP-2) in malarial infection of erythrocytes. Blood 86: 3196-3204.
Maier, A. G., M. Rug, M. T. O'Neill, M. Brown, S. Chakravorty, T. Szestak, J. Chesson, Y. Wu, K. 
Hughes, R. L. Coppel, C. Newbold, J. G. Beeson, A. Craig, B. S. Crabb & A. F. Cowman, 
(2008) Exported proteins required for virulence and rigidity of Plasmodium falciparum- 
infected human erythrocytes. Cell 134: 48-61.
Marinkovic, M., M. Diez-Silva, I. Pantic, J. J. Fredberg, S. Suresh & J. P. Butler, (2008) Febrile 
temperature leads to significant stiffening of Plasmodium falciparum parasitized 
erythrocytes. Am J Physiol Cell Physiol.
Marsh, K., D. Forster, C. Waruiru, I. Mwangi, M. Winstanley, V. Marsh, C. Newton, P. 
Winstanley, P. Warn, N. Peshu & et al., (1995) Indicators of life-threatening malaria in 
African children [see comments]. N Engl J Med  332:1399-1404.
Marti, M., R. T. Good, M. Rug, E. Knuepfer & A. F. Cowman, (2004) Targeting malaria virulence 
and remodeling proteins to the host erythrocyte. Science 306:1930-1933.
McCormick, C. J., A. Craig, D. Roberts, C. I. Newbold & A. R. Berendt, (1997) Intercellular 
adhesion molecule-1 and CD36 synergize to mediate adherence of Plasmodium 
falciparum-infected erythrocytes to cultured human microvascular endothelial cells. J 
Clin Invest 100: 2521-2529.
McGready, R., K. Stepniewska, S. A. Ward, T. Cho, G. Gilveray, S. Looareesuwan, N. J. White & 
F. Nosten, (2006) Pharmacokinetics of dihydroartemisinin following oral artesunate 
treatment of pregnant women with acute uncomplicated falciparum malaria. EurJ Clin 
Pharmacol 62: 367-371.
Medana, I. M. & G. D. Turner, (2006) Human cerebral malaria and the blood-brain barrier. IntJ 
Parasitol 36: 555-568.
Medana, I. M. & G. D. Turner, (2007) Plasmodium falciparum and the blood-brain barrier- 
contacts and consequences. J Infect Dis 195: 921-923.
Mercier, P. A., N. A. Winegarden & J. T. Westwood, (1999) Human heat shock factor 1 is 
predominantly a nuclear protein before and after heat stress. J Cell Sci 112 ( Pt 16): 
2765-2774.
Meremikwu, M., K. Logan & P. Garner, (2000) Antipyretic measures for treating fever in 
malaria. Cochrane Database Syst Rev: CD002151.
Miller, J., R. Knorr, M. Ferrone, R. Houdei, C. P. Carron & M. L. Dustin, (1995) Intercellular 
adhesion molecule-1 dimerization and its consequences for adhesion mediated by 
lymphocyte function associated-1. J Exp Med 182:1231-1241.
Miltenyi, S., W. Muller, W. Weichel & A. Radbruch, (1990) High gradient magnetic cell 
separation with MACS. Cytometry 11: 231-238.
Mohandas, N., M. R. Clark, M. S. Jacobs & S. B. Shohet, (1980) Analysis of factors regulating 
erythrocyte deformability. J Clin Invest 66: 563-573.
1 76
Montgomery, J., F. A. Mphande, M. Berriman, A. Pain, S. J. Rogerson, T. E. Taylor, M. E. 
Molyneux & A. Craig, (2007) Differential var gene expression in the organs of patients 
dying of falciparum malaria. Mol Microbiol 65: 959-967.
Moon, Y. J., L. Wang, R. DiCenzo & M. E. Morris, (2008) Quercetin pharmacokinetics in 
humans. Biopharm Drug Dispos 29: 205-217.
Morimoto, R. I., (1998) Regulation of the heat shock transcriptional response: cross talk 
between a family of heat shock factors, molecular chaperones, and negative 
regulators. Genes Dev 12: 3788-3796.
Muanza, K., F. Gay, C. Behr & A. Scherf, (1996) Primary culture of human lung microvessel 
endothelial cells: a useful in vitro model for studying Plasmodium falciparum-infected 
erythrocyte cytoadherence. Res Immunol 147:149-163.
Mueller, I., P. A. Zimmerman & J. C. Reeder, (2007) Plasmodium malariae and Plasmodium 
ovale--the "bashful" malaria parasites. Trends Parasitoi 23: 278-283.
Multhoff, G., C. Botzler, M. Wiesnet, E. Muller, T. Meier, W. Wilmanns & R. D. Issels, (1995) A 
stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of 
human tumor cells, but noton normal cells. IntJ Cancer 61: 272-279.
Nagai, N., A. Nakai & K. Nagata, (1995) Quercetin suppresses heat shock response by down 
regulation of HSF1. Biochem Biophys Res Commun 208:1099-1105.
Nair, M. P., S. Mahajan, J. L. Reynolds, R. Aalinkeel, H. Nair, S. A. Schwartz & C. Kandaswami, 
(2006) The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis 
factor alpha) gene expression in normal peripheral blood mononuclear cells via 
modulation of the NF-kappa beta system. Clin Vaccine Immunol 13: 319-328.
Nakabe, N., S. Kokura, M. Shimozawa, K. Katada, N. Sakamoto, T. Ishikawa, O. Handa, T. Takagi, 
Y. Naito, N. Yoshida & T. Yoshikawa, (2007) Hyperthermia attenuates TNF-alpha- 
induced up regulation of endothelial cell adhesion molecules in human arterial 
endothelial cells. IntJ Hyperthermia 23: 217-224.
Nash, G. B., E. O'Brien, E. C. Gordon-Smith & J. A. Dormandy, (1989) Abnormalities in the 
mechanical properties of red blood cells caused by Plasmodium falciparum. Blood 74: 
855-861.
Naumann, K. M., G. L. Jones, A. Saul & R. Smith, (1991) A Plasmodium falciparum exo-antigen 
alters erythrocyte membrane deformability. FEBS Lett 292: 95-97.
Navarro, M. & K. Gull, (2001) A pol I transcriptional body associated with VSG mono-allelic 
expression in Trypanosoma brucei. Nature 414: 759-763.
Newbold, C., P. Warn, G. Black, A. Berendt, A. Craig, B. Snow, M. Msobo, N. Peshu & K. Marsh, 
(1997) Receptor-specific adhesion and clinical disease in Plasmodium falciparum [see 
comments]. Am J Trop Med Hyg 57: 389-398.
Newman, P. J., M. C. Berndt, J. Gorski, G. C. White, 2nd, S. Lyman, C. Paddock & W. A. Muller, 
(1990) PECAM-1 (CD31) cloning and relation to adhesion molecules of the 
immunoglobulin gene superfamily. Science 247:1219-1222.
Newton, P. N., K. I. Barnes, P. J. Smith, A. C. Evans, W. Chierakul, R. Ruangveerayuth & N. J. 
White, (2006) The pharmacokinetics of intravenous artesunate in adults with severe 
falciparum malaria. EurJ Clin Pharmacol 62:1003-1009.
Ng, O. T., E. E. Ooi, C. C. Lee, P. J. Lee, L. C. Ng, S. W. Pei, T. M. Tu, J. P. Loh & Y. S. Leo, (2008) 
Naturally acquired human Plasmodium knowlesi infection, Singapore. Emerg Infect Dis 
14: 814-816.
Nonaka, T., T. Akimoto, N. Mitsuhashi, Y. Tamaki & T. Nakano, (2003) Changes in the number 
of HSF1 positive granules in the nucleus reflects heat shock semiquantitatively. Cancer 
Lett 202: 89-100.
Nunes, M. C. & A. Scherf, (2007) Plasmodium falciparum during pregnancy: a puzzling parasite 
tissue adhesion tropism. Parasitology 134:1863-1869.
O'Neill, P. M. & G. H. Posner, (2004) A medicinal chemistry perspective on artemisinin and 
related endoperoxides. J Med Chem 47: 2945-2964.
177
O'Neill, P. M., S. A. Ward, N. G. Berry, J. P. Jeyadevan, G. A. Biagini, E. Asadollaly, B. K. Park & P. 
G. Bray, (2006) A medicinal chemistry perspective on 4-aminoquinoline antimalarial 
drugs. Curr Top Med Chem 6: 479-507.
Oakley, M. S., S. Kumar, V. Anantharaman, H. Zheng, B. Mahajan, J. D. Haynes, J. K. Moch, R. 
Fairhurst, T. F. McCutchan & L. Aravind, (2007) Molecular factors and biochemical 
pathways induced by febrile temperature in intraerythrocytic Plasmodium falciparum 
parasites. Infect Immun 75: 2012-2025.
Ockenhouse, C. F., R. Betageri, T. A. Springer & D. E. Staunton, (1992a) Plasmodium falciparum- 
infected erythrocytes bind ICAM-1 at a site distinct from LFA-1, Mac-1, and human 
rhinovirus [published erratum appears in Cell 1992 Mar 6;68(5):following 994], Cell 68: 
63-69.
Ockenhouse, C. F., N. N. Tandon, C. Magowan, G. A. Jamieson & J. D. Chulay, (1989) 
Identification of a platelet membrane glycoprotein as a falciparum malaria 
sequestration receptor [see comments]. Science 243:1469-1471.
Ockenhouse, C. F., T. Tegoshi, Y. Maeno, C. Benjamin, M. Ho, K. E. Kan, Y. Thway, K. Win, M. 
Aikawa & R. R. Lobb, (1992b) Human vascular endothelial cell adhesion receptors for 
Plasmodium falciparum-infected erythrocytes: roles for endothelial leukocyte 
adhesion molecule 1 and vascular cell adhesion molecule 1. J Exp Med 176:1183-1189.
Oh, S. S., S. Voigt, D. Fisher, S. J. Yi, P. J. LeRoy, L. H. Derick, S. Liu & A. H. Chishti, (2000) 
Plasmodium falciparum erythrocyte membrane protein 1 is anchored to the actin- 
spectrin junction and knob-associated histidine-rich protein in the erythrocyte 
skeleton. Mol Biochem Parasltol 108: 237-247.
Park, H. G., S. I. Han, S. Y. Oh & H. S. Kang, (2005) Cellular responses to mild heat stress. Cell 
Mol Life Sci 62:10-23.
Parker, P. D., L. Tilley & N. Klonis, (2004) Plasmodium falciparum induces reorganization of host 
membrane proteins during intraerythrocytic growth. Blood 103: 2404-2406.
Patel, K. D., M. U. Nollert & R. P. McEver, (1995) P-selectin must extend a sufficient length 
from the plasma membrane to mediate rolling of neutrophils. J Cell Biol 131: 1893- 
1902.
Paul, F., S. Roath, D. Melville, D. C. Warhurst & J. O. Osisanya, (1981) Separation of malaria- 
infected erythrocytes from whole blood: use of a selective high-gradient magnetic 
separation technique. Lancet 2: 70-71.
Paulitschke, M. & G. B. Nash, (1993) Membrane rigidity of red blood cells parasitized by 
different strains of Plasmodium falciparum. J Lab Clin Med 122: 581-589.
Pavithra, S. R., G. Banumathy, O. Joy, V. Singh & U. Tatu, (2004) Recurrent fever promotes 
Plasmodium falciparum development in human erythrocytes. J Biol Chem 279: 46692- 
46699.
Pei, X., X. An, X. Guo, M. Tarnawski, R. Coppel & N. Mohandas, (2005) Structural and functional 
studies of interaction between Plasmodium falciparum knob-associated histidine-rich 
protein (KAHRP) and erythrocyte spectrin. J Biol Chem 280: 31166-31171.
Pei, X., X. Guo, R. Coppel, N. Mohandas & X. An, (2007) Plasmodium falciparum erythrocyte 
membrane protein 3 (PfEMP3) destabilizes erythrocyte membrane skeleton. J Biol 
Chem 282: 26754-26758.
Peters, W. G., H, (1995) Tropical Medicine and Parasitology. Mosby-Wolfe.
Pino, P., I. Vouldoukis, J. P. Kolb, N. Mahmoudi, I. Desportes-Livage, F. Bricaire, M. Danis, B. 
Dugas & D. Mazier, (2003) Plasmodium falciparum-infected erythrocyte adhesion 
induces caspase activation and apoptosis in human endothelial cells. J Infect Dis 187: 
1283-1290.
Pongponratn, E., G. D. Turner, N. P. Day, N. H. Phu, J. A. Simpson, K. Stepniewska, N. T. Mai, P. 
Viriyavejakul, S. Looareesuwan, T. T. Hien, D. J. Ferguson & N. J. White, (2003) An 
ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop 
Med Hyg 69: 345-359.
178
Pouvelle, B., V. Matarazzo, C. Jurzynski, J. Nemeth, M. Ramharter, G. Rougon & J. Gysin, (2007) 
Neural cell adhesion molecule, a new cytoadhesion receptor for Plasmodium 
falciparum-infected erythrocytes capable of aggregation. Infect Immun 75: 3516-3522.
Powers, M. V. & P. Workman, (2007) Inhibitors of the heat shock response: biology and 
pharmacology. FEBS Lett 581: 3758-3769.
Price, R., M. van Vugt, F. Nosten, C. Luxemburger, A. Brockman, L. Phaipun, T. 
Chongsuphajaisiddhi & N. White, (1998) Artesunate versus artemether for the 
treatment of recrudescent multidrug-resistant falciparum malaria. Am J Trop Med Hyg 
59: 883-888.
Price, R. N., E. Tjitra, C. A. Guerra, S. Yeung, N. J. White & N. M. Anstey, (2007) Vivax malaria: 
neglected and not benign. Am J Trop Med Hyg 77: 79-87.
Prudencio, M., A. Rodriguez & M. M. Mota, (2006) The silent path to thousands of merozoites: 
the Plasmodium liver stage. Nat Rev Microbiol A: 849-856.
Ralph, S. A., C. Scheidig-Benatar & A. Scherf, (2005) Antigenic variation in Plasmodium 
falciparum is associated with movement of var loci between subnuclear locations. Proc 
Natl Acad Scl USA  102: 5414-5419.
Rayner, J. C., (2006) Erythrocyte exit: Out, damned merozoite! Out I say! Trends Parasitol 22: 
189-192.
Reeder, J. C , A. F. Cowman, K. M. Davern, J. G. Beeson, J. K. Thompson, S. J. Rogerson & G. V. 
Brown, (1999) The adhesion of Plasmodium falciparum-infected erythrocytes to 
chondroitin sulfate A is mediated by P. falciparum erythrocyte membrane protein 1. 
Proc Natl Acad Scl USA  96: 5198-5202.
Roberts, D. D., J. A. Sherwood, S. L. Spitalnik, L. J. Panton, R. J. Howard, V. M. Dixit, W. A. 
Frazier, L. H. Miller & V. Ginsburg, (1985) Thrombospondin binds falciparum malaria 
parasitized erythrocytes and may mediate cytoadherence. Nature 318: 64-66.
Roberts, D. J., A. G. Craig, A. R. Berendt, R. Pinches, G. Nash, K. Marsh & C. I. Newbold, (1992) 
Rapid switching to multiple antigenic and adhesive phenotypes in malaria [see 
comments]. Nature 357: 689-692.
Rock, E. P., E. F. Roth, Jr., R. R. Rojas-Corona, J. A. Sherwood, R. L. Nagel, R. J. Howard & D. K. 
Kaul, (1988) Thrombospondin mediates the cytoadherence of Plasmodium falciparum- 
infected red cells to vascular endothelium in shear flow conditions. Blood 71: 71-75.
Rogerson, S. J., S. C. Chaiyaroj, K. Ng, J. C. Reeder & G. V. Brown, (1995) Chondroitin sulfate A is 
a cell surface receptor for Plasmodium falciparum-infected erythrocytes. J Exp Med 
182:15-20.
Rowe, A., J. Obeiro, C. I. Newbold & K. Marsh, (1995) Plasmodium falciparum rosetting is 
associated with malaria severity in Kenya. Infect Immun 63: 2323-2326.
Rowe, J. A., J. M. Moulds, C. I. Newbold & L. H. Miller, (1997) P. falciparum rosetting mediated 
by a parasite-variant erythrocyte membrane protein and complement-receptor 1. 
Nature 388: 292-295.
Rug, M., S. W. Prescott, K. M. Fernandez, B. M. Cooke & A. F. Cowman, (2006) The role of 
KAHRP domains in knob formation and cytoadherence of P falciparum-infected human 
erythrocytes. Blood 108: 370-378.
Safeukui, I., J. M. Correas, V. Brousse, D. Hirt, G. Deplaine, S. Mule, M. Lesurtel, N. Goasguen, 
A. Sauvanet, A. Couvelard, S. Kerneis, H. Khun, I. Vigan-Womas, C. Ottone, T. J. Molina, 
J. M. Treluyer, O. Mercereau-Puijalon, G. Milon, P. H. David & P. A. Buffet, (2008) 
Retention of Plasmodium falciparum ring-infected erythrocytes in the slow, open 
microcirculation of the human spleen. Blood 112: 2520-2528.
Scherf, A., R. Hernandez-Rivas, P. Buffet, E. Bottius, C. Benatar, B. Pouvelle, J. Gysin & M. 
Lanzer, (1998) Antigenic variation in malaria: in situ switching, relaxed and mutually 
exclusive transcription of var genes during intra-erythrocytic development in 
Plasmodium falciparum. EmboJ 17: 5418-5426.
Scherf, A., J. J. Lopez-Rubio & L. Riviere, (2008) Antigenic variation in Plasmodium falciparum. 
Annu Rev Microbiol 62:445-470.
179
Scherf, A., B. Pouvelle, P. A. Buffet & J. Gysin, (2001) Molecular mechanisms of Plasmodium 
falciparum placental adhesion. Cell Microbiol 3:125-131.
Schieck, E., J. M. Pfahler, C. P. Sanchez & M. Lanzer, (2007) Nuclear run-on analysis of vargene 
expression in Plasmodium falciparum. Mol Biochem Parasitol 153: 207-212.
Schofield, L. & F. Hackett, (1993) Signal transduction in host cells by a 
glycosylphosphatidylinositol toxin of malaria parasites. J Exp Med  177:145-153.
Schofield, L., S. Novakovic, P. Gerold, R. T. Schwarz, M. J. McConville & S. D. Tachado, (1996) 
Glycosylphosphatidylinositol toxin of Plasmodium up-regulates intercellular adhesion 
molecule-1, vascular cell adhesion molecule-1, and E-selectin expression in vascular 
endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine 
kinase-dependent signal transduction. J Immunol 156:1886-1896.
Shah, A., E. Unger, M. D. Bain, R. Bruce, J. Bodkin, J. Ginnetti, W. C. Wang, B. Seon, C. C. 
Stewart & S. S. Evans, (2002) Cytokine and adhesion molecule expression in primary 
human endothelial cells stimulated with fever-range hyperthermia. Int J Hyperthermia 
18: 534-551.
Shelby, J. P., J. White, K. Ganesan, P. K. Rathod 8t D. T. Chiu, (2003) A microfluidic model for 
single-cell capillary obstruction by Plasmodium falciparum-infected erythrocytes. Proc 
Natl Acad Sei USA  100:14618-14622.
Siau, A., F. S. Toure, O. Ouwe-Missi-Oukem-Boyer, L. Cicéron, N. Mahmoudi, C. Vaquero, P. 
Froissard, U. Bisvigou, S. Bisser, J. Y. Coppee, E. Bischoff, P. H. David & D. Mazier, 
(2007) Whole-transcriptome analysis of Plasmodium falciparum field isolates: 
identification of new pathogenicity factors. J Infect Dis 196:1603-1612.
Simpson, J. A., T. Agbenyega, K. I. Barnes, G. Di Perri, P. Folb, M. Gomes, S. Krishna, S. 
Krudsood, S. Looareesuwan, S. Mansor, H. Mcllleron, R. Miller, M. Molyneux, J. 
Mwenechanya, V. Navaratnam, F. Nosten, P. Olliaro, L. Pang, I. Ribeiro, M. Tembo, M. 
van Vugt, S. Ward, K. Weerasuriya, K. Win & N. J. White, (2006) Population 
pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of 
artesunate in malaria patients. PLoS Med 3: e444.
Singh, B., L. Kim Sung, A. Matusop, A. Radhakrishnan, S. S. Shamsul, J. Cox-Singh, A. Thomas & 
D. J. Conway, (2004) A large focus of naturally acquired Plasmodium knowlesi 
infections in human beings. Lancet 363:1017-1024.
Singh, K., A. G. Gittis, P. Nguyen, D. C. Gowda, L. H. Miller & D. N. Garboczi, (2008) Structure of 
the DBL3x domain of pregnancy-associated malaria protein VAR2CSA complexed with 
chondroitin sulfate A. Nat Struct Mol Biol 15: 932-938.
Skinner, T. S., L. S. Manning, W. A. Johnston & T. M. Davis, (1996) In vitro stage-specific 
sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol 
26: 519-525.
Skorokhod, A., E. Schwarzer, G. Gremo & P. Arese, (2007) HNE produced by the malaria 
parasite Plasmodium falciparum generates HNE-protein adducts and decreases 
erythrocyte deformability. Redox Rep 12: 73-75.
Smilkstein, M., N. Sriwilaijaroen, J. X. Kelly, P. Wilairat & M. Riscoe, (2004) Simple and 
inexpensive fluorescence-based technique for high-throughput antimalarial drug 
screening. Antimicrob Agents ChemotherAS: 1803-1806.
Smith, J. D., C. E. Chitnis, A. G. Craig, D. J. Roberts, D. E. Hudson-Taylor, D. S. Peterson, R. 
Pinches, C. I. Newbold & L. H. Miller, (1995) Switches in expression of Plasmodium 
falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes 
of infected erythrocytes [see comments]. Cell 82:101-110.
Smith, J. D., A. G. Craig, N. Kriek, D. Hudson-Taylor, S. Kyes, T. Fagen, R. Pinches, D. I. Baruch, C. 
I. Newbold & L. H. Miller, (2000) Identification of a Plasmodium falciparum intercellular 
adhesion molecule-1 binding domain: a parasite adhesion trait implicated in cerebral 
malaria. Proc Natl Acad Sei USA  97:1766-1771.
Smith, J. D., B. Gamain, D. I. Baruch & S. Kyes, (2001) Decoding the language of var genes and 
Plasmodium falciparum sequestration. Trends Parasitol 17: 538-545.
1 8 0
Smith, J. D., S. Kyes, A. G. Craig, T. Fagan, D. Hudson-Taylor, L. H. Miller, D. I. Baruch & C. I. 
Newbold, (1998) Analysis of adhesive domains from the A4VAR Plasmodium 
falciparum erythrocyte membrane protein-1 identifies a CD36 binding domain. Mol 
Biochem Parasitol 97:133-148.
Springer, A. L, L. M. Smith, D. Q. Mackay, S. 0 . Nelson & J. D. Smith, (2004) Functional 
interdependence of the DBLbeta domain and c2 region for binding of the Plasmodium 
falciparum variant antigen to ICAM-1. Mol Biochem Parasltol 137: 55-64.
Staalsoe, T., H. A. Giha, D. Dodoo, T. G. Theander & L. Hviid, (1999) Detection of antibodies to 
variant antigens on Plasmodium falciparum- infected erythrocytes by flow cytometry. 
Cytometry 35: 329-336.
Staunton, D. E., M. L. Dustin, H. P. Erickson & T. A. Springer, (1990) The arrangement of the 
immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. 
Cell 61: 243-254.
Su, X. Z., V. M. Heatwole, S. P. Wertheimer, F. Guinet, J. A. Herrfeldt, D. S. Peterson, J. A. 
Ravetch & T. E. Wellems, (1995) The large diverse gene family var encodes proteins 
involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected 
erythrocytes [see comments]. Cell 82: 89-100.
Suwanarusk, R., B. M. Cooke, A. M. Dondorp, K. Silamut, J. Sattabongkot, N. J. White & R. 
Udomsangpetch, (2004) The deformability of red blood cells parasitized by 
Plasmodium falciparum and P. vivax. J Infect Dis 189:190-194.
Taylor, T. E., W. J. Fu, R. A. Carr, R. O. Whitten, J. S. Mueller, N. G. Fosiko, S. Lewallen, N. G. 
Liomba & M. E. Molyneux, (2004) Differentiating the pathologies of cerebral malaria by 
postmortem parasite counts. Nat Med 10:143-145.
ter Kuile, F., N. J. White, P. Holloway, G. Pasvol & S. Krishna, (1993) Plasmodium falciparum: in 
vitro studies of the pharmacodynamic properties of drugs used for the treatment of 
severe malaria. Exp Parasitol 76: 85-95.
Tilley, L, R. Sougrat, T. Lithgow & E. Hanssen, (2008) The twists and turns of Maurer's cleft 
trafficking in P. falciparum-infected erythrocytes. Traffic 9:187-197.
Toure, F. S., 0 . Ouwe-Missi-Oukem-Boyer, U. Bisvigou, O. Moussa, C. Rogier, P. Pino, D. Mazier 
& S. Bisser, (2008) Apoptosis: a potential triggering mechanism of neurological 
manifestation in Plasmodium falciparum malaria. Parasite Immunol 30: 47-51.
Träger, W. & J. B. Jensen, (1976) Human malaria parasites in continuous culture. Science 193: 
673-675.
Treutiger, C. J., A. Heddini, V. Fernandez, W. A. Muller & M. Wahlgren, (1997) PECAM-1/CD31, 
an endothelial receptor for binding Plasmodium falciparum- infected erythrocytes [see 
comments]. Nat Med  3:1405-1408.
Tripathi, A. K., D. J. Sullivan & M. F. Stins, (2006) Plasmodium falciparum-infected erythrocytes 
increase intercellular adhesion molecule 1 expression on brain endothelium through 
NF-kappaB. Infect Immun 74: 3262-3270.
Tripathi, A. K., D. J. Sullivan & M. F. Stins, (2007) Plasmodium falciparum-infected erythrocytes 
decrease the integrity of human blood-brain barrier endothelial cell monolayers. J 
Infect Dis 195: 942-950.
Tse, M. T., K. Chakrabarti, C. Gray, C. E. Chitnis & A. Craig, (2004) Divergent binding sites on 
intercellular adhesion molecule-1 (ICAM-1) for variant Plasmodium falciparum isolates. 
Mol Microbiol 51:1039-1049.
Tsvetkova, N. M., I. Horvath, Z. Torok, W. F. Wolkers, Z. Balogi, N. Shigapova, L. M. Crowe, F. 
Tablin, E. Vierling, J. H. Crowe & L. Vigh, (2002) Small heat-shock proteins regulate 
membrane lipid polymorphism. Proc Natl Acad Sei USA  99:13504-13509.
Turner, G., (1997) Cerebral malaria. Brain Pathol 7: 569-582.
Turner, G. D., H. Morrison, M. Jones, T. M. Davis, S. Looareesuwan, I. D. Buley, K. C. Gatter, C. I. 
Newbold, S. Pukritayakamee, B. Nagachinta & et al., (1994) An immunohistochemical 
study of the pathology of fatal malaria. Evidence for widespread endothelial activation
181
and a potential role for Intercellular adhesion molecule-1 In cerebral sequestration. 
Am J Pathol 145:1057-1069.
Udomsangpetch, R., B. Plpltaporn, S. Krishna, B. Angus, S. Pukrlttayakamee, I. Bates, Y. 
Suputtamongkol, D. E. Kyle & N. J. White, (1996) Antlmalarlal drugs reduce 
cytoadherence and resetting Plasmodium falciparum. J Infect Dis 173: 691-698.
Udomsangpetch, R., B. Plpltaporn, K. Sllamut, R. Pinches, S. Kyes, S. Looareesuwan, C. Newbold 
& N. J. White, (2002) Febrile temperatures induce cytoadherence of ring-stage 
Plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci U S A 99: 11825- 
11829.
Udomsangpetch, R., P. H. Reinhardt, T. Schollaardt, J. F. Elliott, P. Kubes & M. Ho, (1997) 
Promiscuity of clinical Plasmodium falciparum Isolates for multiple adhesion molecules 
under flow conditions. J Immunol 158: 4358-4364.
Vieblg, N. K., E. Levin, S. Dechavanne, S. J. Rogerson, J. Gysln, J. D. Smith, A. Scherf & B. 
Gamaln, (2007) Disruption of var2csa gene Impairs placental malaria associated 
adhesion phenotype. PLoS ONE 2: e910.
Voss, T. S., J. Healer, A. J. Marty, M. F. Duffy, J. K. Thompson, J. G. Beeson, J. C. Reeder, B. S. 
Crabb & A. F. Cowman, (2006) A var gene promoter controls allelic exclusion of 
virulence genes in Plasmodium falciparum malaria. Nature 439:1004-1008.
Wagner, M., I. Hermanns, F. Bittinger & C. J. Kirkpatrick, (1999) Induction of stress proteins in 
human endothelial cells by heavy metal ions and heat shock. Am J Physiol 277: L1026- 
1033.
Waller, K. L., L. M. Stubberfield, V. Dubljevic, W. Nunomura, X. An, A. J. Mason, N. Mohandas, 
B. M. Cooke & R. L. Coppel, (2007) Interactions of Plasmodium falciparum erythrocyte 
membrane protein 3 with the red blood cell membrane skeleton. Biochlm BiophysActa 
1768: 2145-2156.
Wang, P., Q. Wang, P. F. Sims & J. E. Hyde, (2007) Characterisation of exogenous folate 
transport in Plasmodium falciparum. Mol Blochem Parasitol 154: 40-51.
Wassmer, S. C., V. Combes, F. J. Candal, I. Juhan-Vague & G. E. Grau, (2006a) Platelets 
potentiate brain endothelial alterations induced by Plasmodium falciparum. Infect 
Immun 74: 645-653.
Wassmer, S. C., J. B. de Souza, C. Frere, F. J. Candal, I. Juhan-Vague & G. E. Grau, (2006b) TGF- 
betal released from activated platelets can induce TNF-stimulated human brain 
endothelium apoptosis: a new mechanism for microvascular lesion during cerebral 
malaria. J Immunol 176:1180-1184.
Wassmer, S. C., C. Lepolard, B. Traoré, B. Pouvelle, J. Gysin & G. E. Grau, (2004) Platelets 
reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated 
endothelial cells. J. Infect. Dis. 189:180-189.
Waterkeyn, J. G., M. E. Wickham, K. M. Davern, B. M. Cooke, R. L. Coppel, J. C. Reeder, J. G. 
Culvenor, R. F. Waller & A. F. Cowman, (2000) Targeted mutagenesis of Plasmodium 
falciparum erythrocyte membrane protein 3 (PfEMP3) disrupts cytoadherence of 
malaria-infected red blood cells. EmboJ 19: 2813-2823.
Wickham, M. E., M. Rug, S. A. Ralph, N. Klonis, G. I. McFadden, L. Tilley & A. F. Cowman, (2001) 
Trafficking and assembly of the cytoadherence complex in Plasmodium falciparum- 
infected human erythrocytes. EMBOJ20: 5636-5649.
Williams, T. N. & C. I. Newbold, (2003) Réévaluation of flow cytometry for investigating 
antibody binding to the surface of Plasmodium falciparum trophozoite-infected red 
blood cells. Cytometry 56A: 96-103.
Wilson, N. O., M. B. Huang, W. Anderson, V. Bond, M. Powell, W. E. Thompson, H. B. Armah, A. 
A. Adjei, R. Gyasi, Y. Tettey & J. K. Stiles, (2008) Soluble factors from Plasmodium 
falciparum-infected erythrocytes induce apoptosis in human brain vascular endothelial 
and neuroglia cells. Mol Blochem Parasitol 162:172-176.
Winstanley, P. & S. Ward, (2006) Malaria chemotherapy. Adv Parasitol 61: 47-76.
182
Vang, L., J. R. Kowalski, P. Yacono, M. Bajmoczi, S. K. Shaw, R. M. Froio, D. E. Golan, S. M. 
Thomas & F. W. Luscinskas, (2006) Endothelial cell cortactin coordinates intercellular 
adhesion molecule-1 clustering and actin cytoskeleton remodeling during 
polymorphonuclear leukocyte adhesion and transmigration. J Immunol 177: 6440- 
6449.
Yang, Y., C. D. Jun, J. H. Liu, R. Zhang, A. Joachimiak, T. A. Springer & J. H. Wang, (2004) 
Structural basis for dimerization of ICAM-1 on the cell surface. Mol Cell 14: 269-276.
Yipp, B. G., D. I. Baruch, C. Brady, A. G. Murray, S. Looareesuwan, P. Kubes & M. Ho, (2003a) 
Recombinant PfEMPl peptide inhibits and reverses cytoadherence of clinical 
Plasmodium falciparum isolates in vivo. Blood 101: 331-337.
Yipp, B. G., M. J. Hickey, G. Andonegui, A. G. Murray, S. Looareesuwan, P. Kubes & M. Ho, 
(2007) Differential roles of CD36, ICAM-1, and P-selectin in Plasmodium falciparum 
cytoadherence in vivo. Microcirculation 14: 593-602.
Yipp, B. G., S. M. Robbins, M. E. Resek, D. I. Baruch, S. Looareesuwan & M. Ho, (2003b) Src- 
family kinase signaling modulates the adhesion of Plasmodium falciparum on human 
microvascularendothelium underflow. Blood 101: 2850-2857.
Zhao, R. & G. X. Shen, (2007) Involvement of heat shock factor-1 in glycated LDL-induced 
upregulation of plasminogen activator inhibitor-1 in vascular endothelial cells. 
Diabetes 56:1436-1444.
Zhou, M., A. Zhang, B. Lin, J. Liu & L. X. Xu, (2007) Study of heat shock response of human 
umbilical vein endothelial cells (HUVECs) using cDNA microarray. Int J Hyperthermia 
23: 225-258.
183
